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Abstract of a thesis submitted in partial fulfilment of the 
requirements for the Degree of Doctor of Philosophy. 
Abstract 
Longitudinal in vivo monitoring of the neuropathology in ovine  
neuronal ceroid lipofuscinoses 
 
by 
Katharina Natalie Russell 
 
Batten disease or neuronal ceroid lipofuscinoses (NCLs) is one of the most common reasons for 
childhood dementia, characterized by brain atrophy, blindness, mental decline and premature death. 
Although animal model neurological research is traditionally conducted using small rodents, large 
animal models are becoming more popular for several reasons. Longitudinal monitoring of disease 
progression and individual variations are essential in the development of translational medicine and 
whereas small rodents have relatively short life spans and different brain structures compared with 
humans, sheep provide an excellent model for long-term studies of diseases and their treatment. 
Three naturally occurring ovine models are currently being utilised to increase knowledge about 
different types of NCL and to aid in development of treatment strategies for translation to humans. 
These sheep models include a CLN5 Borderdale, a CLN6 South Hampshire and a CLN6 Merino model. 
This thesis contains investigations of techniques for longitudinal in vivo monitoring that can be 
correlated with the progression of neuropathological events in all three ovine NCL models, both in the 
natural progression of the diseases and in trials of potential therapeutic regimes. 
Previous studies have described the neuropathological development of disease in the CLN5 
Borderdale and the CLN6 South Hampshire models. In the present study similar investigations were 
conducted with the CLN6 Merino model, and the three ovine models compared. The general 
development of neuropathology in CLN6 Merino sheep follows that of the other two models. Common 
themes are neuronal loss from the cerebral cortex that proceeds in a regional pattern, with 
neuroinflammation, neurogenesis and ubiquitous accumulation of storage material within the cells. 
Immunohistochemistry indicated possible cross-regulation between the CLN5 and CLN6 proteins.  
In vivo techniques are essential in the monitoring of progressive diseases such as the NCLs. 
Neuroimaging through computed tomography (CT) and magnetic resonance imaging (MRI) are 
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suitable tools to describe neuropathological changes without the need to sacrifice animals. Here, 
current techniques and protocols for CT scanning in ovine NCL research were reviewed and improved. 
The congruence of brain size and intracranial volume (ICV) in ovine NCL was established and 
techniques for the monitoring of brain size in therapeutic trials were validated and correlated with 
neuropathological changes. Furthermore, 3-dimensional reconstruction was used to monitor 
regionality of the cortical changes and this could be correlated with findings from post examination. 
CT based surgery planning was used to improve accuracy of intracereboventricular gene therapy 
delivery and reduce duration of the surgical procedure.  
Pilot studies on the use of MRI as a longitudinal in vivo monitoring modality in ovine NCL research 
were conducted and these indicated that MRI will yield enhanced detail compared with CT and that 
MRI measurements can be closely correlated with the neuropathological changes observed at post 
mortem examination. However, some specific technical issues were identified and will need to be 
addressed in the future. These include image quality, fit of templates and an important need to 
establish ovine-specific image acquisition protocols.  
Blindness in ovine NCL results from atrophy of photoreceptor cells in the retina as well as changes in 
the central visual pathways. Treatment should aim not only to treat the atrophy of the brain, but also 
to prevent or halt the development of blindness. Previous trials have indicated the need for ocular 
delivery of therapy to achieve this. As for neurodegeneration, in vivo monitoring of retinal pathology 
is essential for the longitudinal assessment of treatment efficacy. Here, protocols were established for 
the use of repeated electroretinography (ERG) to monitor the development of blindness in the CLN5 
Borderdale and the CLN6 South Hampshire models. The results show that ERG is an invaluable tool for 
monitoring the progression of retinal degeneration in ovine NCL. Furthermore, it was established that 
the course of development of retinal changes differs between the two ovine models that were 
investigated. The measurements enabled some degree of differentiation between the retinal and 
central components of the blindness in ovine NCL.  
Finally, it was shown that the in vivo monitoring tools established throughout the studies described in 
this thesis are invaluable for the assessment of treatment efficacy in gene therapy trials for ovine NCL. 
The measures evaluated here were shown to correspond with other clinical measures of treatment 
efficacy, such as behavioural observations, maze-testing and neuropathology.  
Key words: Neuronal ceroid lipofuscinosis, Batten disease, lysosomal storage disease, large animal 
models, sheep, neuroimaging, neurodegeneration, neuroinflammation, gene therapy, computed 
tomography, magnetic resonance imaging, electroretinography, in vivo monitoring.  
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1 INTRODUCTION 
1.1 LARGE ANIMAL MODELS FOR TRANSLATIONAL RESEARCH OF GENETIC AND 
NEURODEGENERATIVE DISEASES  
The use of animals to increase our knowledge about how the human body functions, in both 
physiological and pathological terms, and for medical research is well established in human culture 
(Ericsson et al., 2013). Biomedical research has traditionally been based on mouse models that are 
developed from readily available, well-established and genetically homogenous strains. 
Furthermore, genetically engineered knock-in and knock-out mouse models of disease are relatively 
common (Ericsson et al., 2013). Advantageous attributes of mouse models include their genetic 
homogeneity, short generation interval, large litter size, short life span, and thus short experimental 
length, as well as their availability in large numbers, ensuring statistical power through large sample 
sizes. However, some of these attributes have been viewed as disadvantages, and it could be argued 
that their genetic homogeneity, small body size, and short life span largely fail to mimic human 
physiology and pathology, leaving a gap between mouse models and their translation to human 
disease. Examples of this include the failure to show disease phenotype despite of the presence of 
the genetic lesion in mouse models of neuronal ceroid lipofuscinosis (NCL) type 5 (CLN5), Tay-Sachs 
disease or cystic fibrosis (Phaneuf et al., 1996; Grubb & Boucher, 1999; Kopra et al., 2004). 
Furthermore, for neuropathological investigations, the small size and lissencephalic structure of the 
murine brain does not mimic the gyrencephalic, more complex, and much larger human brain well. 
The short life span and genetic homogeneity of mice used for translational research largely 
eliminates the possibility of longitudinal, repeated monitoring of disease development or 
therapeutic efficacy and limits the extent of individual variation. However, the human population is 
genetically diverse and individual differences in treatment response need to be anticipated. A 
traditional alternative to small rodents for translational research has been non-human primates, 
such as rhesus macaque monkeys, but this introduces a range of practical and ethical issues 
associated with their use. In 2013 it was estimated that one rhesus macaque monkey for research 
purpose would cost US $5000-$10,000 to buy, not including housing costs (Morton & Howland, 
2013). Ethical concerns arise when non-human primates are used in the research of 
neurodegenerative diseases, as they develop depression and behavioural issues similar to humans 
(Morton & Howland, 2013). Larger animals could provide the translational bridge between small 
rodents and human disease and the most widely used large animal models are dogs and pigs (Casal 
& Haskins, 2006; Holm et al., 2016; Eaton & Wishart, 2017). Research pigs, such as the Göttingen 
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minipig, have been bred to provide genetically homogenous cohorts with little individual variation, 
leading to some of the same concerns as the use of mouse models (Holm et al., 2016). A canine 
model for Alzheimer disease exists (Martin et al., 2011) and studies of naturally occurring NCLs in 
dogs have contributed greatly to the understanding of these diseases. The first detailed description 
of a naturally occurring NCL in large animals was in English Setter dogs in Norway (Koppang, 1962, 
1966) and, since then, a range of NCL cases has been described in several dog breeds (Jolly et al., 
1994; Palmer et al., 2011). Regardless of the relatively common occurrence of canine NCLs, currently 
only one active canine NCL research colony exists, which comprises Dachshunds with CLN2 disease 
(Katz et al., 2008). Translational results from investigations into enzyme replacement therapy in 
these dogs has led to clinical trials for enzyme replacement therapy in children with CLN2 disease 
(Katz et al., 2014; Schulz et al., 2016). The interest in other large animal models to study genetic 
diseases and for the development of translational therapies has recently increased (Morton & 
Howland, 2013; Palmer et al., 2015; Pinnapureddy et al., 2015; Roth & Tuggle, 2015; Eaton & 
Wishart, 2017). Concerns about the social acceptance of using companion animals in research have 
been raised and need to be considered (Eaton & Wishart, 2017). Initiatives have been established to 
promote the use of large animal models discovered in farm animal populations such as ‘Sharing 
Advances on LArge Animal Models’ (SALAAM) from the European Cooperation in Science & 
Technology (http://www.salaam.genzentrum.lmu.de/) and the ‘Online Mendelian Inheritance in 
Animals’ (OMIA) catalogue from the University of Sydney (http://omia.angis.org.au/home/, Nicholas, 
2003). A range of naturally occurring and transgenic large animal models has been established for 
neurodegenerative diseases (reviewed by Eaton & Wishart, 2017). Advantages of farm animals for 
translational research are the well-established systems for their breeding, housing, handling and 
transport as well as their similarities to humans in terms of physiology and size (Scheerlinck et al., 
2008; Roth & Tuggle, 2015). Sheep in particular have been increasingly utilised as model animals for 
genetic and neurodegenerative disease research (Morton & Howland, 2013; Palmer et al., 2015; 
Pinnapureddy et al., 2015) and a fully annotated sequence of the sheep genome is now publicly 
available (https://genome.ucsc.edu/cgi-bin/hgGateway; Jiang et al., 2014). Sheep are docile and 
easy to handle. They have a similar body size to humans, new-born lambs weighing between 3 and 4 
kg and adult ewes between 50 and 100 kg, and a similar physiology with exception of the gastro-
intestinal tract (Scheerlinck et al., 2008). Sheep are relatively long-lived (10 – 15 years) and can be 
kept in simple outdoor grazing conditions. The sheep brain is ideal for the investigation of 
neurodegenerative disorders, being approximately one tenth of the size of the human brain, 
gyrencephalic, and similar in structure and organisation (Palmer et al., 2015). All this enables more 
realistic approximations for human treatment and the up-scaling from sheep to human for both 
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treatment dosages and surgical procedures is less extreme than between mice and human. 
Resources like the Michigan brain atlas (https://msu.edu/~brains/brains/sheep/index.html) and a 
recently developed magnetic resonance imaging (MRI) atlas of the sheep brain (Ella & Keller, 2015; 
Ella et al., 2017) increase the applicability of sheep as models for human neurodegenerative disease. 
Furthermore, sheep are suitable for investigations of cognitive functions, as they possess good facial 
and emotional recognition and memory skills, display executive decision-making ability, and can 
learn novel tasks (Tate et al., 2006; Morton & Avanzo, 2011; Nowak et al., 2011; Knolle et al., 2017). 
Currently a range of naturally occurring and induced neurodegenerative diseases in sheep are being 
utilised as models for human conditions, including the ovine CLN5 and CLN6 NCL models described in 
this thesis (see sections 1.3.2.2, 1.4.2.2 and 1.4.2.3), and models for Gaucher disease type 1, Tay-
Sachs disease and Huntington disease (Jolly & West, 1976; Cook et al., 2002; Jacobsen et al., 2010; 
Torres et al., 2010; Karageorgos et al., 2011). In the light of the recent and ongoing advances in gene 
editing techniques, the development of a range of engineered sheep models of other human 
diseases should be anticipated (Tu et al., 2015; Whitelaw et al., 2016).  
1.2 GENERAL FEATURES OF THE NEURONAL CEROID LIPOFUSCINOSES 
1.2.1 Overview 
The neuronal ceroid lipofuscinoses (NCLs or Batten disease) are a group of mainly autosomal 
recessively inherited lysosomal storage diseases (LSDs) leading to degenerative and fatal 
encephalopathies in children (Haltia, 2006). The estimated incidence of NCL worldwide is 1:12,500 
live births (Rider & Rider, 1988). The genetic background of the NCLs is heterogeneous, currently 
including mutations in 13 different genes, leading to the different forms of NCL 
(http://www.ucl.ac.uk/ncl/SummaryTableMay2015.htm). Despite this genetic diversity, the NCLs are 
characterised by a range of common features. Affected children develop normally at first but then 
develop blindness combined with progressive motor degeneration, epilepsy and dementia, 
eventually reaching total dependency and premature death (Mole et al., 2005, 2011; Kousi et al., 
2012). Pathologically the NCLs are unified through severe cerebral neurodegeneration, 
neuroinflammation and the nearly ubiquitous intracellular accumulation of storage bodies 
containing specific proteins (Mole et al., 2005; Kousi et al., 2012; Palmer, 2015). Despite these 
characterising similarities, large individual variations in disease onset, course and severity are 
observed (Mole et al., 2005; Anderson et al., 2013).  
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1.2.2 Classification 
Traditionally the NCLs were classified based on the age of onset, namely infantile, late-infantile, 
juvenile and adult (Haltia, 2003). The discovery of more forms, a growing understanding of the 
genetic background, and the observation of large individual variation, even within the same disease 
type, has led to a revised nomenclature based on the defective gene (Table 1.1) (Williams & Mole, 
2012; Kousi et al., 2012; Warrier et al., 2013). With the ongoing discovery of new NCL forms, such as 
the more recently described CLN4 and CLN11 – CLN14 (Smith et al., 2012, 2013; Bras et al., 2012; 
Staropoli et al., 2012), there has been ongoing discussion about which criteria should be fulfilled for 
a disease to be identified as an NCL (Palmer et al., 2013). 
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Table 1.1 Classification of the NCLs  
(modified from http://www.ucl.ac.uk/ncl/, Williams et al., 2011; Palmer et al., 2013; Cotman et al., 2013; Kollmann et al., 2013; Warrier et al., 2013) 
NCL gene 
(alternative name) 
Gene product 
Type of 
protein 
Cellular localisation NCL types Storage material 
CLN1 (PPT1) PPT1 Soluble Lysosomal matrix Classic Infantile, late-infantile, juvenile SAP A and D  
CLN2 (TPP1) TTP1 Soluble Lysosomal matrix Classic late-infantile, juvenile Subunit c 
CLN3 CLN3 
Trans-
membrane 
Endosomal/lysosomal membrane Classic juvenile Subunit c 
CLN4 (DNAJC5) CSPα, DNAJC5 Soluble Cytosolic, vesicular membrane associated Perry disease (juvenile to adult onset)  SAP A and D  
CLN5 CLN5 Soluble Lysosomal matrix Variant late-infantile, juvenile, adult Subunit c 
CLN6 CLN6 
Trans-
membrane 
ER membrane Variant late-infantile, Kufs A (adult-onset) Subunit c 
CLN7 (MFSD8) MFSD8 
Trans-
membrane 
Lysosomal membrane Variant late-infantile, juvenile, adult Subunit c 
CLN8 CLN8 
Trans-
membrane 
ER/ER-Golgi membrane Late-infantile, Northern epilepsy Subunit c 
CLN10 (CTSD) Cathepsin D  Soluble Lysosomal matrix, extracellular Congenital, late-infantile, adult SAP A and D  
CLN11 (GRN) Progranulin Soluble Extracellular Adult Not confirmed 
CLN12 (ATP13A2) ATPase 13A2 
Trans-
membrane 
Lysosomal membrane Juvenile Not confirmed 
CLN13 (CTSF) Cathepsin F  Soluble Lysosomal matrix Kufs B (adult-onset) Not confirmed 
CLN14 (KCTD7) KCTD7 Soluble Cytosolic, membrane associated Infantile  Subunit c 
      
Abbreviations: CLN1 etc. ceroid lipofuscinosis, neuronal 1 etc.; CSPα cysteine string protein alpha; CTSD cathepsin D; CTSF cathepsin F; DNAJC5 DnaJ (Hsp40) homolog, 
subfamily C, member 5; ER endoplasmic reticulum; KCTD7 potassium channel tetramerization domain-containing protein 7; MFSD8 major facilitator superfamily domain 
containing 8; PPT1 palmitoyl protein thioesterase 1; SAP sphingolipid activator protein; subunit c of the mitochondrial ATP synthase; TPP1 tripeptidyl peptidase 1 
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1.2.3 Accumulation of storage material 
The accumulation of storage material in the lysosomes of neurons and most other visceral cells is 
one of the defining features of the NCLs. The material is positive for Sudan black and Luxol fast blue, 
fluorescent and electron dense and has traditionally been described as resembling the aging 
pigments lipofuscin and ceroid, giving rise to the name of these diseases (Rider & Rider, 1988). 
Investigations into the nature of the storage material in the ovine CLN6 South Hampshire sheep 
model revealed that it did not comprise aging pigments but that at least 50% was made up from the 
subunit c of the mitochondrial ATP synthase (Palmer et al., 1989; Fearnley et al., 1990). Initial 
investigations confirmed the same storage material in the human CLN2 and CLN3 diseases (Fearnley 
et al., 1990; Palmer et al., 1992) and subsequently in the human CLN5, CLN6, CLN7, CLN8, and CLN14 
diseases (Hall et al., 1991; Tyynelä et al., 1997; Haltia, 2006; Elleder et al., 2011; Staropoli et al., 
2012) as well as in several animal models (Faust et al., 1994; Pardo et al., 1994; Koike et al., 2000; 
Cook et al., 2002; Jolly et al., 2002). In the CLN1, CLN4 and CLN10 diseases, the storage material 
mainly consists of the sphingolipid activator proteins A and D (Tyynelä et al., 1993; Nijssen et al., 
2003; Siintola et al., 2006; Nosková et al., 2011). No analyses of the material in the remaining newly 
discovered NCLs (CLN11, CLN12 and CLN13) have been published so far.  
The reason for the accumulation of storage material still remains elusive. Traditionally it was 
assumed that a direct connection between storage accumulation and neuronal death existed, 
however this paradigm has recently been challenged by Palmer and his co-authors (Palmer et al., 
2013; Palmer, 2015). Studies have shown independence of neuronal pathology and storage 
accumulation (Oswald et al., 2005; Kay et al., 2006) and despite the accumulation of storage material 
in most visceral cells, no consistent pathology is seen in any organs other than the brain (Palmer et 
al., 2013, 2015). Furthermore, gene therapy trials in a CLN1 mouse model that resulted in successful 
clearance of storage accumulation in the brain, showed no improvement in clinical disease signs 
(Griffey et al., 2006). It is, therefore, now assumed that storage accumulation and neuronal 
pathology are two independent manifestations of the NCLs rather than one being caused by the 
other (Palmer et al., 2013).  
1.2.4 Selective neuronal loss  
A key characteristic of the NCLs is the progressive neuronal loss that leads to remarkable atrophy of 
the brain, which in human subjects is obvious at post mortem examination or from imaging studies 
(Autti et al., 1992; Haltia, 2003, 2006; Jadav et al., 2014). Already these basic observations reveal a 
heterogeneous pattern of atrophy with regional differences and differences between the disease 
types. For example, is there a varying incidence of cerebellar atrophy depending on disease type that 
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is obvious on macroscopic examination (Tyynelä et al., 1997; Jadav et al., 2014) and it has been 
shown that the cortical atrophy is more pronounced in areas of the brain with primary sensory 
function compared with those involved in motor function (Mitchison et al., 2004; Oswald et al., 
2005). Initial investigations using autopsy tissue from human subjects indicated the selective loss of 
inhibitory interneurons that use γ-aminobutyric acid (GABA) as a neurotransmitter (i.e. GABAergic 
neurons) and this has since been confirmed in a variety of animal models (Williams et al., 1977; 
Cooper et al., 1999; Oswald et al., 2001; Mitchison et al., 2004; Bible et al., 2004; Tyynelä et al., 
2004; Kielar et al., 2007). Investigations of several mouse models, such as CLN1 (PPT1-/-), CLN10 
(CTSD-/-), CLN8 (mnd/mnd) and others, have shown that initial pathology occurs in the thalamus with 
loss of mainly sensory relay neurons and is only subsequently followed by cortical neuron loss 
(Cooper et al., 2006; Kielar et al., 2007; Partanen et al., 2008; Kuronen et al., 2012). However, 
studies in CLN5 mutant mice have shown a contrasting trend to these findings, as here the neuron 
loss begins in the cortex and only subsequently reached the thalamic relay nuclei (von Schantz et al., 
2009). Similar findings were made from the CLN6 South Hampshire sheep model, where thalamic 
changes such as the loss of GABAergic interneurons and generalised atrophy were not seen until 
late-stage disease (Oswald et al., 2005, 2008; Sawiak et al., 2015).  
1.2.5 Neuroinflammation 
Over the last two decades the perception about the NCLs being a mainly neuronal disease has 
changed. Studies of the well characterised CLN6 South Hampshire sheep model have shown that 
neuroinflammation plays a major role in the development of the disease. Activated astrocytes, 
positive when immunostained for glial fibrillary acidic protein (GFAP), were present in the 
developing cerebral white matter of sheep embryos at 40 days, and in the grey matter at 20 days, 
before birth, and activated perivascular cells were found in the white matter at 40 days before birth 
(Kay et al., 2006). These changes were most pronounced in the somatosensory and occipital cortices 
and no activation of neuroinflammatory markers was detected in the cerebellum. 
Neuroinflammation clearly precedes the neurodegeneration as it has been shown that the brain 
volumes and cortical thicknesses of affected sheep were similar to those of normal animals at birth 
and cortical thinning did not commence until 4 months of age (Oswald et al., 2005, 2008; Kay et al., 
2006; Mitchell, 2016). Similar findings have been reported for a range of NCL mouse models 
(Pontikis et al., 2004; Kielar et al., 2007; Partanen et al., 2008; von Schantz et al., 2009; Kuronen et 
al., 2012; Schmiedt et al., 2012). Neuroinflammation has also been found in other lysosomal storage 
diseases,  Tay-Sachs disease, mucopolysaccharidosis IIIB and Sandhoff disease (Wada et al., 2000; 
Ohmi et al., 2003; Jeyakumar et al., 2003). The role of neuroinflammation in neurodegenerative 
diseases remain controversial because astrocytes and other glial cells can have both neuroprotective 
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and neurotoxic properties (Sofroniew, 2005; Sofroniew & Vinters, 2010), and therefore the role of 
these events, especially in relation to  the neuropathological cascade, also remains elusive in the 
NCLs (Palmer et al., 2013; Cooper et al., 2015; Chen, 2016). 
1.2.6 Neurogenesis  
The traditional view that neurogenesis in mammals occurs only in the developing brain has been 
challenged over the last few decades and it is now generally accepted that some degree of 
neurogenesis also occurs in the adult brain, specifically in the subventricular zone (SVZ) of the lateral 
ventricles and in the subgranular zone (SGZ) of the dentate gyrus of the hippocampus (reviewed by 
Ming & Song, 2011). Different pathological states have different effects on adult neurogenesis and 
self-repair is seen after brain insults, however some functions of neurogenesis remain elusive. For 
example, the effect of seizure activity on adult neurogenesis has been questioned in mice 
(Jessberger & Parent, 2015). Also there is some discussion about neurogenesis being a positive 
mechanism, for example enabling self-repair in epileptic disease, or a negative mechanism, 
inasmuch as seizure-induced alteration of neurogenesis might contribute further to epileptic disease 
(Jessberger & Parent, 2015). Signs of self-repair were seen after induced stroke in rats (Arvidsson et 
al., 2002). Here it was shown that stroke lead to marked increases of cell proliferation in the SVZ and 
that the cells migrated to, and proliferated into, the area and cell type that was lost during the 
stroke (Arvidsson et al., 2002). The effect of neurodegeneration on adult neurogenesis is also 
complex, and different factors in diseases such as Alzheimer, Parkinson and Huntington can have 
either stimulating or inhibiting effects on adult neurogenesis (reviewed by Winner et al., 2011). 
Studies in normal sheep have shown that these animals also exhibit adult neurogenesis in the SVZ 
and SGZ and that the migrating cells follow the rostral migration stream to the olfactory bulbs in a 
similar way to that seen in humans (Brus et al., 2010, 2013; Low et al., 2013). Increased neurogenesis 
occurs in the CLN6 South Hampshire and CLN5 Borderdale sheep as well as in the CLN3-/- and PPT1-/- 
mouse models (Dihanich et al., 2009, 2012; Mitchell, 2016).  
1.2.7 Blindness 
Loss of vision occurs in most forms of the NCLs and is often one of the first presenting signs of 
disease (Haltia, 2003; Anderson et al., 2013). The adult-onset forms are exceptions from this 
generalisation (Berkovic et al., 1988; Arsov et al., 2011). Autopsy findings from eyes of human NCL 
patients are generally characterized by substantial loss of photoreceptors and their cell bodies from 
the outer nuclear layer, storage accumulation and infiltration of inflammatory cells such as 
macrophages, astrocytes and microglia (Goebel et al., 1974; Schochet et al., 1980). In vivo findings 
from human patients are based on ocular examinations, funduscopy and electroretinography (ERG). 
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The rate of retinal degeneration and thus loss of ERG responses varies between the different disease 
forms, but ultimately an extinct ERG response is observed in most NCL types (Weleber, 1998). A 
range of differing funduscopic findings have been reported for the different NCL types, including 
atrophy of the pigment epithelium, peripheral bone spicules, bull’s eye maculopathy and variable 
disk pallor (Hainsworth et al., 2009). Detailed investigations of the pathological changes of the retina 
have been conducted in various animal models of the NCLs. For instance, retinal degeneration was 
measured in the CLN6-/- South Hampshire sheep through ERG and this was correlated to 
histopathological changes (Graydon & Jolly, 1984; Mayhew et al., 1985). The results showed a 
progressive loss of photoreceptor cells and nuclei from the outer nuclear layer that coincided with a 
progressive reduction of ERG responses (Graydon & Jolly, 1984; Mayhew et al., 1985). 
Ultrastructural investigations showed loss of rod receptor outer segments and inclusion of storage 
material throughout most retinal cells, and ingested outer segments and melanin granules in the 
pigment epithelium (Graydon & Jolly, 1984; Mayhew et al., 1985; Goebel, 1992). In contrast to 
findings from human patients, CLN6-/- South Hampshire sheep did not show atrophy of the optic disc, 
vascular attenuation or abnormal pigmentation of the fundus. Both in CLN6-/- and CLN5-/- sheep 
initial visual impairment was seen at 5 – 8 months of age and severely affected vision by 12 – 14 
months (Mitchell, 2016). Similar findings were recorded in a dog model of CLN2 (tripeptidyl 
peptidase 1; TPP1) disease. Here loss of menace response was noticed at 7 months of age and the 
dogs appeared to be clinically blind by 10 months (Katz et al., 2008). Funduscopy revealed increased 
granularity and generalised vascular attenuation(Katz et al., 2008). At 7 months the dogs also had a 
reduced ERG response which declined progressively and was abolished by 10 months of age. Storage 
material was abundant throughout most retinal cells and the photoreceptors had irregularly shaped 
outer segments and were reduced in number (Katz et al., 2008). A mouse model of CLN5 disease 
provided similar findings, including progressively declining and eventually diminished ERG 
recordings, damaged and apoptotic photoreceptors, accumulation of storage bodies in most retinal 
cells and infiltration by inflammatory cells such as microglia and astrocytes (Leinonen et al., 2017). A 
different mouse model of CLN3 disease showed less typical phenotype, with late loss of 
photoreceptors, no change of the fundus or the ERGs, but accumulation of storage bodies was 
observed (Seigel et al., 2002). 
The loss of vision in the NCLs also has a central component. The primary visual cortex was found to 
be the region showing the most severe and earliest signs of both neurodegeneration and 
inflammation, leading to signs of functional blindness even before the loss of photoreceptors was 
evident in the CLN6 South Hampshire sheep model (Oswald et al., 2005; Mitchell, 2016). 
Observations of pathology in other parts of the visual pathway have also been made, such as loss of 
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large projection neurons within the lateral geniculate nucleus (Weimer et al., 2006). Whether this is 
a causative change or a downstream result of atrophy of the retina and the primary visual cortex 
remains to be determined.  
1.3 CLN5 DISEASE 
1.3.1 Human CLN5 disease 
CLN5 disease in humans was first identified in Finland as a variant of the late infantile NCL (Finnish 
vLINCL) (Santavuori et al., 1982, 1993; Savukoski et al., 1998) The initial clinical signs of CLN5 disease 
are mental impairment, visual failure and epilepsy and are typically seen in children at around 5 
years of age. The patients die in their teenage years or as young adults (Santavuori et al., 1982). 
Neurodegeneration spans the entire brain and is characterised by neuronal loss in the cerebrum, 
destruction of Purkinje cells in the cerebellum, and myelin loss and gliosis in the white matter (Autti 
et al., 1992; Tyynelä et al., 1997). Imaging studies of CLN5 patients have also found dilation of all 
cerebral ventricles and hyperintense zones in the white matter on MRI (Autti et al., 1992; Holmberg 
et al., 2000). Accumulation of subunit c of the mitochondrial ATP synthase and sphingolipid activator 
protein A and D is present in most visceral cells and is increased in the brain. Retinal degeneration 
accompanies the degeneration of the brain (Tyynelä et al., 1997). 
1.3.2 Animal models of CLN5 disease 
1.3.2.1 Cln5 mouse 
An exon 3 knock-out CLN5 mouse model has been created (Kopra et al., 2004). The mice show loss 
of vision, accumulation of storage material and loss of GABAergic neurons from the cortical grey 
matter, however most of the other disease phenotypes, such as progressive motor dysfunction and 
seizures that are evident in humans, are not seen in this mouse model.  
1.3.2.2 CLN5 Borderdale sheep 
NCL in Borderdale sheep was first described in 2002 after commercially bred Borderdale sheep were 
observed to show clinical signs consistent with NCL and a research flock was established (Jolly et al., 
2002). The causative mutation was located to the ovine equivalent of the CLN5 gene (Frugier et al., 
2008). The initial characterisation of this model revealed that blindness in these sheep is seen at 
around 10 – 11 months, and the pathological changes are severe atrophy of the cerebral cortex, 
accumulation of fluorescent storage bodies that contain the subunit c of the mitochondrial ATP 
synthase, neuronal loss and astrocytosis (Jolly et al., 2002; Frugier et al., 2008). Subsequently the 
ovine CLN5 disease has been described in more detail (Mitchell, 2016). Initial disease signs seen from 
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approximately 6 months of age include low head carriage and baulking, especially when passing 
through gates, laneways, shadows or negotiating steps. From around 11 months of age the sheep 
become functionally blind, which manifests as reduced or lost visual reflexes such as menace 
response, pupillary light reflex and dazzle response. At the same age the CLN5 affected Borderdale 
sheep develop a reduced herding instinct and increased self-segregation. As the disease progresses 
so does the severity of the clinical signs. Reduced mentation, increased somnolence, and repetitive 
behaviour such as sham eating and circling can be observed from around 14 months of age. The 
motor functions of affected sheep also become impaired at this stage, which manifests as 
proprioceptive dysfunction and intermitted episodes of facial tremors. Towards end-stage disease, 
after 15 months of age, the sheep show reduced awareness of their surroundings, extended periods 
of somnolence, low mentation, and lack of responsiveness and loss of body condition. Whole-body 
tremors can be induced in some sheep from 13 months of age, however there is large individual 
variation in the severity of disease progression. The humane endpoint for the disease is reached at 
18 – 22 months of age (Mitchell, 2016). 
The neuropathological changes in CLN5 affected Borderdale sheep are largely common to the NCLs 
(Mitchell, 2016). The brain weight of affected animals is close to that of normal sheep at birth but is 
already reduced to 89% at 4 months. Thereafter the cerebral atrophy continues, reaching 81% of 
normal brain volume at 12 months, 73% at 18 months and declining to 58% at end-stage disease. 
Disruption of the laminar architecture of the cerebral grey matter is already mildly evident in the 
primary visual cortex at birth, obvious in the parieto-occipital and the somatosensory cortices at 4 
months and reaches the entire cortical mantle by 6 – 9 months. At end-stage disease, by 24 months, 
cellular aggregates are present at the lamina I/II boundary and loss of neurons is evident throughout 
the entire cortical grey matter. Grey matter thinning observable in the visual, parieto-occipital and 
somatosensory cortices from birth, reaches the frontal association cortex at 9 months and the 
remaining cortical areas at 15 months of age. Neuroinflammation characterised by activation of 
microglia and astrocytes largely follows the same pattern as the grey matter thinning, starting in the 
visual, parieto-occipital and somatosensory cortices and then spreading to the remaining cortical 
regions. Initial activation is seen in the upper cortical laminae (II/III) and subsequently reaches the 
lower layers (IV-VI). Ongoing neurogenesis is evident throughout the entire disease progression with 
newly generated neurons travelling from the SVZ to the affected cortical areas. The subcortical 
regions, the cerebellum and the brain stem are largely spared of pathological changes besides of the 
progressive accumulation of fluorescent storage material ubiquitous in the entire brain and most 
other cells of the body (Mitchell, 2016). 
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1.3.3 CLN5 gene, mutations and gene product 
The human CLN5 gene is located on chromosome region 13q21.1-q32, consists of four exons and has 
several potential methionine start sites (Savukoski et al., 1994, 1998; Åberg et al., 2011). Alignment 
with other species has shown that only the third possible human initiation site is evolutionary 
conserved, making it most likely to be the true start codon, leading to a protein of 358 amino acids 
that is soluble and localised to the lysosome but whose function remains elusive (Isosomppi et al., 
2002; Holmberg et al., 2004; Kopra et al., 2004; Houweling et al., 2006; Frugier et al., 2008; Schmiedt 
et al., 2010). A CLN5 gene product consistent with these findings has been identified (Sleat et al., 
2007, 2009). Interaction of the CLN5 gene with a range of other NCL genes, namely CLN1/PPT1, 
CLN2/TPP1, CLN3, CLN6 and CLN8, has been suggested (Vesa et al., 2002; Lyly et al., 2009). To date 
36 disease-causing mutations are known in humans 
(http://www.ucl.ac.uk/ncl/CLN5mutationtable.htm), all leading to a similar disease phenotype 
(Holmberg et al., 2000; Mole et al., 2005). The most common mutation in human patients is a 2 
basepair (bp) deletion in exon 4 (c.1175delAT), which results in a truncated protein (Savukoski et al., 
1998). The mutation in the Borderdale sheep is a nucleotide substitution (c.571+1G>A) leading to 
the splicing out of exon 3 and a shortened protein (Frugier et al., 2008).  
1.4 CLN6 DISEASE 
1.4.1 Human CLN6 disease 
A variant late infantile NCL (vLINCL), Kufs disease, and other adult-onset forms of NCL were all 
assigned to mutations in the CLN6 gene (Lake & Cavanagh, 1978; Sharp et al., 1997; Arsov et al., 
2011). The clinical signs of CLN6 deficiency are largely general to the NCLs. The age of onset of the 
vLINCL lies between 18 months and 5 years and although the course of disease may vary, the first 
signs are usually seizures and motor disabilities, followed by loss of vision and speech, cognitive 
impairment and premature death before the third decade of life (Teixeira et al., 2003; Mole et al., 
2005). CLN6 disease is found in all ethnic groups (Alroy et al., 2011). Besides the vLINCL form, type A 
Kufs disease, an adult-onset NCL, and teenage-onset progressive myoclonus epilepsy have also been 
attributed to CLN6 deficiencies (Arsov et al., 2011; Andrade et al., 2012). No loss of vision is 
observed in the teenage onset and adult forms.  
1.4.2 Animal models of CLN6 disease 
1.4.2.1 nclf mouse 
There are three naturally occurring animal models of the human CLN6 deficiency disease. Nclf mice 
have some clinical and pathological similarities with the human disease, such as progressive motor 
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neuron disease, loss of vision and accumulation of fluorescent storage material and it was shown 
that the nclf gene is located on a region that is homologous for the location of the human CLN6 gene 
(Bronson et al., 1993, 1998).  
1.4.2.2 CLN6 South Hampshire sheep 
Ovine CLN6 disease was discovered in South Hampshire sheep in the 1970s and the biochemical and 
pathological features of this model are well characterized (Jolly & West, 1976; Jolly et al., 1980, 
1989). The disease progression and neuropathological changes parallel those of human CLN6 
disease. Initial studies established that CLN6 affected sheep are born without clinical signs but 
disease symptoms develop between 10 and 14 months of age (Mayhew et al., 1985; Jolly et al., 
1989). These are progressive atrophy of the cerebral cortex leading to psychomotor decline and loss 
of retinal photoreceptor cells leading to blindness (Mayhew et al., 1985; Jolly et al., 1989). More in-
depth observations of the development of the clinical status have revealed that initial signs can be 
detected from 7 months of age, including low head carriage, especially when passing through 
gateways, races and shadows (Mitchell, 2016). From 9 months visual deficits can be observed and 
visual reflexes such as the menace response, pupillary light reflex and dazzle response are reduced. 
Most CLN6 affected South Hampshire sheep are functionally blind from approximately 12.5 months 
of age. Loss of condition is observed from 10 to 12 months of age and reduced mentation, 
spontaneous episodes of head nodding and facial twitches become evident from approximately 15.5 
months of age. Affected sheep die prematurely at approximately two years of age, but large 
individual variation in both disease severity and progression should be expected (Mayhew et al., 
1985; Jolly et al., 1989; Mitchell, 2016).  
The accumulation of periodic acid-Schiff-positive, fluorescent material that stained with Sudan Black 
in CLN6 affected South Hampshire sheep was initially described when the disease in these animals 
was discovered (Jolly & West, 1976). Since then this model has been used to identify the specific 
storage of subunit c of the mitochondrial ATP synthase which is a common feature for most of the 
NCLs (section 1.2.3) (Palmer et al., 1989, 1992; Fearnley et al., 1990; Palmer, 2015). The 
neuropathological changes are well described in the CLN6 South Hampshire sheep. Although 
prenatal neuroinflammatory changes can be observed, the sheep are born without clinical signs and 
no macroscopic changes of the brain are seen in the first 4 months of their lives (Oswald et al., 2005; 
Kay et al., 2006; Mitchell, 2016). At this point however, the brain weights of affected sheep are 
already reduced to 81% of those of unaffected controls. From then on progressive loss of brain 
volume is evident; brain weights of affected sheep being reduced to 69% of those of normal sheep at 
12 months, and to 54% when the humane endpoint of the disease is reached at 24 months. Although 
no macroscopic changes are observed early in life, disruption of the cellular architecture of the 
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cortical layers of the cerebrum becomes apparent as early as 2 months of age in the primary visual 
and parieto-occipital cortices, at 6 months in the somatosensory cortex, at 12 months in the primary 
motor cortex and affects the entire cortical mantel at 18 months. Cortical thinning follows this 
disruption of cellular architecture. The visual and parieto-occipital cortices show thinning at 2 
months of age, then the somatosensory cortex at 9 months, the entorhinal and frontal association 
cortices at 12 months and the primary motor cortex at 18 months of age (Oswald et al., 2005; 
Mitchell, 2016).  
Another hallmark of the NCLs initially described in the South Hampshire CLN6 model are the 
neuroinflammatory changes that occur in the course of the disease. Astrocytosis and glial activation 
precede neurodegeneration and cortical atrophy. Activated astrocytes can be detected 40 – 20 days 
before gestation and activated microglia can be found shortly after birth (Kay et al., 2006). Clusters 
of activated microglia can be seen in the cortical regions most vulnerable to neurodegeneration in 
pre-symptomatic animals, e.g. the visual and the parieto-occipital cortices (Oswald et al., 2005; Kay 
et al., 2006; Mitchell, 2016). Astrocytosis and activation of microglia starts in the outer cortical 
laminae (II and III), and subsequently the infiltration spreads to the lower laminae (IV-VI) until finally 
the cellular architecture is lost and replaced by a diffuse mesh of activated astrocytes, spanning the 
entire cortical mantle and also including subcortical regions (Oswald et al., 2005; Mitchell, 2016). 
Accompanying the neuroinflammation and degeneration is an ongoing neurogenesis where newly 
formed neurons travel from the SVZ along the white matter tracts towards the cortical regions that 
are most severely affected by neurodegeneration (Dihanich et al., 2009; Mitchell, 2016). The 
cerebellum and brain stem are relatively spared from neuropathological changes (Oswald, 2004; 
Mitchell, 2016). 
1.4.2.3 CLN6 Merino sheep 
The CLN6 disease in Merino sheep was first identified in a commercial Merino flock in 1997 and a 
research flock was established at the University of Sydney, Australia (Tammen et al., 2001; Cook et 
al., 2002). The overall clinical and pathological development of CLN6 disease in Merino sheep 
resembles that of South Hampshire sheep. Clinical signs can be detected between 7 and 12 months 
of age and include mild behavioural changes, decreased but still measurable visual function, reduced 
herding instinct and low head carriage that is exaggerated when passing through gates and laneways 
or over steps (Cook et al., 2002). After the age of 12 months and as the disease progresses, the 
clinical signs worsen. The sheep show increasing behavioural changes such as poor response to 
auditory stimuli, reduced awareness of surroundings, somnolence, repetitive behaviour and 
disturbances of feeding behaviour such as sham eating and drinking which ultimately lead to 
anorexia and loss of condition. In the later disease course the motor deficits worsen and the sheep 
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show proprioceptive issues, episodes of head shaking and tremors of the face and forelimbs. 
Inducible tremors can be seen when the sheep are kept alive to late-stage disease at a maximum age 
of 27 months (Cook et al., 2002).  
Brain atrophy is also a defining feature of CLN6 disease in Merino sheep. The mean brain weights of 
a group of CLN6 affected Merino sheep aged 10 to 27 months were reduced to 54% of normal, 
ranging from a low of 38% to 70%, and there was visible loss of the cerebral grey matter on 
sectioning at post mortem examination (Cook et al., 2002). Accumulation of subunit c of the 
mitochondrial ATP synthase is evident throughout most cell types of the body and precedes the 
manifestation of any clinical signs (Cook et al., 2002). Neuropathological changes include loss of 
cellular architecture, neuronal loss and neuroinflammation. There is a progressive loss of 
photoreceptor cells in the retina (Cook et al., 2002). 
1.4.3 CLN6 gene, mutations and gene product 
The human CLN6 gene located on chromosome 15q23 contains 7 exons and encodes a 311-amino 
acid membrane protein (Sharp et al., 1997, 2003; Gao et al., 2002; Wheeler et al., 2002). To date, 71 
different disease-causing mutations of the CLN6 gene are known in humans 
(www.ucl.ac.uk/ncl/CLN6mutationtable.htm). The ovine CLN6 gene located on sheep chromosome 
7q13-15 and the nclf mouse gene  located on murine chromosome 9 are both syntenic with the 
human chromosomal location (Bronson et al., 1998; Broom et al., 1998). The disease-causing 
mutation in South Hampshire sheep is a 402 bp deletion and 1 bp insertion (g.-251_+150del and 
g.+150_151insC) leading to the deletion of some 5’UTR, the ATG start codon and the whole of exon 
1 (Tammen et al., 2006; Mohd Ismail, 2014). In the affected Merino sheep, CLN6 disease is caused by 
a missense mutation (c.184C>T) leading to a single amino acid change (p.Arg62Cys) (Tammen et al., 
2006). The mutation in nclf mice is a 1 bp insertion in exon 4 (c.307insC) leading to a frameshift and 
a premature stop codon (Gao et al., 2002; Wheeler et al., 2002). The CLN6 protein is a 
transmembrane endoplasmic reticulum (ER) resident protein of 27 kDa, modelled to have an N-
terminal cytoplasmic domain, seven transmembrane domains and a luminal C-terminus (Heine et al., 
2004, 2007; Mole et al., 2004). The function of the CLN6 protein remains unknown, but involvement 
in lysosomal endocytosis of exogenous protein has been suggested (Heine et al., 2004; Mole et al., 
2004). Because the protein is unknown, the effects that the different mutations have on the gene 
products in humans and the animal models are not resolved.  
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1.5 CURRENT STRATEGIES OF THERAPY FOR THE NCLS  
Because only limited information is available about the downstream effects of the mutations in the 
different NCLs, most currently investigated treatment strategies are based on replacing either the 
mutated gene or supplying the affected protein. Because the NCLs appear to affect the entire brain, 
therapies most likely need to be delivered in a manner that reaches the entire brain (Chang et al., 
2011). The blood brain barrier (BBB) limits the possibilities of systemic administration of therapies to 
the brain. Therefore, the current treatment trials for NCLs are focusing on protein or gene delivery 
directly to the brain, either through intraparenchymal injections or through delivery via the 
cerebrospinal fluid by intracerebroventricular or intrathecal injections.  
Lysosomal proteins are synthesised and glycosylated in the rough endoplasmic reticulum and 
transported through vesicular trafficking to the Golgi apparatus where they undergo post-
translational modification and sorting processes (Kornfeld, 1987). During these processes soluble 
lysosomal enzymes receive a mannose or mannose-6-phosphate and bind to a mannose-6-
phosphate receptor which allows trafficking towards the lysosome. However, approximately 5-20% 
of the lysosomal enzymes do not reach the lysosome but are secreted from the plasma membrane 
of the cell and therefore available for endocytosis by other cells (Kornfeld, 1987). After endocytosis 
these enzymes can be correctly sorted and trafficked to the lysosome. This enables the phenomenon 
called ‘cross-correction’ whereby a cell with a lysosomal enzyme deficiency can be phenotypically 
corrected though uptake and utilisation of lysosomal enzymes from other cells which are functioning 
normally (Fratantoni et al., 1968). Cross-correction has, since its discovery, been seen as a promising 
strategy for treatment of LSDs in general (Sands & Davidson, 2006). However, it is likely that 
different treatment strategies are needed for the different types of NCLs, depending on whether the 
involved gene codes for a soluble or membrane bound protein (Chang et al., 2011).  
1.5.1 Enzyme replacement therapies 
Current trials are exploring the efficacy of enzyme replacement in the NCLs. It has to be kept in mind 
that enzyme replacement is likely to have an effect only in the NCLs involving soluble proteins (e.g. 
CLN1, 2, 5, 11, 10 and 13). CLN2 disease is currently the only NCL for which experimental enzyme 
replacement therapy in mouse and dog models has led to clinical trials in children, which yielded 
encouraging results (Vuillemenot et al., 2011; Katz et al., 2014; Schulz et al., 2016). Recombinant 
CLN2 (TPP1) enzyme is now commercially available for CLN2 patients. Nevertheless, challenges are 
still to be overcome to improve the long-term feasibility for life-long enzyme replacement therapy in 
neuropathic LSDs, such as the NCLs. In non-neuropathic LSDs, like Fabray, Gaucher and Pompe 
diseases, it is possible to deliver the enzyme systemically, either by injection or orally, because it 
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does not need to cross the BBB to reach its target (see review by Ortolano et al., 2014). However in 
NCLs and other neuropathic LSDs, the target is the central nervous system (CNS) and the enzyme 
replacement trials mentioned above are based on biweekly delivery of the exogenous enzyme 
directly to the cerebrospinal fluid (CSF) through either intracerebroventricular or intrathecal 
(lumbar) catheters (Katz et al., 2014; Schulz et al., 2016). One of the dogs in the described study 
developed asymmetrical hydrocephalus and 46% of the children experienced pyrexia, both of which 
could be attributed to the implanted catheter (Katz et al., 2014; Schulz et al., 2016). Other studies 
encountered adverse effects of longitudinal intrathecal catheterisation such as meningeal infiltrates, 
catheter track inflammation, spinal cord compression, fibrosis and gliosis, and nerve fibre 
degeneration (Butt, 2011).  
1.5.2 Gene therapies 
An alternative option for the treatment of the NCLs and other LSDs is viral mediated gene therapy. 
Using a recombinant viral vector, a functional copy of the mutated or missing gene can be 
introduced to diseased cell populations, leading to endogenous expression of the missing gene 
product, and also enabling cross-correction. This is an advantage in tissues that are hard to access, 
like the CNS, because not all cells need to be transduced if sufficient amounts of the gene product 
are secreted from those that are. Viral vectors commonly used for gene therapy are the adeno-
associated viruses (AAV) (reviewed by Naso et al., 2017). Recombinant episomal DNA delivered with 
the AAV does not integrate into the host DNA and can therefore not be transferred from one cell to 
another. The effect of gene therapy is likely to decline over time as transduced cells die through 
either natural turnover or pathological events. The first successful gene therapy trial for an NCL was 
performed in a CLN1 mouse model and led to reduced storage accumulation and increased brain 
weight and cortical thickness (Griffey et al., 2004). Since then, gene therapy has been performed in 
several animal models of NCLs, including CLN2 mice, CLN3 mice, CLN2 dogs, and CLN5 and CLN6 
sheep yielding promising results (Haskell et al., 2003; Sondhi et al., 2014; Katz et al., 2015; Palmer et 
al., 2015; Mitchell, 2016; Mitchell et al., 2017). These have led to initial clinical trials in humans for 
CLN2 disease (Worgall et al., 2008), and more are currently underway (www.clincaltrial.gov; 
NCT01161576, NCT01414985). The current gene therapy research programmes in ovine CLN5 and 
CLN6 models have also yielded promising results and a human trial for AAV mediated CLN6 gene 
therapy was initiated in 2016 (NCT02725580). An important advantage of gene therapy over enzyme 
replacement therapy is the reduced need for repetition of the therapy. However, there are 
questions about possible immune responses, especially in the case of repeated treatment, as well as 
vector safety and possible risks of overexpression of the exogenous gene that need to be addressed 
(reviewed by Sands & Davidson, 2006).  
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1.6 EXPERIMENTAL RATIONALE 
The well-established ovine models of NCL have contributed greatly to NCL research over recent 
decades and current gene therapy trials are yielding promising results (Palmer et al., 2015; Mitchell, 
2016; Mitchell et al., 2017). An advantage of large animal models for translational research is the 
capacity for longitudinal in vivo monitoring of disease progression in individual animals, reducing the 
numbers of animals required and providing insight into individual variation that needs to be 
anticipated in the human population (section 1.1). Longitudinal monitoring has been fairly limited in 
ovine NCL research, especially in the descriptions of neuropathological progression of the animals, 
which has been based largely on time point observations requiring sacrifice of animals. Although in 
vivo imaging through computed tomography (CT) has been utilised in ovine NCL research for over a 
decade, the focus has been mainly on time point averages of animal groups instead of individual 
longitudinal observations (Woods et al., 1993; Bell et al., 2005; Prof. David Palmer, personal 
communication). Other imaging techniques for the longitudinal in vivo monitoring of 
neuropathology in ovine NCL have had little investigation so far. One MRI study performed on CLN6 
affected South Hampshire sheep (Sawiak et al., 2015) indicated the usefulness of this technique for 
observing the development of neuropathological events in individual sheep. However, the study was 
performed entirely on late-stage diseased animals, from 16 to 22 months of age, at which point the 
neuropathological changes are already well established (Oswald et al., 2005, 2008).  
Recently, advances have been made within the longitudinal descriptions of behavioural changes, 
cognition and neurological status in ovine NCL (Mitchell, 2016). Some of these tests rely partly on 
the ability of animals to see but do not test vision alone. Some observations have been conducted on 
the development of retinal pathology (section 1.2.7), however currently no techniques for the 
longitudinal in vivo monitoring of retinal pathology in ovine NCL are established. Recent gene 
therapy trials that yielded promising results for the treatment of brain atrophy in the sheep NCL 
models, did not halt the retinal pathology (Mitchell, 2016; Mitchell et al., 2017). 
To date, three active ovine models of NCL exist (sections 1.3.2.2; 1.4.2.2; 1.4.2.3). The CLN5 
Borderdale and CLN6 South Hampshire models are well described in terms of neuropathology and 
behavioural changes (Oswald et al., 2005, 2008; Mitchell, 2016). Behavioural changes in the CLN6 
Merino model are also well described, however the neuropathological cascade in this model is 
described in less detail than that it is in the two other models (Cook et al., 2002). To be able to utilise 
all three models fully and to compare their relative disease progression, neuropathology and 
treatment efficacy, all three models should be described to a similar level of intensity and the 
techniques for neuropathological assessment and longitudinal in vivo monitoring should be aligned.  
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1.6.1 Research aims and objectives 
The aim of this study was to establish techniques for longitudinal in vivo monitoring that can be 
correlated with the progression of neuropathological events in all three ovine NCL models, both in 
the natural progression of the diseases and in trials of potential therapeutic regimes.  
Initially there was a need to describe the neuropathology of the CLN6 Merino model using histology 
and immunohistochemistry, to provide a background of information similar to that which has been 
developed for the CLN6 South Hampshire and the CLN5 Borderdale models (Oswald et al., 2005, 
2008; Mitchell, 2016). This enabled all three sheep models to have a standard base for comparison. 
Secondly, longitudinal in vivo neuroimaging, using both CT and MRI, was employed to determine its 
utility as a monitoring tool in the different models. Standardised techniques for CT scanning were 
established for the CLN6 South Hampshire and the CLN5 Borderdale models and MRI scanning was 
explored in pilot studies involving all three sheep models. To monitor the progression of blindness, 
ERG was used for the longitudinal in vivo monitoring of retinal pathology in the CLN6 South 
Hampshire and CLN5 Borderdale models.  
Finally, the usefulness of these monitoring techniques for assessing the efficacy of experimental 
therapeutic protocols was explored in the CLN5 Borderdale model. 
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2 GENERAL METHODS 
2.1 ANIMALS 
2.1.1 Breeding regimes 
The sheep described in this study are part of the ovine NCL research flocks that are maintained at 
Lincoln University and the University of Sydney. The first CLN6 flock was established after the 
description of the disease in South Hampshire sheep in 1976 (Jolly & West, 1976), and the second 
one was discovered in 1997 in Merino sheep (Tammen et al., 2001). The CLN5 flock was established 
after the discovery of NCL in a group of Borderdale sheep in 2002 (Jolly et al., 2002). The South 
Hampshire and the Borderdale flocks are maintained through mating of heterozygous ewes with 
homozygous affected rams, which results in a 1:1 ratio of heterozygous and affected offspring born 
each year. Throughout the maintenance of the two flocks, cross breeding of affected rams with 
wildtype ewes of other breeds (Friesian, Finn and Coopworth) has been conducted to introduce new 
genetic material and thereby guarantee genetic diversity and improve sheep characteristics such as 
fertility, mothering ability and handling behaviour. This has resulted in obligate heterozygous 
offspring from which the ewes have been included in the subsequent breeding program. The CLN6 
Merino research flock is maintained by mating of heterozygous parent animals which results in a 
2:1:1 ratio of heterozygous, normal, and affected offspring.  
2.1.2 Genotyping  
Causative mutations for all the ovine NCL models have been identified (sections 1.3.3 and 1.4.3). For 
the CLN6 South Hampshire and CLN5 Borderdale genotyping, genomic DNA (gDNA) was extracted 
from Whatman FTA cards (Whatman, Brentford, Middelsex, UK) or from EDTA blood samples using 
Quick-gDNA Miniprep extraction kits (Zymo Research Corp., Irvine, CA, USA). The CLN6 South 
Hampshire genotyping is based on a gene polymorphism (c.822G>A) used as an indirect disease 
marker, which is located on the ovine CLN6 gene, 111 bp downstream from the 5’ end of exon 7 
(Tammen et al., 2006). This leads to a change in the restriction site for the enzyme HaeII, depending 
on whether the third base of a triplet coding for alanine is either A or G. The South Hampshire 
research flock is configured so that all affected animals are AA, all normal animals are GG and all 
carriers are AG. Based on this, all offspring produced in the South Hampshire flock were genotyped 
by polymerase chain reaction (PCR) amplification from gDNA, enzyme cleavage and agarose gel 
separation (Tammen et al., 2006). This method has produced reliable results over 15 years with over 
900 sheep. However, when crossbreeding is carried out to introduce new genetic material into the 
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research flock, it has to be borne in mind that screening of other breeds has shown that the A allele 
is not uncommon in wildtype animals (Tammen et al., 2006).  
The disease causing mutation in the CLN5 Borderdale flock is a single nucleotide substitution at a 
consensus splice site (c.571+1G>A), which leads to excision of exon 3 (Frugier et al., 2008). gDNA was 
extracted as described above and amplified through PCR with primers in exon 3 and intron 3 
resulting in a 538 bp product. This was then sequenced at the Lincoln University Sequencing Facility 
on an Applied Biosystems 3130cl Gene Analyser (Applied Biosystems, Foster City, CA, USA).   
The method for genotyping of CLN6 Merino sheep is based on an alteration of the cleavage site for 
the restriction enzyme HaeIII enabled by the disease causing single nucleotide substitution 
(c.184C>T) and is described in detail (Tammen et al., 2006). In brief, gDNA is extracted from EDTA 
blood samples using Qiagen DNeasy blood and tissue kit (Qiagen, Hilden, Germany) and amplified 
through PCR with primers in exon 2. The resulting 151 bp products are digested with HaeIII (New 
England Biolabs, Ipswich, MA, USA) and separated on agarose gels. The normal PCR amplicon is 
cleaved to produce a 50 bp fragment and a 101 bp fragment, but the 151 bp affected gene product 
remains un-cleaved. Heterozygous carriers have all three products (Tammen et al., 2006).  
2.2 STATISTICS 
All statistical analyses were performed in Microsoft Excel 2013 (Microsoft Corp., Seattle, WA, USA) 
and GenStat for Windows 16th Edition (VSN International 2011, Hemel Hempstead, UK). For the 
neuropathological studies, means and standard errors of the mean (SEM) were calculated for each 
set of measurements for each animal. The means were used to compare affected, normal and 
treated sheep. Depending on study design, the appropriate type of analysis of variance (ANOVA) was 
used, i.e. one way, two way or repeated measure ANOVA. Where sample sizes were too small or 
repeats were too inconsistent to allow for the use of ANOVAs, results were grouped across all ages 
and Student’s t-tests were performed to compare groups. Results were regarded as significant 
where P ≤ 0.05. The magnitude of effects were expressed either as percentage of normal or by using 
Cohen’s d as measure of effect size. These were regarded as follows: 0.2 = small; 0.5 = medium, 0.8 = 
large; 1.3 = very large. 
Cohen’s d was calculated as:  𝐶ℎ𝑜ℎ𝑒𝑛′𝑠 𝑑 =
(𝑥1 −  𝑥2)
𝑠𝑝𝑜𝑜𝑙𝑒𝑑
 
Where the pooled standard deviation was calculated as: 𝑠𝑝𝑜𝑜𝑙𝑒𝑑 = √
(𝑛1 −  1)𝑠1
2 +  (𝑛2 −  1)𝑠2
2
𝑛1 + 𝑛2 − 2
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3 NEUROPATHOLOGY IN CLN6 AFFECTED MERINO SHEEP 
3.1 INTRODUCTION  
Neuropathological studies of human NCLs are limited and mainly based on biopsy and post mortem 
findings, therefore do not describe the entire brain or development of neuropathology 
systematically. Main findings from these samples include autofluorescent storage bodies, 
progressive neuronal loss, astrocytosis and macrophage infiltration (Haltia, 2003; Jadav et al., 2014). 
Using the sheep models to investigate neuropathology at different time points will increase the 
understanding of the pathologic cascade and help identifying time windows and possible starting 
points for therapies. 
Detailed studies regarding the natural history of ovine NCL have been carried out in the CLN6 South 
Hampshire model and the CLN5 Borderdale model. The general sequence of clinical and 
neuropathological events in the two models is strikingly similar, with only a slight difference in the 
time of onset, where CLN5 affected animals show more pronounced neuropathological changes 
earlier than CLN6 affected South Hampshire sheep (Oswald et al., 2005; Kay et al., 2006; Mitchell, 
2016). 
Another form of ovine CLN6 deficiency disease has been described in Merino sheep (Tammen et al., 
2001, 2006; Cook et al., 2002). The genetic cause for the CLN6 disease in these is remarkably 
different to that of the CLN6 South Hampshire sheep, as the disease causing mutation in the Merino 
sheep is a (c.184C>T) missense mutation leading to a single amino acid change (p.Arg62Cys) whereas 
the one in South Hampshire sheep is a 402 bp deletion and 1 bp insertion (g.-251_+150del and 
g.+150_151insC) leading to the deletion of some 5’UTR, the ATG start codon and the whole of exon 
1 (Tammen et al., 2006; Mohd Ismail, 2014). However, preliminary natural history descriptions have 
shown that initial clinical signs in CLN6 Merino sheep can be detected from between 7 and 12 
months of age and that the macroscopic and microscopic changes resemble those of both the CLN5 
Borderdale sheep and the CLN6 South Hampshire sheep at end-stage disease (Cook et al., 2002).  
To date, 71 disease causing mutations of the CLN6 gene are known in humans 
(http://www.ucl.ac.uk/ncl/CLN6mutationtable.htm) and 47 of these result in variant late infantile 
NCL (vLINCL). The remainder cause type A and B forms of Kufs disease, as well as other forms of 
adult NCL, a teenage NCL and a cerebellar ataxia without blindness 
(http://www.ucl.ac.uk/ncl/CLN6mutationtable.htm). Both known forms of ovine CLN6 disease 
(Merino and South Hampshire) have been classified as models for vLINCL (Tammen et al., 2001; Cook 
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et al., 2002). Nevertheless, in the light of the wide range of mutations leading to human vLINCL it is 
important to investigate similarities and differences between these two ovine forms of CLN6 
deficiency disease.  
3.2 AIMS AND OBJECTIVES 
The primary aim of this study was to describe the neuropathology of ovine CLN6 disease in Merino 
sheep so this form of ovine NCL could be compared to the two other known forms. To achieve this, 
the investigations on brains of CLN6 affected Merino sheep and unaffected controls reflected the 
work that had been carried out previously with CLN5 Borderdale sheep and CLN6 South Hampshire 
sheep. The following themes were investigated: 
 gross pathological changes and brain atrophy 
 cortical thinning and changes in cellular architecture  
 white matter changes 
 neuroinflammation  
 neurogenesis 
 expression of the endogenous CLN5 and CLN6 proteins 
 accumulation of fluorescent storage material 
3.3  MATERIALS AND METHODS 
3.3.1 Tissue collection 
Brains from 8 CLN6 affected (CLN6-/-) Merino sheep, both male and female, and from 5 unaffected 
controls (both CLN6+/- and CLN6+/+) were included in the study (Table 3.1). The brains were collected 
at Sydney University and at Lincoln University between the years 2008 to 2015. For euthanasia, 
sheep were either anaesthetised by intravenous (IV) injection of a mixture of 0.5 mg/kg life weight 
(LW) diazepam and 5 mg/kg LW ketamine, combined in the same syringe, or stunned using a captive 
bolt device between vertebrae C1 and C2. Anaesthesia or stunning was followed by immediate 
exsanguination and formalin fixation of the brain. While most brains were fixed by perfusion and 
removed from the head afterwards, several brains were removed immediately after exsanguination 
and fixed by immersion in 10% formalin in 0.9% saline solution at pH 7.4. Perfusion fixation and 
tissue preparation was performed using the method described by Oswald et al. (2005). Using a 
gravity flow system, blood was flushed from the head through one of the carotid arteries using 0.9% 
saline solution at 37 °C. Once all blood was removed, the heads were perfused using approximately 
500 ml 10% formalin in 0.9% saline solution at pH 7.4, 37° C. Following perfusion fixation, the skulls 
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were opened and the brains removed intact. The medulla oblongata were severed transversely at a 
point perpendicular to the caudal margin of the cerebellum and the brains were weighed. The brains 
were bisected along the sagittal midline and kept in 10% formalin in 0.9% saline solution for one 
week after collection. Thereafter, the cerebral hemispheres were placed in an equilibration solution 
consisting of 10% ethylene glycol and 20% sucrose in phosphate buffered saline solution (PBS) at 4 
°C for up to one week and then stored at -80 °C until sectioning. Cryosectioning was performed on a 
freezing sliding microtome (MICROM International, Walldorf, Germany). Consecutive sagittal 50 µm 
sections were cut through the mediolateral extent of the hemispheres. The sections were 
individually placed into the wells of a 96-well plate containing cryoprotectant (30% ethylene glycol, 
15% sucrose and 0.05% sodium azide in PBS, pH 7.4) and stored at -20 °C until further processing. 
Following the definitions provided by Oswald et al. (2005), sagittal levels 1 – 5 were defined during 
cryosectioning (Figure 3.1). Different brain regions of interest can be identified on different levels 
(Figure 3.1 and Table 3.2). 
 
 
 
 
 
 
 
Table 3.1 Summary of brains available at each age for histology and immunohistochemistry 
The experiments were: Nissl staining for cortical thickness measurements Nissl; Luxol fast blue staining for 
measurements of the corpus callosum LFB, glial fibrillary acidic protein to detect astrocytes GFAP; α-D-
galactose specific isolectin IB4 from Griffonia simplicifolia to detect microglia GSB4; Polysialylated-neural 
cell adhesion molecule to detect neurogenesis PSA-NCAM; and detection of autofluorescent storage bodies 
SB. Controls were both unaffected heterozygous (CLN6+/-) and other normal (CLN6+/+) sheep.  
  Staining 
Age Genotype Nissl LFB GFAP GSB4 
PSA-
NCAM 
SB CLN5 CLN6 
≤2 
Affected - - - - - - 1 1 
Control - - - - - - 1 1 
7 
Affected 2 2 2 2 2 1 2 2 
Control 2 1 1 1 1 1 2 2 
13 
Affected 2 2 2 2 2 2 2 2 
Control 2 2 2 2 2 2 2 2 
16 
Affected 2 2 2 1 2 2 2 2 
Control 1 1 1 1 1 1 3 3 
19 
Affected 2 2 2 2 2 2 2 2 
Control 1 1 1 1 2 1 - - 
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Table 3.2 Regions of interest in the brain and sagittal levels on which the regions can be found 
Parieto-occipital cortex POC, lateral geniculate nucleus LGN, entorhinal cortex Ent, somatosensory cortex S1, 
hippocampal formation HP, frontal association cortex FC, occipital white matter Occ WM, primary visual 
cortex V1, primary motor cortex M1, caudate nucleus CN, corpus callosum Cc, cerebellum Cer. 
 POC LGN ENT S1 HP FC 
Occ 
WM 
V1 M1 CN Cc Cer 
 
Level 2 * * *           
Level 3    *          
Level 4     * * *     *  
Level 5        * * * * *  
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3.3.2 Histology 
3.3.2.1 Nissl staining 
Sections from sagittal levels 2-5 were mounted on glass slides using a chrome alum mounting 
solution (0.5% gelatine, 0.05% chrome potassium sulphate (CrK(SO4)2.12H2O) and 0.05% sodium 
azide (NaN3) in water) and air-dried overnight. Sections were dehydrated through a series of 
increasing ethanol concentrations and cleared with xylene. The sections were then rehydrated 
through a series of decreasing ethanol concentrations, washed in water and incubated in pre-
warmed Nissl solution (0.05% cresyl violet acetate, Sigma C5042, Sigma-Aldrich, St. Louis, MO, USA; 
0.05% acetic acid in water) at 37 °C for 10 min. Thereafter sections were washed in water, 
dehydrated through the ethanol gradient, cleared with xylene and coverslipped in p-xylene-
bis(pyridinium bromide) (DPX, BDH, Poole, England). 
3.3.2.2 Luxol fast blue 
Sections from sagittal levels 4 and 5 were kept in individual wells of 6-well plates, were washed in 
water, dehydrated through an increasing ethanol gradient and incubated in Luxol fast blue (LFB) 
solution (0.1% Solvent Blue 38, Sigma-Aldrich, St. Louis, MO, USA; in 95% ethanol) at 40 °C overnight. 
Sections were then rinsed in 95% ethanol, rehydrated through a series of decreasing ethanol 
concentrations and finally rinsed in water. Sections were de-stained in 0.05% lithium carbonate 
(LiCO3) for 3 min, rinsed twice with 70% ethanol and flooded with water. Finally, sections were 
mounted in 1:1 glycerol in water, air-dried briefly, coverslipped with glycerol, pressed for up to 7 
days and sealed with nitrocellulose (nail polish).  
For detection of auto-fluorescent storage bodies, level 5 sections were mounted on glass slides in 
chrome-alum solution, air-dried, coverslipped in glycerol, pressed and sealed as above.  
3.3.3 Immunohistochemistry  
All immunohistochemistry was based on an avidin-biotin amplification system and 0.05% (0.5 
mg/ml) 3, 3’-diaminobenzadine (DAB; D5637; Sigma-Aldrich) and 0.01% H2O2 in PBS was used to 
visualize staining. The following primary antibodies were used (Table 3.3): rabbit anti-cow glial 
fibrillary acidic protein (GFAP, 1:5000, Z0334, polyclonal; Dako, Ely, England) to detect astrocytes; 
rabbit anti-sheep CLN5 and CLN6 (1:500, polyclonal; Dr Stephanie Hughes, University of Otago, 
Dunedin, New Zealand) to detect the endogenous proteins; α-D-galactose specific isolectin IB4 from 
Griffonia simplicifolia (GSB4, biotinylated, 1:500; B-1205; Vector Laboratories, Burlingame, CA, USA) 
to detect microglia and mouse anti-polysialylated-neural cell adhesion molecule (PSA-NCAM, 1:1000; 
MAB5324, monoclonal; Chemicon, Temecula, CA, USA) to indicate neurogenesis and migrating 
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neurons. Secondary antibodies used were (Table 3.3): biotinylated goat anti-rabbit IgG (1:1000; 
B7389; Sigma-Aldrich) for GFAP, CLN5 and CLN6 and affinity purified biotin-conjugated IgM (1:500; 
AP500B; Chemicon) for PSA-NCAM. All antibodies were diluted in 10% normal goat serum (NGS, Life 
Technologies NZ Ltd, Auckland, NZ) in PBS containing 0.3% Triton-X (PBST).  
All immunohistochemistry was carried out on free-floating cryosections in 6-well plates on a rocking 
platform, with a volume of 3 ml of each solution in each well. All sections belonging to the same 
experiment were processed simultaneously. Sagittal levels used for each experiment were: GFAP 
and GSB4: levels 2, 4, and 5; CLN5 and CLN6: level 4 and PSA-NCAM: level 5. Sections were washed 
in PBS prior to the experiment to remove all residual cryoprotectant and each step was followed by 
three PBS washes. Endogenous peroxidase activity was quenched with either 1% H2O2 in PBS (CLN5, 
CLN6, GFAP, PSA-NCAM) or with 1% H2O2 in 50% MeOH in PBS (GSB4) for 30 min at room 
temperature. Thereafter the sections were blocked in 15% NGS in PBST for at least 60 min prior to 
incubation with the appropriate primary antibody overnight at 4 °C. After this, sections were 
incubated with the corresponding secondary antibody for 2 h, and then with ExtrAvidin horseradish 
peroxidase (HRP, 1:1000, E-2886, Sigma-Aldrich) in PBST for 2 h. Staining was visualized through 
incubation with DAB for a standardized length of time (Table 3.3). The DAB reaction was stopped by 
applying ice-cold PBS to the wells. After the final set of washes, the sections were mounted on glass 
slides using the same chrome alum mounting solution as used for histology, air-dried overnight, 
dehydrated in 100% ethanol, cleared in xylene and coverslipped with DPX.  
 
 
 
Table 3.3: Primary and secondary antibodies and standard DAB incubation times 
 Primary antibodies  Secondary antibodies, biotinylated DAB 
incubation 
time 
 
Supplier Dilution Host (1°)  Host (2°) Supplier Dilution 
CLN5 
University of 
Otago 
1:500 Rabbit  Goat Sigma 1:1000 7 min 
CLN6 
University of 
Otago 
1:500 Rabbit  Goat Sigma 1:1000 7 min 
GFAP Dako 1:5000 Rabbit  Goat Sigma 1:1000 7 min 
GSB4 Vector 1:500      5 min 
PSA-
NCAM 
Chemicon 1:1000 Mouse  Rabbit Chemicon 1:500 3 min 
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3.3.4 Microscopy 
All microscopy and imaging was carried out on a Nikon Eclipse 50i microscope with a Nikon Digital 
Sight DSFi1 camera using NIS-Elements Software (Nikon Instruments Inc., Tokyo, Japan). Cortical 
thicknesses of the following regions were measured perpendicular to the surface from the pia to the 
boundary between grey and white matter on Nissl stained sections using the x4 microscope lens: 
primary visual cortex, primary motor cortex, frontal association cortex, somatosensory cortex, 
parieto-occipital cortex, entorhinal cortex and cerebellum. The thickness of the corpus callosum was 
measured in the same manner on LFB stained sections. At least 25 measurements were obtained for 
each region. 
GFAP and GSB4 stained sections were evaluated for staining intensity of the different cortical layers 
in the primary visual cortex, motor cortex and parieto-occipital cortex as well as in the lateral 
geniculate nucleus, the hippocampus, the caudate nucleus and the occipital white matter. All images 
were taken through the x20 lens at fixed microscope settings for each experiment. From each 
cortical layer five images were taken containing cortical levels I-III and another five images were 
taken containing levels IV-VI. Five images were also obtained from each non-cortical region. The 
images were then analysed in ImageJ 1.51a (National Institutes of Health, Bethesda, MD, USA), using 
the colour thresholding function to determine the percentage of DAB staining in each image.  
PSA-NCAM sections were analysed in a descriptive manner.  
Cell counts were performed in the hilus of the hippocampus on CLN5 and CLN6 stained sections 
using the x20 lens. Stained cells were counted in 5 fields of view (FOV) for each animal. Cell counts 
were compared between CLN6-/-, CLN6+/- and CLN6+/+ animals.  
Fluorescent microscopy of storage material was performed on unstained sections using a 450-490 
nm excitation/510 nm emission filter. Digital photographs were obtained from 5 FOV of the 
cerebellum, caudate nucleus, primary motor cortex and primary visual cortex from each animal. The 
images were then analysed in ImageJ 1.51a (National Institutes of Health, Bethesda, MD, USA), using 
the colour thresholding function to determine the percentage of fluorescence in each image.  
3.3.5 Brain weight data 
Brain weights were recorded when the brains were collected for neuropathological analysis. 
Additional recordings of brain weights of CLN6-/- Merino sheep and unaffected control animals at 
post mortem examination are included (courtesy Assoc. Prof Imke Tammen and Dr Nadia Mitchell). 
These brains were collected in a similar matter as for neuropathology. 
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3.3.6 Statistical analyses 
Means and SEM were calculated from each set of measurements for each animal (% area stained, 
cortical and corpus callosum measures, number of stained cells). Student’s t-tests were performed 
to test each region separately for the effect of genotype. Two-way ANOVA were performed to test 
for the effects of genotype, brain region and upper and lower cortical layers where appropriate. P ≤ 
0.05 was regarded as significant.  
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3.4 RESULTS 
3.4.1 Brain weights and general development  
Brains of normal control sheep grew steadily from birth, reaching a mature weight of 121 g ± 3 g (n = 
17) at 18 to 20 months of age. The earliest age when brain weights were available was 3 – 4 months. 
Already at this age, the brain weight of affected animals was reduced compared with unaffected 
control animals (Table 3.4). The loss of brain mass in these animals continued, and at 12 months the 
brain weight of affected animals was reduced to 68% of that of controls. At end-stage disease, 
around 18 – 20 months of age, it was only 52% of that of controls. Only one brain weight of an 
animal over 20 months was recorded, and its brain mass was less than half of that of controls (Table 
3.4). 
 
3.4.2 Cortical thinning  
Cortical thicknesses were measured on Nissl stained sections. No cortical thinning was seen in 
control animals and the development of cortical thickness largely followed the increase in brain 
weight, whereas in affected animals cortical thinning was apparent in all regions except the 
cerebellum compared with controls (Figure 3.2) (P < 0.05). Most severe thinning was seen in the 
parieto-occipital and primary visual cortices, which were reduced to 35% and 41% respectively of 
those of normal brains at 19 months of age. Least affected were the somatosensory and primary 
motor cortices, which were reduced to 61% and 76% respectively compared with normal cortices at 
19 months. Cortical thinning was obvious on macroscopic examination of sagittal sections (Figure 3.3) 
and microscopic examination revealed that the atrophy could be observed in most cortices by 7 
months, and loss of cytoarchitecture and layer definition was observable in the primary visual cortex 
at 13 months of age and reached the motor cortex by end-stage disease at 19 months (Figure 3.3). 
However, layer V pyramidal cells could still be identified at end-stage disease. Accumulation of 
cellular aggregates at the layer I/II boundary in the primary visual cortex was evident early, at 7 
Table 3.4 Mean brain weights of affected and control sheep at different ages 
Mean formalin fixed brain weight ± SEM of CLN6-/- sheep and controls (CLN6+/- and CLN6+/+) grouped by 
age. No brains were available to be analysed at those ages where values are missing. Percentages are the 
ratio of affected to control weights. 
Age group (months) Control (g) Affected (g) Affected/Control   
3 – 4 90 ± 2 (n = 4) 73 ± 4 (n = 3) 82%  
7 – 9 101 ± 4 (n = 5) 84 ± 10 (n = 3) 84%  
10 – 12 102 (n = 1) 69 ± 3 (n = 4) 68%  
13 – 14 113 ± 4 (n = 2) 70 ± 4 (n = 5) 62%  
16 – 17 - 72 ± 6 (n = 4) -  
18 – 20 121 ± 3 (n = 17) 62 ± 2 (n = 8) 52%  
Over 20 - 57 ± 4 (n = 7) -  
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months of age, when a few aggregates could be found. From this age on the abundance of 
aggregates increased and was substantial in the primary visual cortex at 19 months of age (Figure 3.3, 
B). Cellular aggregates were also present in the parieto-occipital cortex at 13 months, in the frontal 
association cortex at 16 months and in all cortices that were investigated besides the entorhinal 
cortex at 19 months.  
There was no evidence of atrophy in subcortical structures and cerebellum. 
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Figure 3.2 Quantitative assessment of cortical thinning 
in CLN6 Merino sheep 
Brains from affected sheep (CLN6-/-) and unaffected 
controls (CLN6+/-) were assessed. For each region, the 
cortical thickness was measured from the pial border to 
the beginning of the white matter. Each point 
represents the mean thickness of 25 measurements per 
animal at different ages (7 months, 13 months, 16 
months and 19 months). Standard errors for each point 
are not displayed but were within 0.9% - 6.3% of the 
means. See Table 3.1 for n. Student’s t-test showed 
significant (P < 0.05) cortical thinning in all regions 
except the cerebellum when compared over all ages. 
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3.4.3 White matter changes 
To investigate the effects of disease on white matter, measurements of the thickness of the corpus 
callosum were performed on LFB stained sections. The thicknesses of the corpus callosum of normal 
animals increased steadily reaching their maximum (1077 µm ± 30 µm) between 15 and 18 months 
of age. Those of affected animals were normal at 7 months of age, but were reduced to 
approximately 60% of normal at 13 months of age and remained relatively stable (658 µm ± 66 µm) 
throughout the consecutive ages. This difference was significant when compared across all ages 
after the thinning was observed (P < 0.01). See Table 3.1 for n.  
3.4.4 Glial activation 
3.4.4.1 Activated astrocytes 
GFAP is a marker for activated astrocytes which are a defining feature of neuroinflammation. After 
immunohistochemical staining for GFAP, thresholding analysis was performed to quantify the 
astrocytic activation in CLN6 affected animals and controls. A low amount of GFAP staining was seen 
along the pial surface in control animals of all ages as well as throughout the grey matter and to a 
greater degree in the white matter, with quiescent astrocytes showing stellate morphology (Figure 
3.4). When compared across all ages, brains from affected animals had increased astrocytosis in all 
regions except the caudate nucleus compared with controls (P < 0.05) (Figure 3.5). The astrocytes 
present in the affected animals were hypertrophic and formed a dense network in the cortical 
layers, spreading from the outer layers (I-III) to the lower layers (IV-VI) with disease progression 
(Figure 3.4). When comparing the stained area in the different regions across all ages in affected 
animals only, the parieto-occipital (POC) and primary visual (V1) cortices had the highest amount of 
staining (POC: 25.2% ± 3.7%; V1: 24.5% ± 5.2%), followed in frequency by the primary motor cortex 
(M1: 17.4% ± 5.7%) (Figure 3.5). The areas stained in the subcortical regions such as the caudate 
nucleus (CN) and the lateral geniculate nucleus (LGN) were significantly smaller (P < 0.001) than in 
the cortical regions (CN: 4.0% ± 2.3%; LGN; 5.2% ± 2.2%) (Figure 3.5). The areas stained in the 
hippocampus and occipital white matter were 14.3% ± 3% and 14.8% ± 3.5%. For the areas stained in 
the cortical layers I-III and IV-VI, the only region in which a difference was found was the parieto-
occipital cortex, where the area stained in the upper layers (I-III: 30.6% ± 3.6%) was significantly 
greater than in the lower layers (IV-VI: 19.8% ± 4.2%) (P < 0.05) (Figure 3.5). 
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Figure 3.5 Astrocytic activation in brains of CLN6 affected Merino sheep and unaffected control animals 
Quantitative thresholding of percentage of area stained after GFAP immunostaining of sagittal sections of brains at different ages expressed as mean percentage of areas 
stained in 5 fields of view for each animal for each region. Error bars represent standard error of the mean where n ≥ 2. See Table 3.1 for n. Results of the primary motor 
cortex, parieto-occipital cortex and primary visual cortex were analysed seperately for both upper (I-III) and lower (IV-VI) laminae. 
 
0
5
10
15
20
25
30
7 13 16 19
Caudate nucleus
0
5
10
15
20
25
30
7 13 16 19
Hippocampus
0
5
10
15
20
25
30
7 13 16 19
Lateral geniculate nucleus
0
5
10
15
20
25
30
7 13 16 19
Occipital white matter
0
10
20
30
40
50
7 13 16 19
Primary motor cortex
0
10
20
30
40
50
7 13 16 19
Primary visual cortex
CLN6 -/- I-III
CLN6 +/- I-III
CLN6 -/- IV-VI
CLN6 +/- IV-VI
0
10
20
30
40
50
7 13 16 19
Parieto-occipital cortex
37 
 
3.4.4.2 Microglia 
GSB4 is a marker for activated microglia and thus for neuroinflammation. Thresholding analysis was 
performed to quantify microglial activation that was revealed by immunohistochemical staining with 
GSB4 of sagittal brain sections from CLN6 affected animals and unaffected controls at different ages. 
No activation of microglia was seen in the control animals at any of the ages (Figure 3.6). At all ages, 
brains from affected animals had increased microglial activation in all cortical regions, the occipital 
white matter and the lateral geniculate nucleus, but not in the caudate nucleus and hippocampus 
compared with controls (P < 0.05). The microglia present in the affected animals at 7 months of age 
were confined to hypertrophic clusters, mainly located in the outer cortical laminae (I-III) (Figure 3.7). 
By 13 months of age two distinct bands of activated cells were obvious, spanning most of the cortical 
mantle though layers II-III and V-VI (Figure 3.7). These bands became denser and less distuingishable 
as the disease progressed and the loss of layer definition described earlier occurred. No difference 
were observed in the staining density in upper and lower cortical layers in any of the regions (P > 
0.05).  
3.4.5 Neurogenesis  
The extent of neurogenesis was investigated through immunohistochemical staining with PSA-
NCAM, which is a marker for developing and migrating neurons. Some degree of neurogenesis was 
observed in the 7 month-old control but this was reduced in older control sheep. In contrast, the 
affected animals showed increased staining with PSA-NCAM over time, indicating ongoing 
neurogenesis and migration. The staining was largely increased in the rostral end of the SVZ of 
affected animals of all ages, showing a dense mesh of fibres in this area. Bands of migrating cells 
extending rostral and dorsal from the SVZ through the white matter tracts were observed in affected 
animals of all ages. Aggregates of densely stained cells were observed in increasing amounts at the 
layer I-II boundary of most cortical regions (Figure 3.8). 
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Figure 3.6 Activation of microglia in brains of CLN6 affected Merino sheep and unaffected control animals 
Quantitative thresholding of percentage of area stained after GSB4 immunostaining of sagittal sections of brains at different ages expressed as mean percentage of areas 
stained in 5 fields of view for each region. Error bars represent standard error of the mean where n ≥ 2. See Table 3.1 for n. Results of the primary motor cortex, parieto-
occipital cortex and primary visual cortex were analysed seperately for both upper (I-III) and lower (IV-VI) laminae. 
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3.4.7 Fluorescent storage material 
The presence of intracellular accumulation of fluorescent storage material is a hallmark of NCL. 
Thresholding analysis was performed to quantify fluorescence in CLN6-/- animals and controls. 
Minimal amounts of fluorescence were observed in control animals. Fluorescence was increased in 
affected animals compared with controls in all four regions that were assessed when compared 
across all ages (P < 0.05) (Figure 3.10), and fluorescent storage material was already present at 7 
months of age. The amount of fluorescent material was lower in the cerebellum compared with the 
caudate nucleus and the two cortical regions that were assessed (P < 0.001) and a trend of increase 
in fluorescence with age could be observed but was not significant.  
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Figure 3.10 Quantitative assessment of fluorescent storage material accumulation 
Quantitative thresholding analysis of percentage of area fluorescing on level 5 sections of brains at 
different ages. Results are expressed as mean percentage of area that is fluorescent in 5 fields of view for 
each region. Error bars represent standard error of the mean where n ≥ 2. For n see Table 3.1. Increased 
amounts of fluorescent material were visible across all ages and in all four regions assessed compared with 
controls (P < 0.05).  
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3.5 DISCUSSION 
The present study provides the first detailed description of the progressive neuropathology of ovine 
CLN6 disease in Merino sheep and allows the neuropathology of this type of ovine NCL to be 
compared to the CLN6 disease in South Hampshire sheep and the CLN5 disease in Borderdale sheep.  
The brain weights and deviation from normal measured in the present study of CLN6-/- Merino sheep 
plus the results from previous studies on CLN6-/- South Hampshire (Oswald, 2004; Mitchell, 2016) 
and CLN5-/- Borderdale sheep (Mitchell, 2016) are summarized in Table 3.5. The comparison shows 
that the brain weights from CLN6-/- Merino sheep are similar to those from CLN6-/- South Hampshire 
sheep at 4, 12 and 18 month of age and overall approximately 10 g lighter than those of CLN5-/- 
Borderdale sheep. Based on the generally larger head and body frame size of the Borderdale sheep 
compared with both Merino and South Hampshire sheep, this difference would be expected. A 
comparison of the percentage of normal brain weights between the studies reveals a discrepancy 
between the three different studies which is likely based on the composition of the control groups. 
The control animals in the present study and the study by Oswald (2004) were of the same breed as 
the respective affected sheep, however the control group in the study by Mitchell (2016) included 
both South Hampshire and Borderdale animals. This could have led to an over-estimation of normal 
brain size in the South Hampshires and an under-estimation of normal brain size in the Borderdales.  
 
The overall pattern of the cortical atrophy and changes of the cytoarchitecture seen in the Merino 
CLN6 affected sheep resembles those described in the CLN5 Borderdale and CLN6 South Hampshire 
sheep (Figure 3.2 and Figure 3.3) (Oswald, 2004; Oswald et al., 2005; Mitchell, 2016). In all three 
types, the parieto-occipital and primary visual cortices were the regions affected earliest and most 
severely by the atrophy, and the frontal association and primary motor cortices were the last cortical 
regions to be affected by the disease (Figure 3.2 and Figure 3.3) (Oswald, 2004; Oswald et al., 2005; 
Mitchell, 2016). Accumulation of cellular aggregates at the layer I/II boundary and the onset of layer 
definition loss has been observed as early as 2 months of age in CLN6 affected South Hampshire 
sheep, and at 4 months in CLN5 affected Borderdale sheep. The earliest samples taken in the 
Table 3.5 Mean brain weight of affected sheep from the three ovine NCL models 
Weights are in grams and % of normal. The information is compiled from the present study and 
Oswald (2004) and Mitchell (2016). 
 
Age group 
(months) 
CLN6-/- Merino 
(% of normal) 
CLN6-/- South Hampshire  
(% of normal) 
CLN5-/- Borderdale  
(% of normal) 
Mitchell (2016) 
 
Oswald (2004) Mitchell (2016)  
3 – 4 73 (82%) 83 (79%) 75 (81%) 82 (89%)  
10 – 12 69 (68%) 70 (74%) 68 (69%) 80 (81%)  
18 – 20 62 (52%) 63 (59%) 66 (67%) 71 (73%)  
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present study were at 7 months of age, and at this stage both of these manifestations were already 
evident. A remarkable loss of neurons from all cortical regions has been noted at end-stage disease 
in all three forms of ovine NCL, with only a few pyramidal neurons remaining (Figure 3.3) (Oswald, 
2004; Oswald et al., 2005; Mitchell, 2016). The lack of cerebellar and subcortical involvement in 
atrophic changes is also common to all three forms (Figure 3.2) (Oswald, 2004; Oswald et al., 2005; 
Mitchell, 2016).  
The present study has shown that some degree of white matter loss occurs in the CLN6-/- Merino 
sheep. The development of the corpus callosum from affected animals followed that of normal 
sheep until 7 months and thereafter the thickness was reduced to approximately 60% of that of 
normal sheep. No further thinning of the corpus callosum was seen after this. Previous studies of the 
other two NCL sheep models have described white matter tract changes as a lack of development 
rather than active degeneration (Oswald, 2004; Oswald et al., 2005; Mitchell, 2016). The present 
results show some amount of active thinning that followed the cortical thinning and did not appear 
to be ongoing. This could indicate that in the CLN6 Merino sheep, loss of white matter is also 
secondary to the cortical thinning rather than being a primary sign of disease.   
Progressively increasing neuroinflammation is one of the defining features of the NCLs (section 
1.2.5) and therefore it is not surprising that the CLN6-/- Merino sheep exhibit this. 
Immunohistochemical staining for both activated astrocytes (GFAP; Figure 3.4 and Figure 3.5) and 
microglia (GSB4; Figure 3.6 and Figure 3.7) revealed that neuroinflammation was well established at 7 
months of age. The development of neuroinflammation paralleled the pattern of atrophy described, 
and followed that described for the other two forms of ovine NCL (Figure 3.5) (Oswald, 2004; Oswald 
et al., 2005; Mitchell, 2016); the primary visual and parieto-occipital cortices being the regions that 
exhibit the earliest and strongest signs of neuroinflammation in all three ovine diseases (Figure 3.4). 
Typical bands of activated astrocytes that are observed first in individual regions, and finally span 
almost the entire cortical mantle, are a feature common to all three ovine NCL forms (Figure 3.4) 
(Oswald, 2004; Oswald et al., 2005; Mitchell, 2016).  
Ongoing neurogenesis is also a common and still largely elusive theme of the NCLs and other 
neurodegenerative diseases (section 1.2.6). PSA-NCAM staining revealed ongoing neurogenesis in 
CLN6-/- Merino sheep (Figure 3.8). Similar findings have previously been reported for both CLN6-/- 
South Hampshire sheep and CLN5-/- Borderdale sheep, as well as in mouse models of NCLs and 
human CLN6 patients, suggesting an attempted self-repair process that is instigated to counteract 
the ongoing loss of neurons in the NCLs (Dihanich et al., 2009, 2012; Mitchell, 2016). Previous 
investigations have shown that the cell aggregates which accumulate at the lamina I/II boundary in 
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the CLN6-/- South Hampshire sheep contain newly differentiated neurons (Sybille Dihanich, 
unpublished data). Similar cell aggregates were seen in the present study (Figure 3.3), which could 
support the existence of an attempted self-repair process in these animals. 
The present study has shown that the accumulation of fluorescent storage material is ubiquitous 
throughout the brain including regions with severe atrophy and neuroinflammation such as the 
cerebral cortex, but also in regions largely spared from atrophy and/or neuroinflammation including 
the subcortical structures and the cerebellum (Figure 3.10). The same pattern of global and 
increasing accumulation not limited to areas affected by other disease signs has been described in 
the two other ovine forms (Oswald et al., 2005; Mitchell, 2016). 
The present study describes the first attempt at quantification of CLN5 and CLN6 protein expression 
in ovine NCL. The pattern of CLN5 and CLN6 protein expression in normal sheep recorded here 
resembles that described by other authors, with a neuronal distribution of expression and 
representative expression of the proteins in the hippocampus (Thelen et al., 2012; Mitchell, 2016). 
CLN6 reactivity was much less pronounced than CLN5 reactivity (Figure 3.9), as has been described 
earlier (Mitchell, 2016), and could indicate either a lower amount of CLN6 protein in tissues or a 
reduced specificity of the CLN6 antibody used compared with that of the CLN5 antibody. The cell 
count revealed a tendency of reduced but not abolished CLN6 protein expression in CLN6-/- Merino 
sheep. Whether the nature of the mutation has an effect on the amount of protein detectable by 
immunohistochemistry remains elusive. One possibility is that the mutation in the Merino sheep, 
being a single nucleotide substitution, results in the production of protein that is not functional but 
is detectable with the antibody and that the mutation in the South Hampshire sheep, by deleting 
vital parts of the gene, inhibits the production of protein. The mutation in the CLN6 mutant nclf mice 
is a single base pair insertion that leads to a premature stop codon (Gao et al., 2002; Wheeler et al., 
2002) and mRNA expression of CLN6 in nclf mice is reduced to 60 – 70% compared with wildtype 
animals (Thelen et al., 2012). This supports the possibility that minor mutations could still lead to the 
production of some, probably faulty, gene product instead of no product at all.   
The results of the immunohistochemical staining for the CLN5 protein in CLN6 affected, 
heterozygous, and CLN6+/+ control animals presented here indicate a possible cross-regulation of 
these genes. This has been suggested previously, based on spatial and temporal co-expression of the 
two proteins (Mitchell, 2016). A possible interaction of CLN5 with several other NCL genes, including 
CLN6 has been proposed earlier (Lyly et al., 2009). In the present study, CLN5 protein expression was 
significantly reduced in both heterozygous and affected CLN6 Merino sheep, following a pattern of 
[CLN6+/+ > CLN6+/- > CLN6-/-] (Figure 3.9) and the same trends were seen in CLN6 South Hampshire 
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sheep (Palmer et al., 2017). This leads to the possibility that the CLN6 protein, being an endoplasmic 
reticulum resident protein (Heine et al., 2004; Mole et al., 2004), might be involved in the correct 
processing of the CLN5 protein, leading to an induced CLN5 deficiency in CLN6 affected  animals. 
This hypothesis has since been supported by results of a quantitative PCR study, showing increased 
CLN5 mRNA expression in both CLN6+/- and CLN6-/- South Hampshire sheep (Palmer et al., 2017). This 
could be interpreted as a compensatory attempt to counteract the reduced CLN5 protein 
expression. Despite the large differences between the mutations in the CLN6 gene of the Merino 
model (c.184C>T; p.Arg62Cys) and the South Hampshire model (g.-251_150del and g.+150insC), this 
phenomenon appears to be present in both breeds and might therefore be regarded as a part of the 
CLN6 disease rather than a breed specific issue.  
Despite the large differences in the two CLN6 mutations, the Merino CLN6 model has a natural 
disease history similar to the South Hampshire CLN6 and the Borderdale CLN5 models. The following 
main themes characterise the disease in all three ovine NCL models: gross brain atrophy, mainly 
through cortical thinning and increasing neuroinflammation indicated by glial activation, which 
follows a very similar pattern of development in all models and spans the entire cortical mantle at 
end-stage disease; ongoing neurogenesis that could be interpreted as an attempt at self-repair to 
counteract an ongoing loss of neurons; and finally accumulation of fluorescent storage material in all 
regions of the brain, including the cerebellum which is otherwise largely spared of the pathological 
changes. The similarity in neuropathology within the three types of ovine NCL is also reflected in 
extensive similarities within the clinical development of disease. In all three models, progressive loss 
of vision and mild behavioural changes such as baulking and low carriage of the head are the first 
clinical signs to be identified between 5 and 12 months of age (Cook et al., 2002; Mitchell, 2016). 
Following these, affected sheep of all three breeds develop progressive loss of mentation, increased 
somnolence, increasing proprioceptive dysfunction, loss of body condition and they all reach 
premature death at 18 to 24 months of age (Cook et al., 2002; Mitchell, 2016). 
Looking forward, these results are encouraging for translation to possible treatment trials in 
humans. Despite the large differences between genetic backgrounds of the three ovine NCL models, 
the neuropathological pathways that will need to be addressed in the development of therapies for 
humans are largely similar and thus treatment might not have to be tailored to the individual types 
of mutation. The same is likely to be true for a potential cross-regulation between the CLN5 and 
CLN6 protein expression, as it is possible that a single treatment regime could be effective for both 
types of NCL.  
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3.6 CONCLUSION 
 The neuropathology of ovine CLN6 disease in Merino sheep largely follows the same 
progression as that of CLN6 South Hampshire sheep and CLN5 Borderdale sheep. 
 Gross atrophy of the brain is slightly more pronounced in CLN6 Merino sheep compared 
with the other two forms of ovine NCL.  
 CLN6 protein is present in CLN6 affected Merino sheep.  
 The occurrence of some CLN5 protein expression in CLN6 affected Merino sheep 
indicates a connection between or a possible cross-regulation of the CLN5 and CLN6 
proteins.  
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4 CT SCANNING IN NCL SHEEP MODELS 
4.1 INTRODUCTION 
Previous investigations have indicated that ovine NCL leads to a reduction of intracranial volume 
(ICV) through ongoing ossification within the skull as it adapts to the atrophying brain (Bell et al., 
2005). Although CT scanning and calculations of ICV have been used previously in ovine NCL 
research, this theory has never been validated. The method for measuring ICV has been based on 
hand tracing of the inner outline of the braincase followed by integration of the area and a 
polynomial approach to determine start and end points of the brain (Kay et al., unpublished). This 
technique was used on CT images obtained through scans with a slice interval of 5 mm, however this 
is a relatively large slice interval and hand tracing of areas provided only a rough estimation of actual 
ICV, with a substantial risk of inter-observer variance. Furthermore, the assessment of ventricular 
spaces also can be inaccurate when calculated from image sets with a high image interval. This 
inaccuracy is likely to be exacerbated if the positioning of the head in the scanner is not consistent 
between scans, so that images cannot be registered on the same anatomical location.  
4.1.1 Brain and intracranial volume changes 
Many physiological factors influence the brain size of an individual. Body mass and size correlate 
with brain size in most species and sexual dimorphism in these measurements appears to be more 
pronounced in humans than in sheep (Ebinger, 1974; Gur et al., 1991; Courchesne et al., 2000; Good 
et al., 2001; Edland et al., 2002; Lenroot & Giedd, 2010; Nuruddin et al., 2013; Nitzsche et al., 2015). 
The cranial vault of humans increases rapidly in the early years of childhood while the brain is 
growing, reaching 70% of its maximal size at 5 years of age and its maximal size at around 16 years 
(Sgouros et al., 1999; Courchesne et al., 2000). Thereafter, the brain volumes of healthy human 
subjects slowly decline throughout normal aging (Courchesne et al., 2000). Remodelling of the skull 
is uncommon in human aging and dementia and it is generally assumed that the ICV reflects the 
maximal brain volume (Courchesne et al., 2000; Farias et al., 2012).  
Brain atrophy and cerebroventricular  enlargement are defining features of NCL in humans, sheep 
and other animals (Jolly & West, 1976; Armstrong et al., 1983; Jolly et al., 1989; Haltia, 2003; 
Anderson et al., 2013). In vivo imaging techniques, such as MRI and CT, have been used to monitor 
the development of brain size and intracerebroventricular volume in both human and ovine NCL 
(Valavanis et al., 1980; Woods et al., 1993; Lobel et al., 2013; Jadav et al., 2014; Sawiak et al., 2015; 
Dyke et al., 2016).  
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4.1.2 Tissue density and its translation to radiodensity 
Different tissues have different abilities to attenuate radiation, i.e. different degrees of radiodensity. 
The CT number or Hounsfield unit (HU) provides quantification of the extent to which a tissue 
attenuates x-rays. The HU scale was introduced by, and is named after, Sir Godfrey Hounsfield who 
invented the CT scanner in 1972. Air is placed at the bottom of the scale with an HU value of -1000, 
water has an HU value of zero and most tissues are represented by HU values between 20 and 60. 
Dense materials such as bone have high HU values, of 500 or more (Hounsfield, 1980). The different 
HU values of tissues can therefore be used to identify boundaries between adjacent tissues with 
different radio-densities. However the apparent HU value of a tissue might vary between scanners 
depending on their calibration and scan settings. Human brain HU values range between 20 and 50, 
and those of cerebrospinal fluid (CSF) vary between -5 and 20 (Arimitsu et al., 1977; Hacker & 
Artmann, 1978). Neurodegeneration may influence the radiodensity of brain tissue. An increase in 
radiodensity of brain tissue was found in both a sheep and a dog model of NCL (Armstrong et al., 
1983; Woods et al., 1993). 
4.2 AIM AND OBJECTIVES 
The aim of this study was to improve the resolution, discrimination and accuracy of longitudinal 
monitoring of ICV and cerebroventricular volumes though in vivo CT imaging in ovine NCL research.  
To reach these goals, the methods of image analysis needed to be improved and semi-automated. 
Next, the relationship between ICV reduction and brain atrophy was investigated. Finally, a 
longitudinal study of unaffected control sheep and CLN5 and CLN6 affected sheep was undertaken 
using these methods.  
  
 
 
50 
 
4.3 MATERIALS AND METHODS 
4.3.1 Identifying Hounsfield units of sheep brain tissue and CSF on historical data 
To improve accuracy and consistency and to increase automation of ICV data analyses, the 
radiodensity (Hounsfield units, HU) of sheep brain tissue and CSF spaces had to be identified. The 
radiodensity of different human tissues is displayed in Table 4.1.  
 
CT scans of 72 sheep were analysed to determine the HU values for brains and CSF. These included 
both males and females, aged between 3.6 and 68.4 months that were CLN5 heterozygous and 
homozygous Borderdales, CLN6 heterozygous and homozygous South Hampshires, and unrelated 
control animals of other breeds (Coopworth and Romney-crosses). All image sets were obtained on 
a GE Prospeed CT scanner (GE Healthcare, Hyogo, Japan) between 2007 – 2015. Images were 
analysed in ImageJ (Rasband, ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA). 
From each image set, five images were selected to measure the HU values of CSF-filled spaces based 
on image quality and visibility of the lateral cerebral ventricles. On each of these images, an ellipsoid 
area within each of the lateral cerebral ventricles was chosen based on visibility and uniformity of 
tissue type within the area. The HU values of these areas were measured using the measurement 
tool in ImageJ (Figure 4.1). The same procedure was used to determine the HU of brain tissues (Figure 
4.1), where a minimum of 2 circular areas were selected on the same five images used for the 
ventricular measurements. Following that, the 99.9% confidence intervals representing the range of 
HU values of brain tissue and CSF spaces were determined.  
 
Table 4.1 Radiodensity of different body materials  
Modified from Hounsfield (1980). 
Hounsfield Units Material  
-1000 Air  
-90 to -70 Adipose  
0 Water  
20 to 60 Tissue (other than adipose and bone)  
>500 Bone  
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A  
 
B  
 
 
Figure 4.1 Representative brain CT image of a 12-month-old Coopworth sheep  
Coronal plane. A) The Hounsfield unit (HU) value of brain tissue was measured in areas only containing 
brain tissue (red circles). B) HU value of cerebrospinal fluid spaces was measured within the lateral 
ventricles (blue circles). 
 
4.3.2 Comparing CT-based ICV and water displacement volume of brains and measuring bone 
thickness on CT scans 
The use of CT-based measurement of ICV is a well-established tool to measure brain size in ovine 
NCL research. It has been assumed that the ICV reflects the brain size in NCL affected animals and 
controls and that a constant ossification of the cranial vault occurs in affected animals. This theory is 
supported by post mortem findings, where the skulls of affected animals appear thicker than those 
of controls (Martin Wellby, personal communication). However, it has not been established whether 
the ongoing ossification of the cranial vault is a symptom or a cause of brain atrophy in ovine NCL.  
This experiment aimed to verify the relationship between brain size and ICV in NCL affected sheep 
and unaffected controls. Furthermore, the occurrence and rate of ossification of the cranial vault in 
NCL affected sheep was investigated. Finally, the effect of disease status on the specific gravity of 
brain tissue was explored.  
4.3.2.1 General scanning protocol and 3-dimensional reconstruction  
All CT scans included in this thesis were conducted on a GE Prospeed CT scanner (GE Healthcare, 
Hyogo, Japan, year 1997). The scans were helical using 120 kV, 100 mA, 1 mm slice thickness and 1 
mm slice interval. Image analyses were performed in 3D Slicer 4.3.1 freeware 
(http://www.slicer.org) (Fedorov et al., 2012). For 3-dimensional (3-D) modelling the ‘editor’ module 
was used to produce label maps of the regions of interest. The previously established HU thresholds 
(section 4.3.1) were used to identify brain tissue and CSF spaces. To measure the entire ICV 
(consisting of both brain tissue and CSF spaces), the ‘threshold paint’ tool was used with the HU 
threshold [-12;56], followed by manual corrections for beam hardening and other scanning artifacts. 
The ICV was labelled from the first image containing the olfactory bulbs to the first image containing 
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only spinal cord. A 3-D model of the ICV was created using the ‘MakeModelEffect’ tool and its 
volume was recorded. The volumes of the lateral and third cerebral ventricles (hereafter referred to 
as ventricular volume) were measured using the previously established HU threshold for CSF space [-
12;23] (section 2.3.1), followed by manual correction and measurement of the 3-D model volume, as 
described above for the ICV. The other CSF filled spaces (the fourth cerebral ventricle, cerebellar 
aqueduct, and subarachnoid spaces) were not included in the CSF space measurements because the 
resolution of the CT scans was insufficient for accurate discrimination between brain tissue and CSF 
in these areas.  
4.3.2.2 CT measurements and water displacement volumes 
All sheep that were killed at the Sheep Research Unit at Lincoln University over a period of 6 months 
were included in this study. These were a heterogeneous group of 25 male and female sheep of 
different breeds, aged 8 to 69 months, including 11 NCL affected animals and 14 unaffected 
controls. Following exsanguination, the heads were CT scanned and the ICVs and cerebroventricular 
volumes were measured following the protocol described above (section 4.3.2.1). Following CT 
scanning, the dorsal parts of the skulls were removed using a hatchet. The meninges were opened, 
and the brains were removed, leaving the pituitary glands, olfactory bulbs, and the dura mater 
behind. The spinal cords were severed transversely at a point perpendicular to the caudal margin of 
the cerebellum, the fresh brain weights recorded, and the brains were then kept at room 
temperature. Within four hours of collection, brain volumes were measured using a water 
displacement method. For this, a horizontal line was drawn on the outside of a glass beaker, which 
was then filled with water at room temperature to this line. After placing each brain in the water, 
which caused the water level to rise as the brain sank, water was removed using a pipette, until it 
was back to its initial level and the removed volume was recorded. The ratios of ICV to brain volume 
were calculated for both affected and normal sheep. The specific gravity of each brain was 
calculated by dividing the fresh brain weight by the water displacement volume. The effect of 
disease status on ICV measures, volume displacement results, ratio of ICV to brain volume and 
specific gravity was investigated. 
4.3.2.3 Skull growth measurements on CT images 
A group of 12 animals consisting of CLN6 affected (n = 3) and unaffected (n = 3) South Hampshire 
sheep and CLN5 affected (n = 3) and unaffected (n = 3) Borderdale sheep, all females, were CT 
scanned bimonthly for 15 months to monitor changes of ICV (see section 4.3.3). Skull thicknesses 
were measured at age 5, 9, 13 and 17 months. Measurements were performed using 3D Slicer 4.3.1 
freeware (http://www.slicer.org) (Fedorov et al., 2012). Initially, each set of images was manually 
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realigned to a standard orientation using the ‘transform’ module, where zero was placed at the 
anterior commissure and the dorsal surface of the skull was horizontal (Figure 4.2). Bregma (the 
intersection of the sagittal and coronal suture lines between the frontal and parietal bones) was 
located on the CT scans. Two measurements were taken of the frontal bone, 1 cm rostral to Bregma 
and 1 cm to either side of the mid line and two measurements were taken of the parietal bone, 
placed 2 cm caudal of Bregma and 1 cm either side of the mid line. Window and level were set to 80 
and 40 HU for all measurements and the measurements were taken in the coronal plane 
perpendicular to the axial plane (Figure 4.2). The average frontal and parietal bone thicknesses were 
calculated from the two measurements for each animal along with the average growth from 5 to 17 
months in NCL affected animals and controls.  
  
A  
B  
C  
 
 
 
 
Figure 4.2 Skull thickness measurements on computed tomography (CT) images  
Axial (red slices), sagittal (yellow slices) and coronal (green slices) views of sheep brain CT scan.  
A) Standardised realignment of images with slice intersection in the anterior commissure (crosshair).  
B) Identification of Bregma (crosshair). C) An example of a measurement of the thickness of the parietal 
bone.   
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4.3.4 Quantitative longitudinal monitoring of changes of ICV and cerebroventricular volume in NCL 
affected sheep and control animals 
After the correlation between ICV and brain volume and 3-D modelling techniques were established, 
these were used to follow a cohort of animals through a longitudinal study to investigate the 
changes of ICV and ventricular volume in CLN5 and CLN6 affected animals and normal controls.  
All experiments were performed in accordance with the Lincoln University Code of Ethical Conduct 
for the Use of Animals (CEC) and the New Zealand Animal Welfare Act 1999 and approved by the 
Lincoln University Animal Ethics Committee. A total of 24 animals were included, consisting of two 
age groups, animals born in 2014 (n = 12) and 2015 (n = 12). Each group of 12 contained CLN6-/- (n = 
3) and CLN6+/- (n = 3) South Hampshire sheep and CLN5-/- (n = 3) and CLN5+/- (n = 3) Borderdale 
sheep. All affected sheep (n = 6) in the 2014 group were males whereas all unaffected sheep (n = 6) 
were females. All sheep in the 2015 group were females (Table 5.1). The sheep were aged between 3 
and 5.8 months when first scanned and scans were performed every 8 weeks until an age of 15 to 19 
months, depending on clinical condition. The sheep were kept outdoors within corresponding mobs 
in a pasture based system. Prior to each CT scan the sheep were fasted for 18 – 24 h and weighed. 
On the day of CT scanning the sheep were anaesthetised by IV injection of a mixture of 0.8 mg/kg 
LW diazepam (Pamlin injection, Troy Laboratories NZ Pty Ltd, Auckland, NZ) and 17 mg/kg LW of 
ketamine hydrochloride (Phoenix Ketamine injection, Phoenix Pharm Distributors Ltd, Auckland, NZ). 
The sheep were intubated and placed on a wooden stretcher in dorsal recumbency and the stretcher 
was placed in the CT scanner. A series of helical scans of the head were performed for each sheep 
following the general scanning protocol described in section 4.3.2.1. After the scanning was 
completed, the general anaesthesia was maintained by inhalation of isoflurane in oxygen (1.5% – 3% 
v/v to effect), as the sheep underwent other tests (Chapter 5). Following completion of these, the 
sheep were extubated and taken to a padded wake-up area where they remained under observation 
until they had recovered. After this the sheep were returned to their corresponding mobs. All 
processing of images and volumetric measurements were performed as described earlier (4.3.2.1). 
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4.3.5 Statistical analyses  
Means and corresponding SEM were calculated for all measures, either group wise or per time 
point. The measures of radiodensity and the measures of CT based ICV measurements and water 
displacement volumes of brains were compared group wise (affected vs. control) using Student’s t-
test to investigate significance and Cohen’s d to evaluate effect size. The measures from the 
longitudinal investigations were grouped by breed and genotype (i.e. CLN5+/-, CLN5-/-, CLN6+/-, CLN6-/-
) and the repeated measurements were allocated into age-groups (3 months, 5 months, 7 months, 
…, 19 months). Means and corresponding SEM were calculated for ICV and ventricular volumes at 
each age of each group of animals and repeated measure ANOVAs were performed on longitudinal 
data. The change in ICV was calculated for each animal for each period (3-5 months, 5-7 month, …, 
17-19 months) and the mean accumulative ICV gain or loss from 3 to 17 months ± SEM was 
determined for each genotype and evaluated for effect size using Cohen’s d and for significance 
using Student’s t-test as described earlier (section 2.2).  
  
Table 4.2 Summary of numbers of animals used 
Genotype 
Breed 
Disease status Sex Age 
  3 months 5 – 17 months 19 months 
CLN5+/- 
Borderdale 
 Female 3 6 3 
Unaffected Male 0 0 0 
 Total 3 6 3 
CLN5-/- 
Borderdale 
 Female 3 3 1 
Affected Male 0 3 1 
 Total 3 6 2 
CLN6+/- 
South Hampshire 
 Female 3 6 3 
Unaffected Male 0 0 0 
 Total 3 6 3 
CLN6-/- 
South Hampshire 
 Female 3 3 1 
Affected Male 0 3 1 
 Total 3 6 2 
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4.4 RESULTS 
4.4.1 Radiodensity of brain tissue and CSF spaces 
The radiodensity of brain tissue in NCL affected animals was greater than that of brain tissue from 
unaffected control animals. There was no such difference in the density of CSF filled spaces (Table 
4.3). The mean brain tissue radio density including both affected and unaffected animals was HU 
39.5 with a standard deviation of 5.2 and thus 99.9% of the brain tissue was represented by the HU 
interval [24;56]. Likewise, 99.9% of CSF spaces was represented in the HU value interval of [-12;23].  
 
4.4.2 Volumetric measurement by CT and water displacement 
Brain volumes measured by water displacement and ICVs measured from CT scans were both lower 
for NCL affected animals compared with those of controls (Table 4.4). The measurements of ICVs and 
brain volumes in unaffected control animals closely matched, but the ICVs of NCL affected animals 
measured by CT scanning were approximately 4 ml larger than the compatible brain volumes 
measured by displacement. Based on this, the ratio of ICV to brain volume was larger in NCL affected 
animals compared with unaffected controls (Table 4.4). NCL affected animals showed a trend of 
increased growth of both the parietal and the frontal bones between the age of 5 and 17 months 
(Figure 4.3). Disease status had no effect on the specific gravity of the brain (Table 4.4). 
 
Table 4.3 Radiodensity of sheep brain tissue and CSF filled spaces 
Radiodensity expressed in Hounsfield Units (HU) of brain tissue and cerebrospinal fluid (CSF) filled spaces of 
NCL affected and unaffected control sheep. Significance was tested by two-sided Student’s t-tests. 
Tissue Disease status HU (mean ± SEM)  Student’s t-test  
Brain tissue 
NCL affected (n = 42) 40.3 ± 0.3 
P = 0.037 
 
Unaffected control (n = 14) 38.4 ± 0.8    
CSF 
NCL affected (n = 42) 5.6 ± 0.5 
P = 0.8 
 
Unaffected control (n = 18) 5.5 ± 0.6  
Table 4.4 Brain and intracranial volume comparisons 
Volumetric brain measurements of NCL affected (n = 11) and unaffected control (n = 14) sheep. Intracranial 
volumes (ICV) measured on CT scans and brain volumes (Volume) measured by water displacement. P ≤ 
0.05 regarded as significant. 
Measurement Affected (mean ± SEM) Control (mean ± SEM) Significance 
ICV (ml) 80.5 (± 2.3) 99.9 (± 1.7) * 
Volume (ml) 76.5 (± 2.1) 101.1 (± 1.7) * 
Ratio ICV:Volume 1.06 (± 0.02) 0.99 (± 0.01) * 
Specific gravity of brain tissue (g/cm3) 0.98 (± 0.2) 1.01 (± 0.01)  
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4.4.3 ICV and ventricular volume measurements 
The progress of changes in ICV of Borderdale sheep is summarised in Figure 4.4. By 3 months, the 
mean ICV of NCL affected Borderdale sheep was smaller than that of unaffected age- and breed 
matched controls (Figure 4.4.A). This difference became significant at 5 months and stayed this way 
until the end of the trial period. The accumulative change of ICV in CLN5+/- control animals showed 
an initial increase between 3 and 5 months, then a plateau until approximate nine months, followed 
by another growth phase, until another plateau from about 15 months of age (Figure 4.4.B). The 
accumulative ICV change of CLN5-/- sheep followed a similar trend as that of control animals in the 
first few months, volume increasing between three and five months. Thereafter the volume 
decreased, plateaued between seven and eleven months, then decreased rapidly until the end of 
the trial period at 19 months (Figure 4.4.B). CLN5-/- sheep lost a total of 6.7 ± 2.6 ml between 3 and 17 
months, while control sheep gained 2.7 ± 1.6 ml.  
Changes in the ICVs of South Hampshire sheep are summarised in Figure 4.5. No significant 
differences were found between the mean ICVs of NCL affected animals and controls, but a trend of 
reduction could be seen in the ICV of CLN6-/- animals (Figure 4.5.A). The accumulative change of ICV 
in CLN6+/- control animals showed a pattern similar to that of CLN5+/- animals. A slow phase of ICV 
gain was seen until the age of approximately 10 months, followed by a short steep ICV increase until 
approximately 15 months, when the ICV plateaued (Figure 4.5.B). The accumulative change of ICV in 
CLN6-/- animals followed the initial increase seen in control animals, then declined slightly between 5 
and 7 months, plateaued until approximately 10 months of age and then declined rapidly until the 
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Figure 4.3 Growth of frontal and parietal bones 
Accumulated growth (mean ± SEM) in thickness of frontal and parietal bones of NCL affected animals (NCL 
affected, n = 6) and unaffected control animals (Control, n = 6) measured on CT scans at 5, 9, 13 and 17 
months of age. 
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end of the trial period at 17 months (Figure 4.5.B). A total ICV loss of 5.8 ± 2.5 ml was seen in CLN6-/- 
sheep between 3 and 17 months, while controls gained 3.8 ± 1.2 ml ICV over the same period.  
The mean ventricular volumes of CLN5-/- animals were significantly larger than those of controls 
throughout the entire trial period (Figure 4.6.A), and although the mean ventricular volumes of  
CLN6-/- animals tended to be higher than those of controls throughout the entire trial period, this did 
not become significant until 17 months (Figure 4.6.B). There were no significant differences between 
any of the ventricular volumes for any single genotype at any age.  
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Figure 4.4: ICV development of CLN5 sheep 
ICV development of CLN5-/- and CLN5+/- Borderdale sheep between 3 and 19 months (for n see Table 5.1). 
A) Mean ICV ± SEM at different ages (* indicating significance at P ≤ 0.05).  B) Mean accumulative ICV gain or 
loss (± SEM, dotted lines) from 3 months of age. 
A 
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Figure 4.5: ICV development of CLN6 sheep  
ICV development of CLN6-/- and CLN6+/- South Hampshire sheep between 3 and 17 months (for n see Table 
5.1). A) Mean ICV ± SEM at different ages. B) Mean accumulative ICV gain or loss (± SEM, dotted lines) from 
3 months of age. 
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Figure 4.6: Cerebroventricular  volumes of CLN5 and CLN6 sheep 
Volumes of intracerebral ventricles (lateral and third ventricles combined) of CLN5-/- and CLN6-/- animals 
and heterozygous controls (for n see Table 5.1). A) Mean ventricular volumes (± SEM) of CLN5-/- and 
CLN5+/- animals. B) Mean ventricular volumes (± SEM) of CLN6-/- and CLN6+/- animals. Significance indicated 
with * where P ≤ 0.05.    
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4.5 DISCUSSION 
Neuroimaging has been part of disease monitoring in ovine NCL research for a long time but, until 
recently, the methods were basic and mainly focused on time-point analysis rather than longitudinal 
monitoring of individual animals. This study set out to improve and automate methods of image 
analysis, establish the relationship between the reduction of ICV and brain atrophy and describe the 
pattern of ICV change in CLN5 affected Borderdale, CLN6 affected South Hampshire, and unaffected 
control sheep.  
The range of the radio-densities of brain tissue and CSF spaces in NCL affected sheep and unaffected 
controls were identified to improve and partly automate image analysis. Increased radiodensity, 
measured in HU, of brain tissue was observed in affected animals compared with controls and this 
has also been described in other models of both ovine and canine NCL (Armstrong et al., 1983; 
Woods et al., 1993). The specific gravity of brain tissue, however, was not increased in affected 
animals compared with controls, which stands in contrast to the description of brains at post 
mortem examination, where the brains of NCL affected sheep appear firmer than those of normal 
sheep (Jolly et al., 1989). The range of HU values representing brain tissue and CSF spaces reported 
here are in close agreement with findings from similar investigations in humans, where the mean HU 
value of grey matter was 39, that of white matter 32 and that of CSF ranged between -5 and 20 
(Arimitsu et al., 1977; Hacker & Artmann, 1978). These results have enabled semi-automated 
analyses of CT scans for longitudinal monitoring of treatment trials.  
The comparison between CT based volumetric measurements of the cranial vault and brain volume 
measured by water displacement yielded satisfying results. The ratio of ICV to brain volume in 
normal sheep was close to 1 in this study. However, the ratio for NCL affected animals was 1.06, 
which was larger than in normal sheep and the measurements therefore show a gap between the 
ICV and brain volume. The reduction of ICV in NCL affected animals that was seen in the present 
study supports the theory of an ongoing ossification of the skull in these animals, however the larger 
ratio of ICV to brain volume shows that the brain atrophy preceded the ossification and that 
therefore the ossification was not a causative reason for brain atrophy, but rather a symptom of it. 
An increased space between the atrophied brain and the cranial vault of NCL affected sheep has 
been reported earlier (Cook et al., 2002).  
The trend of increased accumulative growth of the parietal and frontal bones of NCL affected 
animals found in the present study is supported by post mortem observations and is in line with the 
decrease of ICV in NCL affected animals presented here. However, the mechanism, molecular 
background and regionality of the skull thickening are still poorly understood, and the current study 
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was limited by low image quality and spatial resolution. In human NCLs and other forms of 
dementia, remodelling of the skull is unusual and is mainly seen as part of diseases that also affect 
other parts of the skeleton like mucopolysaccharidosis and other skeletal dysplasias (Jelin et al., 
2017). More detailed investigation into the molecular mechanism and the regional changes are 
needed to fully understand the dynamics of ICV changes in ovine NCL or NCL in other species. 
Overall, the measurements of ICV, brain volume and specific gravity reported here are similar to 
those found by others. Previous studies have used a volumetric measurement device to determine 
the displacement volume of different tissues of the human head and found that the human brain 
tissue density was 1.08 ± 0.003 g/cm3 (Barber et al., 1970). Others have estimated the total brain 
volume of six domestic sheep based on their fresh brain weight and an assumed brain tissue density 
of 1.036 g/cm3, which resulted in an estimated brain volume range from 96.4 to 120.7 ml (Ebinger, 
1974).  
It has long been established that both CLN5 and CLN6 affected sheep exhibit a loss of brain size (Jolly 
& West, 1976; Jolly et al., 1982, 2002), nevertheless longitudinal monitoring is essential to describe 
the rate of this change. As the brain size is greatly affected by overall body size (Ebinger, 1974; 
Courchesne et al., 2000; Edland et al., 2002), large individual variations were also expected in the 
measurements of ICV, which might overshadow disease effects. Assessment of the rate of change 
instead of actual volumes (Figure 4.4 and Figure 4.5) yield a better understanding of disease 
mechanisms by eliminating the effects of initial body and brain sizes. This becomes particularly clear 
when comparing the mean ICV data of CLN5 Borderdale and CLN6 South Hampshire sheep, which 
are two breeds that differ in both build and size. In this trial, CLN5-/- animals could easily be 
distinguished from CLN5+/- animals based on ICV at three months (Figure 4.4). This was not possible in 
CLN6 animals until the very end of the trial period, as the mean ICV of CLN6 affected animals was 
similar to that of controls for longer (Figure 4.5). However, the patterns of ICV change in different 
genotypes become obvious when analysing the accumulative change instead of the mean volume. 
With this, it is possible to distinguish affected animals from controls from a young age. For both 
CLN5 and CLN6 sheep, this trial showed that the ICV of affected animals only changed minimally 
until the approximate age of 10 months, which can be described as an absence of gain rather than 
an active loss, while the ICV of control animals steadily increased throughout the same period. After 
this ICVs were reduced in both CLN5-/- and CLN6-/- animals, while the ICVs of control animals 
plateaued.  
The volumes of the third and lateral ventricles of all four genotypes stayed relatively stable 
throughout the entire trial period. The ventricular volumes of CLN5-/- animals were larger than those 
 
 
63 
 
of controls and a similar trend was observed in CLN6-/- animals, however, this was only significant in 
the very end of the trial period. Overall, ventricular enlargement was more pronounced in CLN5-/- 
animals than in CLN6-/- animals, which may indicate a different pattern of brain atrophy in the 
different types of ovine NCL. Recently, a high-resolution sheep brain MRI atlas has been established 
based on the brains of 18 sheep and the study found the mean volume of the lateral and third 
ventricles combined was approximately 4.9 ml (Ella & Keller, 2015; Ella et al., 2017). The results 
presented here indicate that the resolution of the CT scanner used is not sufficient to accurately 
discriminate tissue borders for small CSF filled spaces, as the range of measurements was wide and 
the ventricular volume of individual sheep in this study could change dramatically between study 
dates.  
4.6 CONCLUSION 
  The CT based measurement of intracranial volume is a valid surrogate measure for brain 
size in both normal and NCL affected sheep. 
 The ossification of the cranial vault is increased in ovine NCL. 
 The pattern of change of intracranial and cerebroventricular volumes of healthy sheep and 
sheep with ovine NCL have been described. 
 These volumetric measures follow the clinical development of ovine NCL and are promising 
tools to use in the assessment of therapy trials.  
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5 ELECTRORETINOGRAPHY AND FUNDUS PHOTOGRAPHY IN OVINE NCL 
5.1 INTRODUCTION 
Since the eye develops as an evagination of the diencephalon in the early development of the 
nervous system in vertebrates, the retina is essentially an extension of the brain (Chow & Lang, 
2001). It is therefore not surprising that blindness is a defining feature of ovine as well as human 
NCL. In the human disease, blindness is often one of the first presenting clinical signs (Haltia, 2003; 
Weleber et al., 2004). Blindness in NCL consists of a central and a peripheral component, as both the 
visual cortex and the retina are affected. The primary visual cortex in sheep shows significant 
reduction in grey matter thickness that is relatively consistent within all three types of ovine NCL (i.e. 
Merino CLN6, South Hampshire CLN6 and Borderdale CLN5) (Mayhew et al., 1985; Cook et al., 2002; 
Oswald et al., 2005; Mitchell, 2016; Chapter 3). In both humans and sheep, retinal involvement leads 
to an almost complete loss of rods, cones, outer nuclear layer and outer plexiform layer, whereas 
the inner layers of the retina are spared from the atrophy (Goebel et al., 1974; Jolly et al., 1982; 
Graydon & Jolly, 1984; Mayhew et al., 1985). Sheep have a mixed retina type similar to humans 
(Nilsson et al., 1973).  
Electroretinography (ERG) is used to measure electrical potentials arising from the retina when 
subjected to a light stimulus. By using a surface electrode placed on the cornea as well as a 
reference and an earth electrode placed on the skin around the eye, these potentials can be 
detected and displayed on an oscilloscope. The reading consists of an a-wave that indicates the 
stimulation of the photoreceptors, a b-wave that originates from the post-synaptic bipolar cells of 
the inner retina and a c-wave that arises from the retinal pigment epithelium and photoreceptors 
(Figure 5.1) (Brown & Wiesel, 1961; Brown, 1968). For each wave two measurements can be 
obtained. One is the latency, which is the duration of time from the stimulus until the peak of the 
response, and the other is the amplitude that describes the size of the response (Figure 5.1). Rod 
photoreceptors are stimulated in dim light, or in scotopic conditions, whereas cone photoreceptors 
respond mainly under background illumination, in photopic conditions. Therefore, different states of 
adaptation (i.e. light or dark adaptation) of the retina (or the patient) can be used to test these two 
systems individually.  
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NCL and has also been described in other species (Katz et al., 2008; Hainsworth et al., 2009). No 
systematic evaluation of the fundus has been performed in the ovine NCL models however 
attenuation of the retinal blood vessels was observed on funduscopy carried out in connection with 
a treatment trial (Mitchell et al., 2017). 
5.2 AIM AND OBJECTIVE 
The aim of this study is to explore the usefulness of electroretinography and fundus photography for 
longitudinal monitoring in ovine NCL research and to describe the development of retinal blindness 
using these techniques in CLN5 and CLN6 affected animals.  
5.3 MATERIALS AND METHODS 
5.3.1 Animals 
All experiments were performed in accordance with the Lincoln University Code of Ethical Conduct 
for the Use of Animals and the New Zealand Animal Welfare Act 1999, and approved by the Lincoln 
University Animal Ethics Committee.  
A total of 24 animals were included, consisting of two age groups: animals born in 2014 (n = 12) and 
in 2015 (n = 12). Each group contained CLN6-/- (n = 3) and CLN6+/- (n = 3) South Hampshire sheep, and 
CLN5-/- (n = 3) and CLN5+/- (n = 3) Borderdale sheep. All affected sheep (n = 6) in the 2014 group were 
rams whereas all unaffected sheep in the 2014 group (n = 6) were ewes. All sheep in the 2015 group 
were ewes. The methods were developed during the year of the study (2015) and the 2014 animals 
were not enrolled until after 11 months of age. All 2015 animals were studied from 3 months of age. 
Animal numbers at different ages are summarized in Table 5.1. The sheep were kept outdoors within 
their corresponding mobs on pasture. Prior to each ERG the sheep were brought indoors, fasted for 
18-24 h and weighed. The sheep were held in a pen with artificial lighting until the ERGs were 
performed. On each day of ERG the sheep were anaesthetised by IV injection of a mixture of 0.8 
mg/kg LW diazepam (Pamlin injection, Troy Laboratories NZ Pty Ltd, Auckland, NZ) and 17 mg/kg LW 
of ketamine hydrochloride (Phoenix Ketamine injection, Phoenix Pharm Distributors Ltd, Auckland, 
NZ). The sheep were intubated and placed on a wooden stretcher. Before the ERG was conducted, 
the sheep underwent CT scans of the brains described in Chapter 4. After the CT scans were 
completed, general anaesthesia was maintained by inhalation of isoflurane in oxygen (1.5% - 3% v/v 
to effect). To dilate the pupils, a drop of 1% tropicamide (Mydriacyl, 10 mg/mL; Alcon NZ Ltd, 
Auckland, NZ) was administered onto each eye at least 30 minutes before the ERG was conducted. 
Following recording of the ERGs, photographs of the fundi of both eyes were obtained using a hand-
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held ‘ClearView’ fundus camera (Optibrand Ltd., Fort Collins, CO, USA). After this the sheep were 
extubated and taken to a padded wake-up area where they remained under observation until they 
had recovered. Finally, the sheep were returned outdoors to their corresponding mobs.  
 
5.3.2 Electroretinography  
Electroretinography was conducted using an Eickemeyer Veterinary ERG system (Eickemeyer - 
Medizintechnik für Tierärzte KG, Tuttlingen, Germany). The live electrode was an ERG-Jet contact 
lens electrode (Fabrinal SA, La Chaux-De-Fonds, Switzerland) and the reference and earth electrodes 
were subdermal 12 mm x 29 gauge needle electrodes (LKC Technologies Inc., Gaithersburg, MD, 
USA).  
A basic clinical protocol described in the Eickemeyer ERG manual was followed. Each eye was 
assessed separately, starting with the right eye. A 40 mm Barraquer speculum was used to keep the 
eye open. The ERG-Jet contact lens electrode was filled with sterile saline solution and placed on the 
eye. The reference electrode was placed approximately 1 cm lateral to the lateral canthus. The earth 
electrode was placed on the dorsal surface of the skull about 1 cm lateral to the midline towards the 
eye that was being measured. The skin was clipped and soaked in saline to improve conduction 
where both needle electrodes were placed. The flash was placed within 1 cm of the eye. Flash 
intensity was approximately 2-3 candela per square metre (cd/m2) with a white flash colour. Each 
reading consisted of the average of four consecutive flashes with a flash interval of 0.8 seconds. 
Following the Eickemeyer ERG handbook protocol, the first recording was performed with the 
ambient light turned on (referred to as ‘light adaptation’ from here). This resulted in a cone-
dominated reading. Then the light was turned off and the second recording was performed 
immediately (referred to as ‘zero minutes dark adaptation’ from here). Finally, following five 
minutes dark adaptation, the third recording was performed (referred to as ‘five minutes dark 
adaptation’ from here). Both the zero minutes dark adaptation and the five minutes dark adaptation 
resulted in mixed-receptor responses. After this, the light was turned on again, and the left eye was 
prepared for recordings. A minimum time of 10 minutes was allowed between right and left eye 
Table 5.1 Summary of numbers of animals used  
Genotype Breed Disease status 
Age  
3 – 9 
months 
11 
months 
13 – 15 
months 
17 
months 
 
CLN5+/- Borderdale Unaffected 3 4 6 4  
CLN5-/- Borderdale Affected 3 6 6 6  
CLN6+/- South Hampshire Unaffected 3 5 6 5  
CLN6-/- South Hampshire Affected 3 6 6 5  
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recordings to allow the left eye to become light adapted before ERGs were conducted. Only the a- 
and b-waves were assessed in the present study. 
5.3.3 Data processing and statistical analysis 
For statistical analysis, animals were grouped by breed and genotype (e.g. CLN5+/-, CLN5-/-, CLN6+/-, 
CLN6-/-) and the repeated measurements were allocated into age-groups (3 months, 5 months, 7 
months, …, 17 months). The ERGs were analysed with the provided software (Eickemeyer). The a- 
and b-wave latencies and amplitudes were measured for each eye for each type of adaptation (i.e. 
light adaptation, zero minutes dark adaptation, five minutes dark adaptation) and an average 
measure was calculated from both eyes. Means and corresponding SEM were calculated for each 
measurement for each genotype for each age. Two-way repeated measures ANOVAs were 
performed for each set of measurements to investigate the effects of time and disease status on the 
latencies and amplitudes of a- and b- waves respectively. Differences were regarded significant 
where P < 0.05.  
5.4 RESULTS 
5.4.1 Fundus photography 
Fundus photography revealed obvious thinning of the retinal blood vessels in both CLN5 and CLN6 
affected animals compared with controls (Figure 5.2). In both genotypes thinning could be observed 
from 11 months of age and was pronounced at the end of the trial period, 17 months.  
5.4.2 Electroretinography 
Disease status had an effect on the latencies of the b-waves after zero minutes of dark adaptation in 
CLN5-/- and CLN6-/- animals, where the latencies were consistently lower than those of controls 
throughout the entire trial period (P < 0.05). The b-waves of CLN5-/- animals had a mean latency of 
16.6 ± 0.3 ms compared with 18.3 ± 0.5 ms in CLN5+/- controls and that of CLN6-/- animals was 16.3 ± 
0.3 ms compared with 18.3 ± 0.2 ms in CLN6+/- controls. Neither disease status nor time had an 
effect on any of the other measures of latency.  
The light adapted ERG showed a trend of a reduction of the b-wave amplitudes in CLN5-/- sheep 
compared with controls and also the a-wave amplitudes tended to be reduced in older sheep (age > 
15 months) (Figure 5.3). Although these trends were not significant in the repeated measures 
ANOVA, most affected animals were distinguishable from controls based on visual assessment of 
their ERG traces from between 9 and 11 months and most animals had near extinguished 
amplitudes at 17 months (Figure 5.5). 
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The a-wave amplitudes from the zero minutes dark ERGs from CLN5-/- animals were significantly 
reduced from 11 months onward, however the b-wave amplitudes were already distinguishable as 
lower than those from controls at 9 months (Figure 5.3). When comparing the ERGs visually, it was 
possible to identify affected animals from between 7 and 9 months of age based on the zero 
minutes dark adaptation ERG, and nearly extinguished amplitudes were seen from 15 to 17 months 
(Figure 5.5). 
The five minutes dark adaptation ERG of CLN5-/- animals showed similar results to the zero minutes 
dark adaptation (Figure 5.3). The control animals had less stable a-wave amplitude measurements 
and thus the trend of reduction of amplitude in CLN5-/- animals did not become significant until 13 
months of age, although the traces from affected sheep were visually distinguishable from those of 
controls after around 7 months of age (Figure 5.5). The amplitudes of b-waves from affected animals 
after 5 minutes of dark adaptation were visually distinguishable as lower than those from controls at 
7 months and were significantly reduced from 9 months and onwards (Figure 5.3 and Figure 5.5). 
Overall, CLN6 animals showed similar changes in their ERGs to those recorded from CLN5 animals. 
The a-wave amplitudes of CLN6-/- animals were stable throughout most of the trial period but 
became reduced after 15 months of age and extinguished amplitudes were seen in some animals 
after this age (Figure 5.4 and Figure 5.6). The b-wave amplitudes of light adapted ERGs showed an 
ongoing reduction throughout the entire trial period which became significant after 11 months of 
age. Extinguished amplitudes were seen between 15 and 17 months (Figure 5.6). The zero minutes 
dark adaptation ERGs, taken immediately after the lights were turned off, had reduced amplitudes 
for both a- and b-waves early in the trial period (Figure 5.4) and the amplitudes were nearly 
extinguished between 13 and 17 months (Figure 5.6). The five minutes dark adaptation ERGs showed 
a similar pattern, with amplitudes from CLN6-/- animals tending to be lower than those from CLN6+/- 
animals from 5 months of age. However, a distinct drop in amplitude in ERGs from CLN6-/- animals 
was seen between the measurements at 9 and 11 months (Figure 5.4). Extinguished amplitudes 
became evident in the same timeframe as in the zero minutes dark adaptation ERGs (Figure 5.6).  
In both CLN5-/- and CLN6-/- sheep all ERG readings showed great individual variation. Some animals 
had abolished ERGs by 13 months, others still had recordable ERGs at 17 months of age when the 
trial ended. 
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Figure 5.3 Mean amplitudes of electroretinography (ERG) a- and b-waves in CLN5 sheep  
Mean amplitudes (± SEM) from CLN5 affected (CLN5-/-) and unaffected controls (CLN5+/-) at different ages. 
For n see Table 5.1. Left column shows a-waves, right column shows b-waves. Light adapted ERGs were 
obtained first (A, B), followed by a measurement immediately after the light was turned off (C, D) and one 
after five minutes of dark adaptation (E, F). * indicates where P < 0.05 after repeated measures ANOVA.  
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Figure 5.4  Mean amplitudes of electroretinography (ERG) a- and b-waves in CLN6 sheep 
Mean amplitudes (± SEM) of CLN6 affected (CLN6-/-) and unaffected controls (CLN6+/-) at different ages. For 
n see Table 5.1. Left column shows a-waves, right column shows b-waves. Light adapted ERGs were 
obtained first (A, B), followed by a measurement immediately after the light was turned off (C, D) and one 
after five minutes of dark adaptation (E, F). * indicates where P < 0.05 after repeated measures ANOVA.   
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5.5 DISCUSSION 
This study has shown electroretinography and fundus photography to be useful quantitative and 
qualitative measures of progressive retinal degeneration accompanying the onset and progression of 
ovine NCL.  
Blindness is a defining feature of human as well as ovine NCL. Recent and ongoing treatment trials 
for ovine NCL are yielding promising results for viral mediated gene replacement therapy, preventing 
or halting brain atrophy, but retinal degeneration leading to blindness continues (Mitchell et al., 
2017). Because the retina can be considered as the most distal part of the CNS as far as viral 
mediated gene therapy is concerned, ocular delivery of gene therapy is likely to be needed to avert 
retinal atrophy. In the light of future ocular gene injection trials, valid and practical protocols for 
longitudinal monitoring of disease development and treatment efficacy are going to be required. 
The results presented here describe gradual and ongoing retinal degeneration in both the ovine 
CLN5 and CLN6 disease. A previous ERG investigation of the pattern of retinal degeneration in CLN6 
sheep revealed a progressive loss of rod photoreceptor function (Graydon & Jolly, 1984). However, 
the present results provide a comprehensive picture of retinal functional changes occurring in two 
ovine models of NCL, CLN5 Borderdale and CLN6 South Hampshire, plus the additional information 
provided by systematic funduscopy.  
The only change in appearance of the fundus observed in this study was attenuation of the retinal 
vasculature, indicating retinal degeneration. This is the first description of retinal vascular 
attenuation in ovine NCL and contrasts previous descriptions where vascular attenuation was not 
seen in CLN6-/- sheep (Graydon & Jolly, 1984; Mayhew et al., 1985). This differs from reported 
findings in several forms of canine NCL, where increased granularity in the mid-peripheral and 
peripheral tapetal fundus has been described (Katz et al., 2008; Whiting et al., 2015). No other 
changes in overall fundus appearance were observed in the sheep. However, changes in fundus 
appearance in NCL tend to be highly individual and vary greatly between patients and disease types, 
with signs ranging from mild to marked vessel attenuation, and from no changes in appearance to 
both increased and decreased pigmentation, granularity and mottling of the fundus (Goebel et al., 
1974; Weleber et al., 2004; Hainsworth et al., 2009). In the light of the very consistent results from 
the ERG study presented here, along with the inability to develop a quantitative measure for 
assessing the images, it is questionable whether the fundus photography in these sheep has yielded 
any significant additional information that would assist in the monitoring of ovine NCL progression 
and potential treatment efficacy.  
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The ERG results revealed that in both CLN5 and CLN6 affected animals, light adapted b-wave 
amplitudes were affected by disease status earlier and to a greater extent than a-wave amplitudes. 
Nevertheless, completely extinguished light adapted ERGs were recorded from some CLN5 and CLN6 
affected animals towards the end of the trial period, indicating that the a-wave also becomes extinct 
in advanced disease. The two mixed receptor measures (zero minutes and five minutes dark 
adaptation) provided more conclusive information than the light adaptation measures. Both a- and 
b-wave amplitudes of affected animals were distinguishable from those of controls relatively early in 
the trial period when comparing the mixed receptor responses. These results are supported by 
histological and ultrastructural findings described by Graydon and Jolly (1984), who noted that the 
loss of rod photoreceptor cells preceded that of cones and was more severe. This suggests that a 
more rod-driven ERG response (i.e. after dark adaptation) would show the effect of retinal atrophy 
earlier than a cone driven, light adapted ERG, and this is evident from the present study.  
The patterns of change of the ERG responses presented here differed between the CLN5 and CLN6 
affected animals and this was particularly obvious in the five minutes dark adapted measures. In 
CLN5-/- animals the amplitudes of both a- and b-waves of these ERG measures followed an almost 
linear pattern of decline having started already at 5 months of age. On the other hand, the 
amplitudes of both a- and b-waves in CLN6-/- animals resembled those of control animals until 
approximately 9 months of age followed by a sudden reduction that was observed at 11 months of 
age and amplitudes stayed reduced for the remainder of the trial period.  
Differences in the pattern of changes of vision and cognition between the CLN6-/- and the CLN5-/- 
animals have been identified in other studies and therefore a difference in the pattern and time 
course of retinal degeneration would be expected between the two types of disease in sheep 
(Mitchell, 2016; Mitchell et al., 2017). In CLN5-/- sheep the earliest observations of behavioural 
changes were made from 5 – 6 months and in CLN6-/- sheep from 7 – 8 months (Mitchell, 2016; 
Mitchell et al., 2017). Initial signs are apprehensive walking, ducking of the head when passing 
through gateways or narrow races, reduced spatial awareness and struggling when moving between 
sun and shade areas or areas with different types of flooring (Mitchell, 2016; Mitchell et al., 2017). 
These signs worsen until the sheep’s cognitive and visual capabilities are severely affected from 
between 12 and 14 months. Visual acuity tests such as menace and dazzle responses and corneal, 
palpebral and pupillary light reflexes are severely reduced from about one year of age in CLN5-/- 
animals and from 14 months of age in CLN6-/- animals (Mitchell, 2016; Mitchell et al., 2017). A maze 
test has been developed to test cognitive and visual function in ovine NCL (Mitchell, 2016; Mitchell 
et al., 2017; Martin Wellby, unpublished data). In this maze test, which is based on the sheep’s 
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age in both CLN5-/- and CLN6-/- sheep and a loss of neurons from the visual cortex is can be detected 
from 6 months in CLN6-/- animals and is significant at 9 months in CLN5-/- animals (Oswald et al., 
2005; Mitchell, 2016). These histological findings in combination with observations of the animals in 
the field, cognitive and clinical testing, plus ERG and funduscopy results can be used to differentiate 
the central blindness caused by cerebrocortical atrophy from the peripheral blindness caused by 
retinal degeneration. Because the early clinical manifestations of blindness considerably precede the 
age of non-recordable ERGs in both CLN5-/- and CLN6-/- animals, it could be argued that the early 
blindness is caused by atrophy of the visual cortex rather than being attributable to atrophy of the 
retina. Furthermore, the inability of affected sheep to complete the maze test almost coincides with 
the time of abolished or at least greatly reduced ERG recordings, indicating complete loss of retinal 
reactivity at this later stage of disease progression (Figure 5.7). In contrast, other authors claim that a 
different course of events describes the development of central and retinal blindness. von Schantz et 
al. (2009) have reported neuronal loss in the primary visual cortex of CLN5 deficient mice that 
coincides with the onset of blindness in these mice and Leinonen et al. (2017) postulate that this is a 
symptom of the retinal degeneration rather than a primary cause of blindness in these mice. 
However, the present results and the development of visual and cognitive changes described above 
suggest a different pattern, in which atrophy of V1 precedes retinal degeneration. A possible 
explanation of the pattern of the development of visual loss seen in ovine NCL could be what is 
termed blindsight in humans. Blindsight refers to a situation where patients with central blindness 
caused by damage to one or both V1 are able to react unconsciously to visual stimulus presented in 
the damaged visual field without consciously recalling seeing the visual stimulus (Pöppel et al., 1973; 
Weiskrantz et al., 1974). Observations have been made on a human patient with bilateral loss of V1 
after two strokes, who appeared clinically blind but was still able to negotiate his way through a 
corridor without hitting obstacles that were placed in the way (de Gelder et al., 2008). Studies in 
monkeys have shown that after unilateral removal of V1, the monkeys were still noticing a light 
stimulus, which was indicated by involuntary eye movement towards the stimulus, however they 
were not performing a learned response to indicate conscious recognition of the stimulus (Cowey & 
Stoerig, 1997). The explanation of blindsight remains inconclusive and has been reviewed in detail 
elsewhere (Overgaard, 2012). Nevertheless, some aspects of blindsight could explain the early 
clinical manifestations of blindness in ovine NCL, where visual acuity is reduced while some 
awareness of surroundings is still present.   
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5.6 CONCLUSION 
 The current study has shown that ERG is an invaluable tool for monitoring the progression of 
retinal degeneration in ovine NCL.  
 Fundus photography provides corroborative evidence of the retinal degeneration in Batten 
sheep but does not have sufficient resolution to become useful as an adjunct to ERG for this 
purpose.  
 The course of development of retinal changes differs between ovine CLN5 and CLN6 disease.  
 These measurements enable some differentiation to be made between retinal and central 
causes of blindness in ovine NCL.   
 ERG will be useful for monitoring the effectiveness of ocular gene therapy.  
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6 PILOT STUDY FOR LONGITUDINAL MAGNETIC RESONANCE IMAGING IN 
OVINE NCL 
6.1 INTRODUCTION 
Magnetic resonance imaging (MRI) is commonly used in the diagnosis and monitoring of human NCL. 
Typical findings are diffuse brain atrophy, regional cortical thinning and signal changes in the white 
matter and thalamus (Autti et al., 1992; Dyke et al., 2013; Jadav et al., 2014). With growing interest 
in sheep models for translational research (section 1.1), the use of imaging modalities such as CT and 
MRI has also increased in sheep. For example MRI in sheep has been used to visualize the 
development of the pituitary gland (Carroll et al., 2007), to study the effects of gonadotrophin-
releasing hormone agonist on brain development (Nuruddin et al., 2013) and to study focal epilepsy 
(Opdam et al., 2002). Furthermore, MRI has been used in sheep for stereotaxic guidance of 
neurosurgery in a stroke model and during acquisition of brain stem biopsies (Dreyer et al., 2012; 
Staudacher et al., 2014), and in a dog model of CLN2 disease for stereotaxic placement of 
intracerebroventricular catheters for the delivery of enzyme replacement therapy (Katz et al., 2008). 
Recently, an attempt has been made at a longitudinal MRI study of CLN6 disease in South Hampshire 
sheep to investigate the pattern of brain atrophy and potential regional differences hereof (Sawiak 
et al., 2015). The animals in this study were aged 17 to 18 months at enrolment and the final scan 
was performed at 22 to 23 months. Because of the late start of the study, brain atrophy was already 
pronounced at baseline scanning. The study found that only small numbers of animals were needed 
for statistical significance, as the differences between affected sheep and controls were large. The 
study used voxel based morphometry; for which study-specific ovine templates were created based 
on the animals included in the sample (Sawiak et al., 2015). In recent years, two ovine specific 
population-averaged MRI brain atlases have been created, facilitating group-wise investigations of 
ovine MRI. One is based on T1 weighted images from a total of 38 adult Merino sheep acquired on a 
1.5 tesla (T) MRI scanner (Nitzsche et al., 2015). The atlas includes tissue probability maps (TPMs) for 
grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) of the cerebrum, but not for the 
cerebellum (Nitzsche et al., 2015). The other atlas is based on both T1 and T2 weighted scans from 
18 sheep acquired on a 3 T MRI scanner (Ella & Keller, 2015). TPMs for GM, WM and CSF were 
created and subsequently a 3-D atlas of 25 external (cortical) and 28 internal (subcortical and 
ventricle) brain structures were generated, including the cerebellum (Ella & Keller, 2015; Ella et al., 
2017).  
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6.2 AIMS AND OBJECTIVES 
The aim of this study was to investigate the usefulness of MRI scanning in longitudinal monitoring of 
ovine NCL and to establish an image analysis pipeline to facilitate investigation of structural MR 
images. To achieve this, two pilot studies were performed and the two different ovine specific MRI 
atlases were applied to the data.  
6.3 MATERIALS AND METHODS 
All animal procedures were performed in accordance with the respective (NZ and Australia) animal 
welfare acts. Two MRI studies were included. The first study was performed on Merino CLN6 sheep 
at the University of Sydney, Australia provided by Dr Imke Tammen. The second was performed in 
collaboration with Dr Tracy Melzer at the New Zealand Brain Research Institute and University of 
Otago, Christchurch, NZ. 
6.3.1 MRI studies conducted at the University of Sydney 
The sheep were born at the University of Sydney farms at the Camden campus (New South Wales) in 
2009 and 2010 and raised outdoors on pasture. CLN6 affected Merino sheep and unaffected age- 
and breed-matched controls were included. Their disease status was identified through direct DNA 
testing (section 2.1.2) (Tammen et al., 2006). Some sheep underwent three MRI scans, others were 
enrolled in the study later and received only one or two MRI scans. Sheep numbers and genotypes 
are summarized in Figure 6.1.  
 
 
 
Figure 6.1 Summary of sheep enrolled in the MRI study at the University of Sydney at different ages 
Each line represents one animal, each dot indicates the age(s) at which each animal received an MRI scan. 
4 5 6 7 8 9 10 11 12 13 14 15
Age (months) when MRI was recieved
Normal
Affected
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The sheep were transported on the same day or a day before MRI to the imaging facility where they 
were housed in indoor pens. Prior to MRI scanning they were pre-medicated with an intramuscular 
injection of diazepam (0.2 mg/kg LW) and morphine (0.3 mg/kg LW). Anaesthesia was induced by IV 
infusion of propofol (4-6 mg/kg LW to effect) followed by endotracheal intubation and maintenance 
of anaesthesia through inhalation of isoflurane in 100% oxygen (1.5% - 3% v/v to effect). Structural 
MR images were acquired with a T1-weighted, 3-D gradient echo acquisition (Echo time/repetition 
time (TE/TR) = 14/34 ms, flip angle = 65 degrees, acquisition matrix = 256×256×104, FOV= 230 mm, 
slice thickness = 0.9 mm, voxel size = 0.9×0.9×0.9 mm3, total scan time = 10:21 minutes) on a 0.25 T 
Esaote Vet-MR Grande scanner (Esaote SpA, Genoa, Italy). Dr Mariano Makara performed the MRI 
scanning. This study will be referred to as ‘the Sydney study’. 
6.3.2 MRI study conducted at the New Zealand Brain Research Institute 
During the course of this project, a collaboration with the New Zealand Brain Research Institute 
(NZBRI) was established for the development of suitable protocols and procedures for longitudinal 
MRI scanning of sheep included in gene therapy trials. A total of 8 sheep of varying genotype and 
treatment status have received MRI scans on three different occasions. Results from one 15 months 
old CLN5 affected (CLN5-/-) and one unrelated (CLN5+/+) age matched control are presented here. The 
sheep were restricted from food and water for 12 h and transported to the NZBRI immediately 
before the MRI was conducted. They were anaesthetised by IV injection of a mixture of 0.8 mg/kg 
LW diazepam (Pamlin injection, Troy Laboratories NZ Pty Ltd, Auckland, NZ) and 17 mg/kg LW of 
ketamine hydrochloride (Phoenix Ketamine injection, Phoenix Pharm Distributors Ltd, Auckland, NZ) 
and placed in the MRI scanner in lateral recumbency. Structural MR images were acquired with a 3D 
T1-weighted, inversion recovery-prepared fast spoiled gradient recalled echo acquisition (BRAVO), 
tuned to brain tissue (TE/TR/ inversion time (TI) = 5.15/12.44/400 ms, Flip angle = 15 degrees, 
acquisition matrix = 256 × 256, FOW = 200 mm, slice thickness 0.8 mm, voxel size = 0.78 × 0.78 × 0.8 
mm3) on a 3 T G HDxt Signa scanner using a closed-end 8 channel human head coil (General Electric, 
Fairfield, Connecticut, USA). Dr Tracy Melzer performed the MRI scanning. This study will be referred 
to as ‘the NZBRI study’.  
6.3.3 Image analysis 
All image analyses were performed by Dr Tracy Melzer at the NZBRI using SPM8 (Statistical 
Parametric Mapping, Wellcome Department of Imaging Neuroscience Group, UCL, UK; 
www.fil.ion.ucl.ac.uk/spm) running in Matlab (R2014a, Mathworks, Massachusetts, USA). The 
images from the Sydney study were processed twice, using the two different ovine brain tissue 
probability maps (TPMs) and stereotaxic atlases (Ella & Keller, 2015; Nitzsche et al., 2015; Ella et al., 
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2017). It has to be noted that the TPM from Nitzsche et al. (2015) does not include the cerebellum. 
Based on the results from the Sydney study, the images from the NZBRI study were analysed using 
the TPMs and atlas from Ella and Keller (2015) and Ella et al. (2017) only. Raw T1-weighted images 
from each sheep were manually reoriented to the template space and then co-registered to the 
sheep template using default parameters in SPM8. T1-weighted images were then intensity bias 
corrected, tissue classified into GM, WM, and CSF, and normalised within a unified model 
(Ashburner & Friston, 2005), utilizing the sheep specific TPMs. Tissue segments were modulated, 
thereby preserving actual tissue volumes. Modulated, normalized GM, WM, and CSF segments, in 
the standardized space of the sheep template, were further analysed. First, the total GM, WM, and 
CSF volumes were extracted and ICV was defined as the sum of the three tissue segments. 
Additionally, the ovine specific cortical atlas (Ella et al., 2017) was used to extract GM volume from 
the following regions, based on their relevance in the neuropathological cascade that was 
determined earlier (Chapter 3): Parietal cortex, occipital cortex, primary visual cortex, frontal 
association cortex, somatosensory cortex, primary motor cortex and cerebellar cortex.  
6.3.4 Statistical analysis 
Based on low animal numbers and only partly repeated measures (Figure 6.1), limited statistical 
power of the current study was expected. Based on the small sample size, all ages were pooled. 
Student’s t-test was used for cross-sectional comparison between affected and controls and Cohen’s 
d was calculated to evaluate effect sizes (section 2.2). Effect sizes were regarded as follows: 0.2 = 
small; 0.5 = medium, 0.8 = large; 1.3 = very large.  
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6.4 RESULTS 
6.4.1 Sydney study 
6.4.1.1 Segmentation 
The results from both segmentations (based on Ella and Keller (2015) and based on Nitzsche et al. 
(2015)) are summarised in Figure 6.2 and Table 6.1. These show a very large significant effect of 
disease status on total ICV regardless of which segmentation method was used. Both segmentations 
showed that the biggest loss of tissue occurred in the grey matter, followed by the white matter. The 
segmentation based on Ella and Keller (2015) showed a very large and significant effect of disease 
status on CSF volume, (Cohen’s d = 7.2), which was increased in affected animals compared with 
controls. However, the segmentation based on Nitzsche et al. (2015) indicated no significant effect 
of disease status on CSF volume (Cohen’s d = 0.01). It appeared that the ICV was increasing slightly 
over time when using the template by Ella and Keller (2015), whereas the measures based on the 
template by Nitzsche et al. (2015) indicated an initial increase of ICV followed by loss of ICV.  
6.4.1.2 Regional measurements 
Grey matter volumes from the parietal, occipital, primary visual, frontal associated, somatosensory, 
primary motor and cerebellar cortices and effect sizes of disease status on grey matter volumes are 
summarised in Figure 6.3. These regional results were consistent with the global results from the 
segmentation, showing that grey matter was reduced in CLN6 affected sheep compared with 
controls. Disease status had the largest effect on the parietal and primary visual cortices volumes, 
followed by the frontal associated, occipital, somatosensory, and the primary motor cortex. The 
effect of disease status on the volume of the cerebellar cortex was small and this effect was not 
significant. When assessing the change of grey matter volume in each of the regions of interest, it 
appeared that grey matter volume increased in both NCL affected and normal CLN6 Merino sheep 
over time. 
Table 6.1 Effect of disaese status on segmented brain tissue volumes of CLN6 merino sheep 
Segementation of MR images from CLN6 affected Merino sheep and controls based on TPMs from Ella and 
Keller (2015) and based on TPMs from Nitsche et al. (2015). Volumes were segmented into grey matter 
(GM), white matter (WM) and cerebrospinal fluid (CSF). Total intracranial volume (ICV) were calculated as 
sum of the three. Significance was investigated by Student’s t-test and effect sizes were calculated as 
Cohen’s d. P ≤ 0.05 was regarded as significant. Effect sizes were regarded as: 0.2 = small; 0.5 = medium, 0.8 
= large; 1.3 = very large.  
 Based on Ella and Keller (2015) Based on Nitzsche et al. (2015)  
 Effect size P-value Effect size P-value  
ICV -6.5 < 0.001 -7.7 < 0.001  
GM -6.7 < 0.001 -8.7 < 0.001  
WM -6.5 < 0.001 -3.6 0.001  
CSF 7.2 < 0.001 0.01 0.5  
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Figure 6.2 Volume changes of segmented brain tissues in CLN6 Merino sheep 
Mean (±SEM) tissue volumes of grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) at 
different ages. Intracranial volumes (ICV) were calculated as sum of all three tissues. MR images were 
segmented twice, once using a template from Ella and Keller (2015) and once using a template from 
Nitzsche et al. (2015). See Figure 6.1 for n.  
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Region Effect size P-value 
Parietal cortex -2.0 < 0.001 
Occipital cortex -1.4 < 0.001 
Primary visual cortex -2.0 < 0.001 
Frontal association cortex -1.8 < 0.001 
Somatosensory cortex -1.2 < 0.001 
Primary motor cortex -1.1 < 0.001 
Cerebellar cortex  0.2 0.34 
 
 Age (months)  
Figure 6.3 Regional volume changes in CLN6 Merino sheep 
Grey matter volumes from the parietal, occipital, primary visual, frontal association, somatosensory, 
primary motor and cerebellar cortices were measured on MRI scans from different ages based on the 
ovine brain template (Ella et al., 2017). CLN6 affected Merino sheep (CLN6-/-) and healthy controls 
(CLN6+/+) were included. See Figure 6.1 for n. Values are presented as means ± SEM at each age. 
Significance was investigated using Student’s t-test. Effect size of disease status was calculated for each 
region using Cohen’s d. Effect sizes were regarded as follows: 0.2 = small; 0.5 = medium, 0.8 = large; 1.3 = 
very large. 
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6.4.2 NZBRI study 
Results from two sheep, one CLN5 affected and a control, that each received a single MRI scan at the 
NZBRI are presented. Volumetric measures from the segmentation of GM, WM and CSF and regional 
cortical GM measures are summarized in Figure 6.4 and example images from the segmentation are 
shown in Figure 6.5. The images in Figure 6.5 show that the segmentation fitted well for the control 
sheep, however some incorrect registration occurred in the images from the NCL affected sheep. It 
appears that some of the grey matter in the cortical segmentation was registered as CSF instead. 
This became obvious when comparing the volumetric measures from the segmentation of affected 
and normal (Figure 6.4). In the normal sheep the GM segment was measured as 48.3 ml and the CSF 
was 21 ml. In the affected sheep the CSF segment only measured 8.2 ml and the GM segment 
measured 43 ml. The regional cortical measurements reflected the global results from the 
segmentation. All regional measures were reduced in the affected animal compared with the 
control.   
 
A 
 
B 
 
Figure 6.4 Example of segmentation and regional volume measures 
Examples of volumetric measurements based on MRI scans of one CLN5 affect (CLN5-/-) and one unrelated 
control (CLN5+/+) sheep, both aged 15 months based on ovine specific TPMs and stereotaxic atlas (Ella & 
Keller, 2015; Ella et al., 2017). A) Measures from segmentations of grey matter (GM), white matter (WM) 
and cerebrospinal fluid (CSF). Intracranial (ICV) was calculated as the sum of GM, WM and CSF. B) Measures 
from regional cortical measurements from the cerebellar cortex (CER), primary visual cortex (V1), occipital 
cortex (OCC), frontal association cortex (FC), primary motor cortex (M1) and parietal cortex (PC).  
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Figure 6.5 Examples of MRI segmentation from CLN5 affected and control sheep 
Examples of axial images from MRI scans of A) one 15 months old healthy control and B) a 15 months old CLN5 affected Borderdale sheep.  
Segmentations are based on ovine specific TPMs (Ella & Keller, 2015). Red = grey matter, blue = white matter, green = cerebrospinal fluid (CSF). Note the 
underrepresentation of GM and overrepresentation of CSF in the affected sheep. 
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6.5 DISCUSSION 
The present study has shown that MRI can be useful to monitor the neuropathological changes in 
ovine NCL. The results showed that the intracranial volume of CLN6 affected Merino sheep was 
reduced compared with unaffected controls and that most of the volume loss occurred in the grey 
matter, with less loss of volume from the white matter. The segmentation based on the template by 
Ella and Keller (2015) showed an increase of CSF volume in CLN6 affected Merino sheep. Overall, 
these results mirror what has been described at post mortem examination and through CT imaging 
in CLN6-/- Merino sheep and the two other ovine NCL models (Oswald et al., 2008; Mitchell, 2016; 
Chapters 3 and 4). However, the observed differences were already evident in base-line scanning at 
approximately 4 to 5 months of age (Figure 6.2) and just slight increases of mean ICV and grey matter 
volumes were seen over time in both affected animals and controls when the images were analysed 
using the template provided by Ella and Keller (2015). Based on the same template, white matter 
volumes of affected Merino sheep decreased slightly over time and the CSF volume was increased at 
all ages. The measures based on the template by Nitzsche et al. (2015) showed a slight decrease of 
ICV in affected Merino sheep over time. However, both grey and white matter measures from 
affected Merino sheep increased over time, and only the CSF measures decreased from the first to 
the last scan. The same was true for control animals, which also had lower CSF volumes on the last 
scanning date compared with the previous scans (Figure 6.2). It is also noteworthy, that 
measurements based on Nitzsche et al. (2015) indicated that disease status had near to no effect on 
CSF volume, although the measures based on Ella and Keller (2015) indicated a very high effect size 
(Table 6.1). Possible explanations for this could be the lack of cerebellum in the template by Nitzsche 
et al. (2015), as through this some amount of CSF is also disregarded, or an error in the 
segmentation, where most voxels are regarded as either GM or WM and not as CSF. In summary, the 
current global measures of GM, WM and CSF volumes have failed to display the progressive nature 
of the brain atrophy that is characteristic in ovine NCL, but were sensitive enough to show that 
affected animals have reduced overall brain volumes compared with controls.  
The present study is the first to apply an ovine specific regional brain atlas to MRI scans from NCL 
affected sheep. Similar to the global measures, the results failed to portray the progressive 
development of the cortical thinning that has been described at post mortem examination (Oswald 
et al., 2008; Mitchell, 2016; Chapters 3 and 4). Nevertheless, general trends from the present results 
follow what was observed at post mortem examination, showing that disease status had the largest 
effect on the parietal and visual cortices, the smallest effect on the motor cortex and that the 
cerebellum was largely spared from atrophy (Figure 6.3). Overall, the templates provided by Ella and 
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Keller (2015) and Ella et al. (2017) appeared to be more applicable to the data in this study. The 
cerebellum is largely unaffected in ovine NCL (Oswald et al., 2008; Mitchell, 2016; Chapter 4) and 
can therefore be regarded as an internal control for volumetric changes of the brain. The lack of the 
cerebellum in the template by Nitzsche et al. (2015) reduces the usefulness of this template, 
especially with regard to NCL. Furthermore, the regional atlas from Ella et al. (2017) enabled detailed 
measurements in vivo that can be compared to histology measures performed at post mortem 
examination. Similar measurements have been performed recently on children with CLN2 disease 
(Dyke et al., 2016). Cortical thickness difference between patients and healthy controls were 
compared by using the surface based MR image analysis tool FreeSurfer 
(http://surfer.nmr.mgh.harvard.edu). While debate exists on the optimum method to quantify brain 
degeneration (Clarkson et al., 2011), both surface-based cortical thickness and voxel-based tissue 
volume estimation methods converge on similar trends observed between findings of the human 
trial and from the present study. In both cases, the occipital, visual and parietal cortices showed 
more atrophy than the frontal and or motor cortices (Dyke et al., 2016).  
The present study has demonstrated the potential of MRI in ovine NCL research for the longitudinal 
in vivo collection of detailed translational data. However, the results have indicated a range of issues 
that need to be addressed to reach this goal. Several factors could have contributed to the 
discrepancy between MRI measures from the Sydney study and post mortem observations. Only one 
of the affected animals underwent MRI scanning three times, one received two scans and the 
remaining two only underwent one MRI scan (Figure 6.1), leading to difficulties describing the 
pattern of change longitudinally. Future trials should emphasize experimental design to improve 
statistical power. Furthermore, the image quality of the Sydney study was limited, which was to be 
expected from a 0.25 T MRI scanner (Figure 6.6). Images exhibited low contrast (low definition 
between GM, WM, and CSF) as well as coarse spatial resolution, making it difficult to detect tissue 
boundaries and register tissues correctly. The findings from the NZBRI study, which were obtained 
on a 3 T scanner, showed that improved image quality enables better segmentation (Figure 6.4). 
However, the same figure also shows that a better segmentation was achieved on images from the 
healthy animal than those from the CLN5 affected sheep. This is to be expected as the brains from 
NCL affected animals not only shrink in size but also are altered in composition. Neuropathology and 
CT imaging in ovine NCL have shown regional patterns of grey matter loss and increases in CSF 
volume (Oswald et al., 2005, 2008; Mitchell, 2016; Chapter 4) and MR imaging studies in human NCL 
have described signal changes of brain tissue (Autti et al., 1992). The TPMs used here are based on 
healthy animals; which is an important issue to consider when analysing brain scans from animals 
with gross neuropathological changes. In this case, segmentation and normalization may be 
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systematically worse in sheep with gross atrophy or neuropathology. When comparing other aspects 
of the present studies with those that produced the TPMs, other areas for improvement appear (Ella 
& Keller, 2015; Ella et al., 2017). Largely improved image quality is achieved by longer acquisition 
times, and while the present studies both had acquisition times under 15 minutes, the TPMs and the 
stereotaxic atlas were constructed from scans with total acquisition times of over 3 h per animal 
(Ella & Keller, 2015; Ella et al., 2017). To achieve this, the sheep were maintained anaesthetised 
through inhalation of isoflurane in oxygen, for which special MR-comparable anaesthesia equipment 
is needed (Ella & Keller, 2015; Ella et al., 2017).  
A Rostral B Rostral  
  
 
Caudal Caudal  
Figure 6.6 Comparison of images aquired on different MRI scanners 
Representative axial ovine brain MR images. Image A) was acquired on a 0.25 T MRI scanner whereas B) was 
acquired on a 3 T MRI scanner. Note the difference in contrast and spatial resolution between the images. 
Grey matter (GM), (WM) and cerebrospinal fluid (CSF) are easily distinguishable on image B. This is not the 
case on image A.  
 
6.6 CONCLUSION 
 MRI is promising to be useful technology for longitudinal in vivo monitoring of 
neuropathology in ovine NCL. 
 CLN6 affected Merino sheep have reduced ICVs compared with healthy controls. 
 The use of TPMs and stereotaxic atlases derived from healthy cohorts for measurements in 
affected animals needs to be treated with caution, but provide an opportunity for further 
study. 
 Longer acquisition times should be applied for future MRI studies in ovine NCL research.  
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7 APPLIED METHODS FOR LONGITUDINAL IN VIVO MONITORING OF GENE 
THERAPY TRIALS 
7.1 INTRODUCTION 
Over the last few decades ovine NCL research has contributed greatly to the understanding of the 
NCLs in general, including human forms. Translational knowledge has been accumulated from 
investigations into the natural history of the disease, such as the identification of the storage 
material subunit c of the mitochondrial ATP synthase (Palmer et al., 1989, 1992; Fearnley et al., 
1990; Palmer, 2015) and description of the neuroinflammatory changes (Oswald et al., 2005, 2008; 
Mitchell, 2016), leading to a different understanding of the pathological cascade (Palmer et al., 2013; 
Palmer, 2015). The natural progression of this work is the establishment of therapy trials (Palmer et 
al., 2015). Functions of the proteins that are coded for by the CLN5 and CLN6 genes are still 
unknown and gene therapy is the most promising treatment option. A significant reduction of 
storage body accumulation in in vitro CLN5-/- neuronal cell cultures after gene therapy using a 
lentiviral vector has been reported (Hughes et al., 2014). Transduction of neurons and neuroblasts 
could be seen in vivo after intra-cortical injection with a vector expressing green fluorescent protein 
(Linterman et al., 2011). These studies have led to the current programme of gene therapy trials 
(Mitchell, 2016).   
Sheep with naturally-occurring disease have many advantages over other models for these 
investigations. Their body size is similar to that of humans, lambs weighing 3.5 – 4.5 kg at birth and 
adult sheep weighing 70 – 110 kg. The gyrencephalic structure of the sheep brain and its spatial 
organisation is similar to that of humans (Palmer et al., 2011, 2015) and, with an adult sheep brain 
weight of 100 – 140 g, realistic approximations of dosage and routes of drug delivery can be made. 
The longer lifespan of sheep compared with small research animals and the similarity of their 
disease course to that of humans allows investigations of long-term effects and possible 
downstream consequences (Palmer et al., 2015). These include effects on the CNS and also possible 
systemic effects of disease that are usually not seen because the CNS symptoms overshadow these 
or because subjects do not live long enough to develop them. Also, possibilities of repeated 
treatment or combinations of treatments can be investigated in the large animal models. Having a 
relatively slow disease progression and long generation intervals (the current breeding programme 
produces one set of offspring each year), leads to the importance of longitudinal in vivo monitoring 
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of disease parameters that allow assessment without the need to sacrifice animals for post mortem 
investigations.  
7.2 AIM AND OBJECTIVES 
The data presented in this section are part of the ongoing gene therapy programme at Lincoln 
University led by Dr Nadia Mitchell and have in parts been presented elsewhere (Mitchell et al., 
2017). Here, the emphasis is to demonstrate the development and use of the techniques for 
longitudinal in vivo monitoring and for improved surgical planning and their importance for therapy 
trials. 
7.3 MATERIALS AND METHODS 
7.3.1 Animals and viral vectors 
All procedures were conducted under the NZ Animal Welfare Act (1999) and approved by the Lincoln 
University Animal Ethics Committee. Where appropriate, the procedures were also approved by the 
Lincoln University Biosafety Committee and in compliance with NZ Environmental Protection 
Authority requirements. The gene therapy trial included four female CLN5-/- sheep that received 
post-symptomatic treatment at approximately seven months of age. The sheep were kept under 
outdoor pastoral conditions together with age- and breed-matched controls. The vector used for the 
gene therapy treatment was a self-complementary (sc) AAV9 expressing the ovine CLN5 (scAAV9-
CLN5), produced by the University of North Carolina Gene Therapy Centre (Mitchell et al., 2017). 
7.3.2 Surgical procedures and CT guided trajectory planning 
Vector delivery was performed through stereotaxic injection surgery based on methods described by 
Linterman et al. (2011) using a Kopf stereotaxic frame (Kopf, model 1630; David Kopf Instruments, 
Tujunga, CA, USA) to target the lateral cerebral ventricles. A total volume of 400 μl containing 4.0 x 
1012 viral genomes in sterile physiological saline solution was injected into each ventricle (Mitchell et 
al., 2017). To improve the accuracy of injection planning and to be able to adjust this for the 
different ages of animals, individual CT-based planning was conducted for each animal. Sheep were 
CT scanned as described earlier (Chapter 4) and the images were realigned in the same way as 
described for the skull thickness measurements (section 4.3.2.3). After identifying the injection 
targets within the lateral ventricles and using bregma as a reference point, the rostro-caudal and 
medio-lateral coordinates for the burr holes in the skull were identified and the depths for the 
injections established (Figure 7.1). This procedure was repeated for animals included in other gene 
therapy experiments not presented here. 
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each ventricle using the same procedure as for the gene therapy surgeries. Then the head was CT 
scanned again to identify the localisation of the contrast fluid.  
7.3.3 Longitudinal monitoring of intracranial volume 
As described in Chapter 4, ICV is a valid surrogate measure of brain size in sheep. The sheep included 
in the gene therapy trial described here received brain CT scans bimonthly and the ICVs were 
measured following the procedures described earlier (Chapter 4). Additionally, 3-D models of the 
ICVs were produced to visualise the volumetric changes and to identify possible regional differences 
within these. In brief, the sheep were starved for 12 h beforehand and anaesthesia was induced by 
intravenous injection of a mixture of ketamine hydrochloride (17 mg/kg LW; Phoenix Ketamine 
injection, Phoenix Pharm Distributors Ltd, Auckland, NZ) and diazepam (0.8 mg/kg LW; Pamlin 
injection, Troy Laboratories NZ Pty Ltd, Auckland, NZ). The sheep were intubated endotracheally and 
placed in the CT scanner in dorsal recumbency. A series of helical scans was performed with a slice 
interval and thickness of 1 mm. Scan times were approximately 10 min. Image analysis was 
performed in 3-D Slicer 4.3.1 (http://www.slicer.org) (Fedorov et al., 2012). Threshold-based manual 
selection of brain tissue and cerebral ventricles was performed, and the volumes were recorded 
after generating 3-D models from the selected areas. 
7.3.4 Electroretinography 
Treated sheep underwent ERG bimonthly as described in Chapter 5 to monitor the development of 
blindness. In brief, following on from the CT procedure, the sheep were placed in sternal 
recumbency and anaesthesia was maintained by inhalation of isoflurane in oxygen (1.5% - 3% v/v to 
effect). Each eye was assessed separately, starting with the left eye. A light adaptation, zero minutes 
dark adaptation and a five minutes dark adaptation recording were performed for each eye. Each 
recording comprised the average of four consecutive readings obtained with a flash-interval of 0.8 
seconds, using a white flash with an intensity approximately 2-3 cd/m2. Following ERG, the sheep 
were extubated and brought to a padded wake-up area where they remained under surveillance 
until they had recovered full consciousness. 
It was established previously (section 5.5) that of the three recordings (light adapted, zero minutes 
dark adapted, and five minutes dark adapted), the five minutes dark adaptation recordings, which 
are mixed-receptor responses, give the best differentiation between affected and normal sheep. 
Therefore, the other two measures were disregarded in this study. Based on the results of Chapter 5, 
only the amplitudes of the recordings were measured.  
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7.3.5 Statistical analysis 
Repeated measure ANOVA or Student’s t-test was performed where appropriate and Cohen’s d was 
calculated to evaluate effect size (section 2.2). A P-value of 0.05 was regarded as significant and 
effect sizes were regarded as follows: 0.2 = small; 0.5 = medium, 0.8 = large; 1.3 = very large.  
7.4 RESULTS 
7.4.1 Extension of lifespan 
The majority of the untreated affected animals reached their humane endpoint for continued 
survival between 18 and 20 months of age. At the time of writing, two of the treated sheep are still 
alive in the field at an age of over 25 months. The other two treated sheep were sacrificed at 
approximately 22.5 months of age for neuropathological examination to be performed by Dr Nadia 
Mitchell. The latest data included in this thesis is from measures at 22 months, but monitoring of the 
animals is continuing.  
7.4.2 CT guided trajectory planning 
The total surgery time and the time from the correct positioning of the head to completion of the 
first and the second intra-cerebroventricular injections were compared between gene therapy 
surgeries where individual CT based surgery planning had been performed and those where it had 
not. There was a reduction of approximately 20% in the average total surgery time when individual 
CT based planning was employed (P < 0.001, Figure 7.2). The injection of radio-contrast fluid after 
individual CT based injection confirmed that this technique correctly located the lateral ventricles 
(Figure 7.2). The average injection coordinates in the present trial were: 8 mm (± 0.0 mm) rostral of 
bregma; 8 mm (± 1.6 mm) lateral either side from the midline and 16 mm (± 0.7 mm) depth from the 
top of the skull.  
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7.4.3 Intracranial volume in treated animals compared with untreated controls 
The mean ICVs of the treated animals were the same as those of untreated affected sheep at 7 
months of age (affected: 88.3 ± 4.2 ml; treated: 89.5 ± 1.2 ml; P = 0.6). The severe and almost linear 
volume loss that untreated animals experience after 11 months of age did not occur in treated sheep 
(Figure 7.3).The ICV loss in the treated sheep from 7 months to 22 months was less than a quarter 
(mean loss: 1.4 ± 1.1 ml) of that in untreated animals between 7 and 17 months (mean loss: 5.8 ± 1.7 
ml), showing a large effect of treatment on ICV changes (Figure 7.3). The bulk of the volume loss in 
treated sheep occurred between 16 and 18 months of age, as the ICVs of treated sheep were 
unchanged until approximately 16 months, thereafter the volumes declined noticeably until 
approximately 18 months of age, then plateaued (Figure 7.3).  
The loss of volume was obvious when the 3-D models of the ICVs of treated, affected and normal 
sheep were compared (Figure 7.4). The appearance of the ICVs of the treated animals was similar to 
those of other affected animals at 7 months, but the noticeable progressive shrinkage of the 
hemispheres evident in untreated affected animals at end-stage disease was not seen in the treated 
sheep, as the shape of the ICVs of these animals largely stayed the same after the therapy was 
A 
 
B  
  
Figure 7.2 CT guided planning of intra-cerebroventricular gene therapy injections 
A) Surgery times were measured for gene therapy surgery with individual CT based modelling (with model; n 
= 16) and without individual modelling (without model; n = 6). Times were measured from induction of 
anaesthesia until the anaesthesia was turned off (Complete surgery times), and the time from the 
positioning of the head in the stereotaxic frame to (First injection completed) and (Second injection 
completed). All three times were significantly shorter when individual CT modelling was used (*P < 0.05, **P 
< 0.001). Data are mean values and vertical lines represent ± SEM. B) To visualise the accuracy of the CT 
based modelling used for the gene therapy injections, the same procedure was conducted on a severed head 
of a sheep. Instead of injecting a viral vector, a radio-contrast fluid was injected and then visualised through 
a post-injection CT scan. A representative sagittal image is shown. Both the lateral cerebral ventricle and the 
burr hole contain the radio-contrast fluid (white medium). Air-filled spaces have arisen within the cranial 
cavity (black areas) where CSF has flowed out after the head was severed. 
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delivered. In affected animals the pronounced cortical atrophy and the sparing of the cerebellum 
makes the latter appear larger in comparison as the disease progresses (Figure 7.4). In the treated 
animals, as in other affected sheep, this was already partly evident at 7 months of age. In the later 3-
D models (18 months and 22 months), the cerebellum appears to be slightly more pronounced 
compared with the same sheep at 7 months and some degree of volume loss can be seen in the 
cortical areas of the cerebrum adjacent to the cerebellum, i.e. the occipital and visual cortices (Figure 
7.4).  
 
 
 
  
A   
B      
  ml change (mean ± SEM) P-value Effect size  
 Affected between 7 and 17 months -5.8 ± 1.7 ml    
 Treated between 7 and 18 months -1.3 ± 1.5 ml 0.036 1.25  
 Treated between 7 and 22 months -1.4 ± 1.1 ml 0.027 1.29  
Figure 7.3  The effect of gene therapy on the mean accumulative ICV gain and loss 
A) Data are expressed as means (solid lines) ± SEM (dotted lines). The intracranial volume (ICV) was 
measured in CLN5-/- sheep that received scAAV9-CLN5 (n = 4) at 7 months of age, untreated CLN5-/- (n = 6) 
and healthy CLN5+/- sheep (n = 6) and the mean accumulative ICV changes were calculated. B) The change of 
ICV was calculated for the period from 7 to 17 months for affected control animals and for the periods 7 to 
18 months and 7 to 22 months for the treated sheep. One-sided Student’s t-tests were performed to 
compare differences and effect size was calculated using Cohen’s d. Effect sizes are regarded as: 0.2 = small, 
0.5 = medium, 0.8 = large, 1.3 = very large.  
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 Figure 7.4 Representative 3-D 
models of cranial volumes of 
treated sheep and controls 
Computer tomography (CT) 
based 3-D modelling of 
intracranial volumes (ICV) 
from sheep that received 
scAAV9-CLN5 gene therapy at 
7 months showed plateauing 
of volume compared with the 
manifest loss of volume 
observed in untreated affected 
sheep. Loss of cranial volume 
and enlargement of lateral 
cerebral ventricles (blue) was 
evident at 7 months of age 
and was not reversed through 
the therapy. However, the 
pronounced loss of volume 
seen in the 17-month-old 
affected sheep was not seen in 
the treated animals. Normal 
controls have almost reached 
their adult ICV at 7 months. 
The top row of each block 
shows the dorsal view, middle 
row shows the dorsal view 
semi-opaque so that the 
lateral ventricles are visible, 
and the bottom row shows the 
lateral view.  
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7.4.4 Electroretinography  
The assessment of mixed receptor responses after five minutes of dark adaption revealed no 
improvement of vision in the scAAV9-CLN5 treated animals compared with untreated controls (P > 
0.05) (Figure 7.5). The course of the development of blindness in the treated sheep was similar to 
that in the untreated sheep, with progressive reduction of ERG responses from the beginning of the 
trial. One sheep had extinguished ERG responses at 14.2 months, while the ERGs of the other three 
gradually became extinguished and all ERG amplitudes were abolished at 22 months.  
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Figure 7.5 Mean amplitudes of a- and b-waves in treated sheep and controls 
Mean amplitudes (± SEM) of a- and b-waves of mixed receptor responses from sheep that received self-
complementary scAAV9-CLN5 gene therapy at 7 months of age (AAV 7m, n = 4), untreated (CLN5-/-) and 
healthy controls (CLN5+/-) (for n see Table 5.1). The amplitudes from the treated sheep were not improved 
compared with controls (P ≥ 0.05).   
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7.5 DISCUSSION  
These results demonstrate the usefulness of in vivo longitudinal monitoring through CT scanning and 
ERG for the assessment of therapy trials as well as imaging for improved surgical planning and in vivo 
visualisation of anatomical changes. The overall results from the treatment trial indicate a positive 
result for the attempt at halting clinical disease in NCL affected sheep.  
The individualised trajectory planning for intracerebroventricular delivery of gene therapy has 
shown to be beneficial, as surgery times were reduced by having more precise localisation of the 
injection targets, also indicated by contrast-agent injection into a severed head (Figure 7.2). A similar 
study of AAV2-mediated transfer of TPP1 into the lateral cerebral ventricles of dogs with CLN2 NCL 
used the Brainsight neuronavigation system (Rogue Resolutions Ltd, Cardiff, UK) (Katz et al., 2015). 
This is an automated, MRI based neuronavigation system, where the head position of the animal is 
matched with a pre-surgical MRI scan which is then used for real time navigation of neurosurgical 
procedures. The present results show that intracerebroventricular therapy delivery is relatively 
uncomplicated and that a stereotaxic frame and generalised coordinates are sufficient for success of 
the procedures (Figure 7.2).  
The longitudinal monitoring and 3-D modelling of intracranial volumes are valuable tools for 
assessing treatment efficacy and disease status of the scAAV9-CLN5 treated sheep. It was shown 
that volume loss was largely halted when compared with untreated affected sheep (Figure 7.3). This 
correlates with observations of other clinical measures of disease progression such as maze traverse 
times and behavioural changes that were halted to a similar extent as the loss of ICV (Mitchell et al., 
2017). The 3-D models showed that most of the volume loss concentrated around the occipital lobe 
of the cerebrum (Figure 7.4). This loss could also be seen at the initial neuropathological assessment 
of the brains of the two sheep that have already been sacrificed, where the visual cortex was 
obviously thinned, and the remaining cerebral regions less atrophied than those in untreated 
controls (Dr Nadia Mitchell, personal communication).  
Longitudinal ERG measures showed that the intracerebroventricular treatment with scAAV9-CLN5 
did not affect the loss of vision seen in ovine NCL (Figure 7.5). All four treated sheep had developed 
abolished ERG amplitudes between 14 and 22 months of age. The present ERG techniques provide a 
simple and relatively timely measure of overall retinal function and the results are of a yes/no 
character which is of value for general assessment of treatment efficacy.  
When correlating the time for loss of vision and the total amount of ICV loss, it becomes clear that 
the same animal that lost its vision early on is also the one that experienced the most pronounced 
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loss of ICV and the animal that was the last to lose its vision also had the largest ICV at 22 months. 
This suggests that the early loss of vision might be more related to atrophy of the visual cortex and 
the later manifestations of blindness might result more from loss of photoreceptor function. Similar 
findings were recorded in another study, where CLN5-/- sheep were treated with scAAV9-CLN5 at 3 
months, before they exhibited clinical signs, and the complete loss of vision was delayed to an 
average age of approximately 25 months, which is later than in untreated affected sheep as well as 
in the sheep of the present study (Mitchell, 2016; Mitchell et al., 2017).   
Looking ahead, the application of MRI technology would be beneficial for the longitudinal in vivo 
monitoring of trials like the present ones, given the increased tissue contrast that can be achieved 
from the use of MRI compared with CT. As described in Chapter 6 new methods have recently been 
developed for segmentation of white matter, grey matter and CSF within images as well as the 
ability to measure the size of specific brain regions based on these high quality MRI images (Ella & 
Keller, 2015; Ella et al., 2017). This would enable investigators to monitor regional changes and grey 
matter volume in vivo without having to sacrifice the animals. However, the accessibility and 
practicality of MRI in the present study was limited by the requirement to use human facilities where 
the number of animals and the frequency of scans was restricted by costs and logistics. 
Nevertheless, there are some benefits of CT over MRI such as speed of image acquisition and 
robustness of the system (Kemmling et al., 2012). The use of tissue probability maps (TPMs) for 
segmentation of white matter, grey matter and CSF, that are based on MRI studies but transferred 
onto CT scan data, has been suggested for use in human brain imaging (Kemmling et al., 2012). 
Development of similar TPMs for sheep brain studies could enable an easier and faster method of 
longitudinal in vivo monitoring of neurodegeneration and its components in ovine NCL treatment 
trials. Possible restrictions of this would be the inferior soft tissue contrast that can be obtained 
from CT compared with MRI, diffuse tissue boundaries, image inhomogeneity and partial volume 
artifacts (Pham et al., 2000).  
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7.6 CONCLUSION 
 Longitudinal CT based in vivo monitoring of intracranial volume is valuable for the 
assessment of treatment efficacy in gene therapy trials for NCLs and reliably reflects the 
progressive changes that are recorded in other clinical parameters.  
 3-D modelling of intracranial volumes provides insight into regional changes that are 
occurring in vivo in NCLs and the models reflect what is seen at post mortem examination, 
however in slightly less detail.  
 CT based trajectory planning increases reliability and speeds up stereotaxic targeting of the 
lateral cerebral ventricles for intraventricular delivery of therapeutic agents.  
 ERG is useful for assessment of treatment efficacy in the eye. It can help to decipher retinal 
blindness from cortical blindness.   
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8 GENERAL DISCUSSION 
8.1 SUMMARY OF FINDINGS 
The aim of this thesis was to establish techniques for longitudinal in vivo monitoring that can be 
correlated with the progression of neuropathological events in all three ovine NCL models, both in 
the natural progression of the diseases and in trials of potential therapeutic regimes.  
The first objective was to describe the neuropathology of ovine CLN6 disease in Merino sheep to an 
extent that enabled the comparison of this form of ovine NCL to the two other known forms. In 
Chapter 3 the gross pathological changes, cortical thinning and changes of cellular architecture, 
white matter changes, neuroinflammation, neurogenesis, expression of endogenous CLN5 and CLN6 
proteins and accumulation of fluorescent storage material were explored in brains from CLN6 
affected Merino sheep of different ages. This is the first detailed description of progressive 
pathological changes in the CLN6 affected Merino sheep and has enabled comparison with the CLN5 
Borderdale model and the CLN6 South Hampshire model.  
Chapter 4 describes the establishment of CT protocols for the in vivo monitoring of atrophic changes 
in the ovine brain. These were then implemented in a longitudinal study following CLN5 and CLN6 
affected animals and healthy controls from 3 months of age and until the animals reached humane 
endpoints between the ages of 17 and 21 months. An increased radiodensity of the brain tissue of 
affected animals compared with controls was found. Furthermore, the relationship between brain 
atrophy and ossification of the cranial vault was established, as it was shown that brain atrophy 
preceded the growth of the skull into the space the brain had atrophied from, thereby indicating 
that ossification of the cranial vault in ovine NCL is secondary to brain atrophy and not vice versa. 
Through this the use of ICV as a surrogate measure for brain volume was validated. The longitudinal 
measures of ICV and ventricular volume showed that the loss of ICV followed similar patterns in 
CLN5 and CLN6 sheep (Figure 4.4, Figure 4.5 and Figure 4.6). Initially both breeds had slight increases in 
ICV, followed by a phase of relatively stable ICV, and finally lost volume rapidly after the age of 
approximately 12 months. The ventricular volumes of CLN5 sheep were increased compared with 
those of controls throughout the entire trial period and those of CLN6 sheep showed a similar trend. 
Finally, the usefulness of 3-D modelling was explored for surgical planning and for the visualisation 
of regional differences in the brain atrophy of ovine NCL.  
Simultaneously with the longitudinal investigations of brain atrophy, longitudinal ERG and fundus 
photography were used to describe the development of retinal pathology in CLN5 Borderdale and 
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CLN6 South Hampshire sheep (Chapter 5). Funduscopy revealed attenuation of the retinal blood 
vessels in affected sheep of both breeds. For ERG, three different adaptations were tested and it was 
found that the b-wave of the longest dark adaptation (5 minutes) yielded the best discrimination 
between affected and normal animals (Figure 5.3 and Figure 5.4). Affected animals of both breeds had 
initial ERGs similar to those of controls but started showing reduced b-wave amplitudes at 7 months 
of age. The recordings from CLN5 Borderdale sheep progressively worsened until b-wave amplitudes 
were largely extinct between 15 to 19 months of age. In CLN6 South Hampshire sheep, the 
recordings remained relatively stable between 7 and 11 months of age, when a sudden drop was 
observed in the b-wave amplitude from the 5 minutes dark adapted ERG. After this, the CLN6 
animals also reached near extinct ERGs at an age of 15 to 19 months. 
Chapter 6 describes two pilot studies investigating the usefulness of MRI for longitudinal in vivo 
monitoring of ovine NCL. The first was a longitudinal study of affected CLN6 Merino sheep and 
healthy controls at Sydney University. The second study consisted of the scan of one affected and 
one control CLN5 Borderdale sheep at the New Zealand Brain Research Institute. The studies were 
used to explore different image analysis tools and to investigate the longitudinal development of 
brain atrophy in CLN6 affected Merino sheep. The measurement showed reduced ICV, grey matter 
and white matter and increased CSF volume in CLN6 affected Merinos compared with controls. 
Some regional differences of the atrophy became visible, indicating a greater effect of disease status 
on the parietal, primary visual and frontal association cortices compared with the primary motor 
cortex. The cerebellar cortex was largely unaffected by the disease. These results showed the 
importance of scanner power and image quality, as the images from the Sydney University were 
obtained on a 0.25 tesla MRI and had low definition and spatial resolution, making it difficult to 
differentiate the tissue types, whereas the other study was conducted on a 3 tesla scanner, which 
resulted in better definition and spatial resolution.  
In Chapter 7 the methods for longitudinal in vivo monitoring that were established throughout this 
thesis were applied on a therapy trial that was conducted by Dr Nadia Mitchell using CLN5-scAAV9 
gene therapy to treat symptomatic CLN5 affected Borderdale sheep. CT based trajectory planning 
for the stereotaxic intracerebroventricular delivery of gene therapy has proved to reduce surgery 
times. It could be shown that CT scanning and ERG were useful for the longitudinal in vivo 
monitoring of treatment trials. The CT measures from treated animals revealed that their ICVs were 
largely stabilised after the treatment was delivered and until they reached an age of approximately 
17 months. Hereafter loss of ICV occurred, however the accumulated ICV loss of treated sheep was 
less than that of untreated affected animals (Figure 7.3). Regional differences of atrophy could be 
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seen on the 3-D reconstructions of ICV, indicating increased volume loss in the occipital and parietal 
regions of the cerebrum (Figure 7.4). ERG revealed no effect of intracerebroventricular gene therapy 
on retinal function.  
8.1.1 Correlation of neuropathology, longitudinal observations and clinical signs in three forms of 
ovine NCL 
The main findings of this thesis together with previous descriptions of the clinical development, in 
vivo monitoring and neuropathological cascades from the other two models are summarised in Table 
8.1, Table 8.2 and Table 8.3. Overall, the investigations revealed striking similarities between the three 
ovine models, which is surprising in the light of the differences in the genetic background of the 
disease. The CLN5 gene is thought to code for a soluble lysosomal protein and the CLN6 gene 
product is likely to be a transmembrane ER resident protein (Isosomppi et al., 2002; Heine et al., 
2004, 2007; Mole et al., 2004; Sleat et al., 2007, 2009; Schmiedt et al., 2010). The Merino CLN6 
mutation is a missense mutation leading to a single amino acid change, whereas the South 
Hampshire CLN6 mutation is a large deletion of 402 bp and 1 bp insertion (Tammen et al., 2006; 
Mohd Ismail, 2014). When comparing the three models only minor differences appear. Initial signs 
that are seen in all three models are low head carriage and baulking at gateways and shadows (Cook 
et al., 2002; Mitchell, 2016); Dr Nadia Mitchell, personal communication). This can be observed as 
early as 5 to 7 months of age in CLN5 Borderdale and CLN6 Merino sheep and at 7 to 9 months in 
CLN6 South Hampshire sheep. From here on the progression of clinical signs follows a similar pattern 
in all three models, with the CLN6 Merino sheep exhibiting signs first, followed by the CLN5 
Borderdale sheep and finally the CLN6 South Hampshire sheep (Table 8.1, Table 8.2 and Table 8.3). 
Nevertheless, sheep from all three models reach humane endpoints from approximately 17 to 22 
months of age, only staying alive longer when intensively cared for. In all three models the clinical 
signs largely reflect the neuropathological changes. The visual cortex is the first brain region to show 
both neuroinflammation and neuronal loss and the initial clinical signs are behavioural changes that 
can be attributed to altered vision to some degree. The results from the ERG study presented here, 
combined with maze-testing and behavioural observations (Dr Nadia Mitchell and Martin Wellby, 
personal communication), draw a detailed picture of the pathological changes in the visual pathways 
(Figure 5.7). Motor dysfunction occurs later in the disease in all three models, and the primary motor 
cortex is affected by neuronal loss only at 15 to 16 months in CLN5 Borderdale and CLN6 Merino and 
at 17 to 18 months in CLN6 South Hampshire sheep. These findings relate to the human CLN5 
disease, where one of the initial signs is visual failure and motor dysfunction is observed later 
(Santavuori et al., 1982, 1993; Savukoski et al., 1998). Human CLN6 disease, on the other hand, 
presents with motor disabilities and seizures which are followed by loss of vision (Teixeira et al., 
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2003; Mole et al., 2005). Another discrepancy between human and ovine NCL is the involvement of 
the cerebellum. Though the cerebellum is largely unaffected by neuronal loss and 
neuroinflammation in all three ovine NCL models, destruction of Purkinje cells is a defining feature 
of human CLN5 disease (Autti et al., 1992; Tyynelä et al., 1997). This is interesting in the light of 
reports of different mutations in the human CLN5 gene leading to largely similar clinical signs and 
neuropathology (Holmberg et al., 2000), indicating that the differences in cerebellar involvement 
might be an inter-species phenomenon rather than resulting from the different mutations involved.  
The results from the longitudinal CT and MR imaging largely parallel the neuropathological findings 
in all three ovine NCL models. The ICV loss commenced earlier and developed faster in the CLN5 
Borderdale compared with CLN6 South Hampshire sheep, which reflects the difference in both the 
neuropathological and clinical development between the two models. The results from the MRI 
measures of CLN6 Merino sheep did not yield satisfying longitudinal data. Nevertheless, they 
reflected regional differences of neuropathology to some degree and the superior image quality of 
the study performed at the New Zealand Brain Research Institute led to better tissue discrimination 
(Figure 6.5 and Figure 6.6). This is promising for the future use of MRI in longitudinal in vivo 
monitoring in ovine NCL research. Studies on the development of brain size in healthy humans have 
shown that after the maximum brain size is reached at approximately 15 years, brain size decreases 
steadily and a loss of approximately 25% of brain volume is to be expected in humans aged 71 to 80 
years (Courchesne et al., 2000). Whether a similar age-related loss of brain volume occurs in healthy 
sheep has not been established. In the light of treatment trials that extend the NCL affected sheep’s 
lives long enough, this is an important question to address as some amount of age-related loss of 
brain volume in healthy controls could occur and needs to be distinguished from disease related 
brain atrophy.  
 
 
 
Figure legend for Table 8.1, Table 8.2 and Table 8.3: 
Information compiled from this thesis and others (Cook et al., 2002; Oswald et al., 2005; Mitchell, 2016) 
Abbreviations: Cer Cerebellum, CSF cerebrospinal fluid, CT computed tomography, Ent entorhinal cortex, 
ERG electroretinography, FC frontal association cortex, GM grey matter, HP hippocampus, ICV intracranial 
volume, LGN lateral geniculate nucleus, M1 primary motor cortex, MRI magnetic resonance imaging, 
OWM occipital white matter, PC parietal cortex, POC parieto-occipital cortex, S1 somatosensory cortex, 
SVZ subventricular zone, V1 primary visual cortex, WM white matter.  
† No brains from CLN6 Merino sheep were available for neuropathological investigations before the age of 
7 months. 
* Cross sectional measure of brain weights from CLN6 affected Merino sheep aged 20 months and over.  
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Table 8.1 Correlation of neuropathological and in vivo measures of disease in CLN6 affected Merino sheep  
Age  
(months) 
Clinical signs 
Vision 
(Clinical) 
Radiology 
(MRI) 
Neuropathology † 
Brain 
weight 
Neuronal loss Neuroinflammation Neurogenesis Storage 
0  Normal         
1           
2           
3       
~73 g 
    
4 Normal         
5  
Low head carriage, baulking at gates and 
shadows, mild behavioural changes 
 
Head tilt 
 Reduced ICV, GM, 
WM and increased 
CSF volumes. 
Largest amount of 
GM loss in PC, V1, 
FC.  
Cerebellar cortex 
largely spared 
     
6       
7  
Difficulties on steps, reduced herding instinct, 
mild stereotypic behaviour 
Largely normal, slightly 
altered PLR and 
pupillary size in dim 
light 
 V1, POC, Ent Lamina II/III of V1 and 
POC. Less in laminae 
II/III of M1 and laminae 
IV-VI of V1.  
Some in HP, LGN and 
OWM 
Increased in SVZ. 
Clusters of newly 
formed cells in 
lamina I/II of 
cortex 
Abundant 
throughout 
entire brain.  
More in 
cerebrum than 
in cerebellum  
8 ~84 g  
9   
10       
11      ~69 g   
12 Poor response to auditory stimuli, reduced 
awareness, somnolence, stereotypic behaviour, 
sham eating/drinking, intermittent localised 
tremors 
Functionally blind       
13     V1, POC, Ent, FC, 
S1 
As above. Increased in 
laminae IV-VI of V1, 
POC 
  
14       
15          
16 Inducible tremor     V1, POC, Ent, FC, 
S1, M1 
As above. Increased in 
laminae IV-VI of M1 
  
17 Humane endpoints from here ↓       
18           
19      ~62 g Few cortical 
neurons remain 
As above. Increased in 
HP, LGN and WM 
Much less 
prominent 
Increased 
overall, more in 
cerebrum than 
in cerebellum 
20       
21      ~57g *    
22          
23          
24           
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Table 8.2  Correlation of neuropathological and in vivo measures of disease in CLN6 affected South Hampshire sheep 
Age  
(months) 
Clinical signs 
Vision 
(ERG and clinical) 
Radiology 
(CT) 
Neuropathology 
Brain 
weight 
Neuronal loss Neuroinflammation Neurogenesis Storage 
0  Normal  Clinically normal  ~50 g  Foci in lamina II/III of 
V1 
SVZ, HP and Cer Sparse, only 
neuronal cells 
1        
2      ~70 g  V1, POC Lamina II/III of V1 
and POC 
  
3   Normal ERG ICV near normal     
4     ~75 g     
5   ERG amplitudes slightly 
reduced but stable 
ICV increase like 
normal 
     
6   ~70 g    SVZ, cortical 
lamina II/III 
Widespread, 
mainly neuronal 
7 Low head carriage, 
baulking through gates and shadows, difficulties 
on steps 
  ICV loss begins    
8        
9     Slow ICV loss ~68 g V1, POC, S1    
10   Sudden drop of ERG 
amplitudes 
     
11         
12 Self-segregation, reduced herding instinct Functionally blind 
based on visual acuity 
tests 
 ~68 g V1, POC, S1, Ent, 
FA 
Lamina II/III and IV-
VI of POC, V1, M1, 
basal ganglia and 
thalamus 
 Neuronal and 
non-neuronal 
13   Rapid ICV loss   
14         
15 Proprioceptive deficits, facial tics, reduced 
mentation, decreased acoustic startle reflex 
Near abolished ERG 
amplitudes 
      
16       
17     Average ICV loss: 
5.8 ± 2.5 ml since 3 
months of age 
     
18 Tetanic seizures,  
sham eating/drinking, 
stereotypic behaviour 
Humane endpoints 
from here ↓ 
  ~66 g V1, POC, S1, FA, 
Ent, M1 
Spanning entire 
cortex 
 Mostly non-
neuronal/ brain 
macrophages 19      
20          
21          
22           
23  
Spontaneous seizures, terminal 
    Few cortical 
neurons remain 
 
Widespread through 
entire brain 
 
Much less 
prominent. 
Widespread 
through entire 
brain 24    ~58 g 
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Table 8.3  Correlation of neuropathological and in vivo measures of disease in CLN5 affected Borderdale sheep 
Age  
(months) 
Clinical signs 
Vision 
(ERG and clinical) 
Radiology 
(CT) 
Neuropathology 
Brain 
weight 
Neuronal loss Neuroinflammation Neurogenesis Storage 
0  Normal Clinically normal  ~55 g Initial signs 
in V1 
Foci in lamina II/III of 
POC and V1 
SVZ, HP and Cer Sparse, only 
neuronal cells 
1        
2           
3   Normal ERG ICV 90% of normal, 
small increase of ICV 
     
4   ~82 g V1, POC, S1 Lamina II/III of POC 
and V1 
Prominent in 
SVZ, cortical 
lamina II/III 
Widespread, 
mainly neuronal 
5  
Low head carriage, 
baulking through gates and shadows, difficulties 
on steps 
Normal ERG Small ICV loss   
6  
Linear decline of ERG 
amplitudes begins 
ICV stable, neither 
growth nor loss 
~80 g  Lamina II/III of POC, V1 
and M1 
  
7     
8      
9      ~79 g V1, POC, S1, FA Lamina II/III and IV-VI 
of POC, V1, M1, basal 
ganglia and thalamus 
  
10 Self-segregation, reduced herding instinct Functionally blind 
based on visual acuity 
tests 
Linear loss of ICV 
begins 
    
11     
12      ~78 g V1, POC, S1, 
FA, Ent 
SVZ, cortical 
lamina II/III 
Neuronal and non-
neuronal 
13 Increased somnolence, 
proprioceptive deficits, 
facial tremors, 
stereotypic behaviour, 
sham eating/drinking 
      
14  
Reduced 
awareness, 
unresponsive, loss 
of body condition 
        
15    ~76 g V1, POC, S1, 
FA, Ent, M1 
Spanning entire cortex   
16 ERG responses 
abolished 
    
17 
Humane endpoints from here ↓ 
 
Average ICV loss: 
6.7 ± 2.6 ml since 3 
months of age 
     
18   ~71 g Entire cortical 
mantle, few 
cortical neurons 
remain 
Widespread through 
entire brain 
Prominent in 
SVZ, cortical 
lamina II/III 
Mostly non-
neuronal/ brain 
macrophages 19       
20           
21            
22            
23 
Spontaneous seizures, terminal 
       
Much less 
prominent 
Widespread 
through entire 
brain 24    ~62 g   
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8.1.2 Longitudinal monitoring and treatment trials 
Currently gene therapy is the most promising treatment strategy for most of the NCLs, as it enables 
treatment of disease even when the gene product remains elusive. The methods for longitudinal in 
vivo monitoring developed in this thesis have proven successful in describing treatment efficacy in 
ovine NCL therapy trials (Chapter 7). The ERG measures showed that the intracerebroventricular 
delivery of gene therapy had no effect on retinal function and the ICV measures showed some loss 
of brain volume after the therapy was delivered. The loss of retinal function was expected, as it is 
unlikely for therapy delivered to the CSF to reach the retina. Similar findings have been described 
after enzyme replacement therapy in TPP1-/- dogs (Whiting et al., 2014). However, a previous gene 
therapy trial in CLN5-/- sheep resulted in a longer preservation of eyesight (up to approximately 24 
months of age) (Mitchell, 2016). Two major differences exist between the previous trial and the trial 
described in Chapter 7. Firstly, the sheep in the previous trial received therapy at 3 months of age, 
before exhibiting any clinical sings, whereas the sheep in the present trial received therapy at 7 
months of age, when pathological changes had already occurred. From the neuropathological 
studies it is known that the visual cortex is one of the areas affected earliest and strongest by 
neuronal loss in all three ovine models (Oswald et al., 2005; Mitchell, 2016; Chapter 3). Likewise, the 
longitudinal ERG observations described in Chapter 5 showed that in CLN5-/- Borderdale sheep, a 
significant reduction of ERG amplitudes was evident at 9 months, and at 7 months this trend was 
already visible (Figure 7.4). Therefore it is to be expected that some visual loss had already occurred 
in the sheep before treatment at 7 months of age and that this loss would not be able to be 
recovered. Secondly, and more interestingly, are the differences in therapy delivery between the 
present trial and the previous gene therapy trial. While in the present trial the entire therapy dose 
was delivered intracereboventricularly, the previous trial also included parenchymal injections into 
the parietal cortex and occipital lobe. It may be that the close proximity of the visual cortex to these 
areas has led to an improved therapeutic effect in the visual cortex compared with the 
intracerebroventricular delivery of therapy in the present trial. This would indicate that the initial 
blindness seen in ovine NCL is mainly due to neuronal loss from the central visual pathways and the 
later visual impairment is due to the loss of photoreceptor cells.  
The ICV reduction seen in the present treatment trial indicates that not all neuropathology can be 
halted after therapy delivery (Figure 7.3), especially in the highly affected areas of the brain such as 
the occipital lobe and visual cortex, which was visualised through 3-D reconstructions of ICVs (Figure 
7.4). Several explanations for this are possible. If the disease processes in these areas were already 
advanced at the time of therapy delivery, as discussed above, the therapy might have slowed the 
neuropathological changes down rather than fully halting them. Similar observations have been 
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made in TPP1 deficient dogs that received AAV mediated gene therapy (Katz et al., 2015). 
Furthermore, it could be suggested that intracerebroventricular delivery of gene therapy is not 
sufficient for the complete rescue of heavily affected brain areas and that parenchymal injections 
are needed in these regions. The AAV9 viral vector is mainly neurotrophic and in the light of 
substantial neuronal loss and astrocytic infiltration occurring early in certain areas of the brain in 
ovine NCL, the use of astrocytrophic viral vectors such as AAV5, vectors that transduce both neurons 
and astrocytes such as AAV4, or a combination of vectors could be beneficial when treating post-
symptomatic animals (Davidson, 2000; Liu et al., 2005; Cearley & Wolfe, 2006).  
Another point that needs critical consideration is the question of repeated delivery of gene therapy, 
as an attenuation of the vector or loss of function of the protein might arise over time. The results 
presented in Chapter 7 indicate some delayed ICV loss in treated sheep and a delay rather than 
complete prevention of clinical signs was also described in the TPP1 AAV9 dog trial (Katz et al., 
2015). Careful consideration of serotypes for re-injection strategies is needed to prevent immune 
responses interfering with the therapy.  
8.1.3 Statistical consideration 
As in all fields of research statistical issues need to be considered carefully when working with large 
animal models. In research in general, and in translational research based on rodent models, the 
traditional goal is to reach results that show significance based on P-values. In recent years the 
controversy around the use of P-values has been increasingly discussed and alternatives suggested 
(Sullivan & Feinn, 2012; Cumming, 2013). Small animal models, with large sample sizes and easily 
repeatable experiments fit the traditional approach of reaching significance through a large numbers 
of observations. If the sample size is large enough, most differences will appear to be significant, 
even if they have no clinical relevance (Sullivan & Feinn, 2012). Numbers in large animal model 
research, however, are often limited by animal availability, housing capacities, practicality of animal 
handling and care, and extended generation intervals. This is reflected in the relatively small sample 
sizes prevailing in the studies described in this thesis, as well as by others conducting trials in large 
animal models of the NCLs, where experimental group sizes rarely exceed 10 animals (Whiting et al., 
2013; Katz et al., 2015; Mitchell, 2016). Effect size offers a valuable addition, or even alternative, to 
P-values to indicate clinical relevance of findings, as large effects can be detected even in small 
sample sizes (Sullivan & Feinn, 2012; Cumming, 2013). The inclusion of measures of effect size, such 
as differences between means, means and their confidence intervals or Cohen’s d in the reporting of 
translational results should be encouraged.  
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8.2 FUTURE DIRECTION 
The current studies have demonstrated the value of longitudinal in vivo monitoring in ovine NCL 
research as well as the usefulness of large animal models for translational research of 
neurodegenerative diseases. Furthermore is it important to note that the present findings provide a 
suite of non-invasive methods for monitoring both the course of the disease and the effectiveness of 
therapeutic trials that are equally translatable to humans and could not have been derived so well 
from rodent-based investigations. Nevertheless, room for improvement always exists, and other in 
vivo monitoring tools could, and should, be added.  
8.2.1 Imaging 
The present studies have demonstrated the importance of in vivo neuroimaging for the collection of 
translational data of disease development and treatment efficacy. Although MRI has superior tissue 
contrast, CT offers several advantages over MRI. Generally the image acquisition is much faster with 
CT than MRI, leading to reduced costs, higher throughput of animals and reduced need for 
anaesthesia and the risks that are correlated with this (Kemmling et al., 2012). Furthermore, the 
access to MRI is limited by logistics and pricing, leaving CT scanning as the most readily available 
option for regular monitoring of large numbers of animals.  
In the light of the potential availability of a high-resolution CT scanner for the monitoring of future 
ovine NCL trials, the use of TPMs for CT scanning should be considered. Kemmling et al. (2012) have 
suggested techniques for human MRI derived TPMs that can be used for segmentation of CT images 
so individual tissue volumes (GM, WM, CSF) can be measured on these. Similar TPMs could be 
developed for sheep to enable more detailed in vivo monitoring of neuropathology in the NCL sheep 
models or other ovine models of neuropathological disease. 
8.2.2 Vision 
The results presented in this thesis show the value of electroretinography for the monitoring of 
visual impairment in ovine NCL. Furthermore the techniques developed in Chapter 5 could be used 
for the work described in Chapter 7 to show that intracerebroventricular delivery of gene therapy 
had no beneficial effect on eyesight in CLN5-/- sheep. These and previous results from ovine NCL 
gene therapy trials (Mitchell, 2016) stress the point that a separate, ocular delivery of gene therapy 
is needed to correct blindness in ovine NCL. Other retinopathies have been treated successfully by 
intravitreal or ocular gene therapy in human trials or animal models. For instance, AAV2 mediated 
subretinal gene therapy for Leber congenital amaurosis has been shown to be effective in human 
patients (Bainbridge et al., 2008; Cideciyan et al., 2009). Both subretinal and intravitreal AAV 
mediated gene therapy have been successful in treating different forms of MPS in animal models, 
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which is promising for the LSDs in general (Ho et al., 2002; Hennig et al., 2004) and intravitreal 
delivery of AAV2 mediated gene therapy has improved disease phenotype in CLN1 (PPT1) mice 
(Griffey et al., 2005). Subretinal gene therapy using an AAV5 vector has led to phenotypic correction 
of achromatopsia in a sheep model (Banin et al., 2015). These results are all promising for the halt of 
ocular pathology in ovine and human NCLs by either intravitreal or subretinal delivery of gene 
therapy. Currently a trial of intravitreal delivery of AAV9 mediated gene therapy to NCL affected 
sheep is underway (Dr Nadia Mitchell, University of Otago). Careful monitoring of ocular pathology is 
crucial for the collection of translational data. The ERG methods presented in this thesis are of a 
yes/no character and are a robust and rapid test for determining retinal function. However, for 
future gene therapy trials, a more in-depth assessment of retinal function might be beneficial. To 
achieve this, a more detailed ERG protocol could be utilised, such as the protocols described in the 
‘Guidelines for clinical electroretinography in the dog’ that were proposed by the European College 
of Veterinary Ophthalmology and that largely follow the standardised protocols for ERG in humans 
suggested by the International Society of Clinical Electrophysiology of Vision (Narfström et al., 2002; 
Ekesten et al., 2013). Furthermore, for in vivo monitoring of the cellular levels of the retina it could 
be beneficial to include optical coherence tomography (OCT) in the assessment of treatment trials. 
OCT has been utilised in the human ocular gene therapy trials described above and could yield useful 
translational data (Bainbridge et al., 2008; Cideciyan et al., 2009). In addition it could be interesting 
to investigate and decipher the central and peripheral components of blindness in ovine NCL. Visual 
evoked potentials (VEP) or functional MRI (fMRI) could facilitate some of this, as the capacity of 
central visual pathways to respond to a visual stimulus can be tested this way.  
8.3 LARGE ANIMAL MODELS IN TRANSLATIONAL RESEARCH 
This thesis emphasised the importance of large animal models for translational research. In recent 
years the discussion about issues regarding the use of small animal models has increased and 
concerns have been raised about the high rate of failures of clinical trials reviewed by Garner (2014). 
It has been pointed out that between the years 2011 and 2012 only 20% of clinical trials reached 
phase II clinical trials and 56% of the failures were due to lack of efficacy (Arrowsmith & Miller, 
2013). Others have found that only one in nine compounds that enter human clinical trial will reach 
the market (Garner, 2014). In Alzheimer disease research for example, out of 200 drug candidates 
that had effect in transgenic mice models, only two showed efficacy in human clinical trials (Zahs & 
Ashe, 2010). Although a range of factors influences these results, concerns have been expressed as 
to whether or not the animal models that are used to identify possible drug candidates are truly 
mimicking human pathology (Phaneuf et al., 1996; Grubb & Boucher, 1999; van der Worp et al., 
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2010; Zahs & Ashe, 2010). It should be questioned whether relying on small animal models for the 
majority of translational research is feasible, not only in a financial but also in an ethical sense, as it 
appears that both resources and animals are wasted on research that might be intrinsically 
unsuitable for translation. The ovine NCL research, and this thesis as a part of it, prove the 
importance of large animal models for human disease research. The development of next generation 
sequencing technologies and the completion of the full genome sequence of sheep should enable 
the screening of populations of domesticated sheep for genetic diseases that could be utilised as 
human disease models (Jiang et al., 2014; Pinnapureddy et al., 2015). Furthermore it is to be 
expected that the recent and ongoing progresses in gene editing techniques, such as the use of 
CRISPR/Cas9 genome editing, can be utilised to develop purpose-built large animal models for 
translational research. In these cases the collection of longitudinal data through in vivo monitoring 
will be crucial for translational success.  
8.4 CONCLUSION 
Throughout the work described in this thesis, techniques for longitudinal in vivo monitoring have 
been developed that could be correlated with the progression of neuropathological events in all the 
ovine NCL models. The neuropathology of the CLN6 Merino sheep is largely similar to that of the 
CLN5 Borderdale and CLN6 South Hampshire models. Standardised techniques for longitudinal in 
vivo monitoring of brain volume changes through CT scanning and eyesight through ERG were 
developed and have proven useful in the monitoring of treatment efficacy. MR imaging has been 
explored for the in vivo monitoring of regional changes in the brain throughout the natural history 
on ovine NCL and initial results were promising.  
This thesis indicates a range of questions and ideas for future investigations. Can the central vs. the 
peripheral components of blindness in ovine NCL be deciphered using more advanced ERG 
techniques combined with other measures of visual function such as OCT, VEP or fMRI? Can CT 
scanning yield greater detail for the in vivo investigation of the regionality of cortical atrophy in 
ovine NCL? Does an age-related loss of brain volume occur in healthy sheep? Will ocular gene 
therapy halt the peripheral component of blindness in ovine NCL and are the methods presented 
here sufficient for the in vivo monitoring of this? Would other viral vectors improve the outcome of 
gene therapy by transducing other cells than only neurons? Does the effect of gene therapy 
decrease over time and is repeated delivery of therapy needed? These questions indicate the need 
for further research, but do not take away from the importance of the techniques developed 
throughout this work and the results presented for the use of large animal models in translational 
research.   
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